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Haemostasis 
In humans and other vertebrates the vascular system provides the infrastructure via which 
blood transports vital substances through the body. In case of damage to the vascular 
system a complex mechanism is activated to limit blood loss. This mechanism is called 
haemostasis and consists of several sequential events. During the first phase of 
haemostasis the loss of blood is mainly limited by vasoconstriction (in small blood vessels) 
and the formation of a primary plug (in larger vessels), which is formed by the aggregation 
of activated platelets. In the next phase the fragile primary plug is enforced by deposition 
of insoluble cross-linked fibrin, the final product of the coagulation cascade. This 
coagulation cascade entails a series of enzymatic reactions culminating in the production 
of large amounts of thrombin, which converts soluble fibrinogen into insoluble fibrin 
fibres.  
Regulation of coagulation in time and place is essential, since bleeding and 
unnecessary clotting can be life threatening. Therefore, processes that initiate coagulation 
(procoagulant pathways) and processes that inactivate coagulation (anticoagulant 
pathways) are under strict control. Control in time is achieved by the constitutive presence 
of coagulation inhibitors in plasma and by the activation of an anticoagulant enzyme 
(protein C) by thrombin. Control in place is achieved by the requirement that all 
coagulation components are present at the site of injury (i.e. a negatively charged 
membrane provided by activated platelets or damaged tissue and activated coagulation 
factors).  
  
Coagulation cascade  
Traditionally, the coagulation cascade is divided in two different pathways, which are 
called the intrinsic and extrinsic pathway (Fig. 1). 
The intrinsic pathway is initiated in the presence of negatively charged surfaces, such 
as glass or kaolin, which are able to activate the so-called “contact factors” (kallikrein, 
high molecular kininogen and factor XII). The physiological relevance of this pathway 
seems minor, as individuals with deficiencies in one of the contact factors in general do not 
develop a bleeding tendency.  
The extrinsic pathway is initiated in the presence of tissue factor (TF), which triggers 
the sequential activation of FVII, FX and prothrombin [1]. This pathway seems to be more 
important in vivo, which is illustrated by the observation that defects in this pathway are 
associated with bleeding disorders, such as (para)haemophilia. In the final stage of the 
coagulation cascade both the intrinsic and the extrinsic pathway share the activation of 
prothrombin and the conversion of fibrinogen to insoluble fibrin (Fig 1). These final steps 
are also referred to as the common pathway.  
Hence, the generation of thrombin in vivo seems to be mainly triggered by binding of 
plasma FVII/FVIIa to the transmembrane protein TF, which is exposed after vascular or 
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endothelial damage. TF functions as a cofactor for FVIIa, which is a vitamin K-dependent 
serine protease involved in the activation of factor IX and factor X. Above a certain thresh-
hold level thrombin will activate the cofactors of activated factor IX and factor X (factor V 
and factor VIII, respectively), which results in the generation of additional thrombin via a 
positive feedback loop. Thrombin can also activate factor XI, which will cause a second 
burst of thrombin generation via the intrinsic pathway [2,3].  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Down-regulation of coagulation  
Down-regulation of activated clotting factors is important to prevent unnecessary clotting. 
Two major systems are responsible for this down-regulation: plasma inhibitors and the 
protein C pathway. 
In blood protease inhibitors circulate, which can bind and block the active sites of 
serine proteases involved in blood coagulation, such as FIXa, FXa and thrombin. Most of 
these inhibitors belong to the family of serine protease inhibitors (serpins) and form 
irreversible enzyme-inhibitor complexes, which are subsequently cleared from the 
Figure 1. Schematic representation of the coagulation cascade. The arrows in this 
scheme represent the actions of the procoagulant and anticoagulant enzymes
participating in the coagulation cascade. The dashed box shows the “common 
pathway”.   
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circulation. Examples of such serpins are antithrombin III, α1-antitrypsin, protein C 
inhibitor (PCI), heparin cofactor II and α2-macroglobulin. Besides serpins also another 
type of inhibitor is present in plasma, which is a modular protein comprised of three 
Kunitz type domains flanked by peptide sequences that are less structured. This inhibitor is 
called tissue factor pathway inhibitor (TFPI) and inhibits the TF/factor VIIa complex, after 
binding to factor Xa [4]. 
The other down-regulating mechanism is the so-called protein C pathway. This 
anticoagulant pathway is activated by thrombin complexed to thrombomodulin, a 
transmembrane protein constitutively expressed on endothelial cells [5]. After binding to 
thrombomodulin the substrate specificity of thrombin changes from clotting factors like 
FV, FVIII, FXI and fibrinogen to the anticoagulant protein C [6]. Especially in larger 
vessels the thrombin-thrombomodulin complex can convert protein C to activated protein 
C (APC), a reaction which also requires the presence of the endothelial protein C receptor 
[7,8]. Subsequently, APC exerts its anticoagulant activity by inactivating activated factor 
V (FVa) and activated factor VIII (FVIIIa) via limited proteolysis. Essential for the 
proteolytic activity of APC is the presence of negatively charged membranes and its 
vitamin-K dependent cofactor, protein S [9].  
The physiological importance of both protein C and protein S is illustrated by the 
observation that heterozygous deficiency in either protein is associated with a 5 to 10 fold 
increased risk of venous thrombosis [10-15], whereas homozygous deficiencies are 
associated with severe thrombotic complications already in the neonatal period [16,17]. 
 
Factor V: structure and function 
Gene and protein structure of FV  
The gene coding for human FV is located on chromosome 1 at q21-25, consists of 25 
exons and spans about 80 kb [18]. Transcription of this gene results in a mRNA of 6.8 kb, 
which predicts a protein of 2224 amino acids including a 28-amino acid leader peptide 
[19]. The mature protein is a large single-chain polypeptide of ~330 kD with a plasma 
concentration of ~20 nmol/L (~7 mg/L), which is mainly produced in the liver [20,21]. It 
has been estimated that about 20% of the total FV pool is present in the α-granules of 
platelets [22]. The origin of platelet FV is still a matter of debate. Some studies have 
reported that megakaryocytes (the precursors of platelets) can produce FV [23-26], 
whereas others have reported that platelet FV is mainly endocytosed by megakaryocytes 
from the plasma FV pool [27,28]. 
FV has a mosaic-like structure (Fig. 2) with a domain structure (A1-A2-B-A3-C1-C2), 
which is similar to that of FVIII [29]. In particular the A and C domains of FV and FVIII 
share considerable homology (about 40%). Furthermore, the A domains are homologous to 
the plasma protein ceruloplasmin, the 3D structure of which has been elucidated. Based on 
this structure a model for FV has been proposed in which the A domains are arranged in a 
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triangular fashion [30,31]. Also for the C-domains a 3D structure has been determined 
based on molecular modelling and the crystal structure of the recombinant C2 domain [32-
34]. The structural models obtained for the individual domains have resulted in 
experimental models for the FV and FVa molecule (Fig. 2), in which the C1 domain is 
positioned on top of the C2 domain. However, this model needs some revision, because 
recent crystallographic data obtained from bovine FVa indicate that the position of the two 
C-domains are parallel thereby forming a platform for the A domains [35].  
Human FV contains multiple posttranslational modifications, including N- and O-
linked glycosylation, sulfation and phosphorylation (reviewed in [36]), which are 
important for the procoagulant and anticoagulant function of FV and FVa. The sites of 
posttranslational alterations have been summarized in Table 1. Total carbohydrate content 
accounts for about 13% of the molecular weight of FV [37], although it is not clear which 
potential glycosylation sites actually contain a carbohydrate side-chain. In particular 
glycosylation of asparagine at position 2181 seems to be relevant for the structure and 
function of FV, since inefficient glycosylation of this site is responsible for the presence of 
two FV isoforms in plasma, designated FV1 and FV2 [38,39]. FV1 contains a 
carbohydrate side-chain at N-2181 and has a light chain of ~74 kD after activation by 
thrombin, whereas FV2 has no carbohydrate side-chain at N-2181 and a light chain of ~71 
kD. The presence of the carbohydrate side-chain at this position has an effect on the 
function of FV, because activated FV1 (FVa1) has lower affinity for negatively charged 
phospholipids than activated FV2 (FVa2), which makes FVa1 less susceptible for 
inactivation by APC [40]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Sites of posttranslational modifications in human FV 
 
Modifications Residues 
Phosphorylation Ser692, Ser804, Ser1506 for platelet casein kinase II; at least 2 sites for protein kinase C on the light chain 
Sulfation Tyr665, Tyr696, Tyr698, Tyr1494, Tyr1510, Tyr1515, Tyr1565 
(Potential) 
N-glycosylation 
Asn23, Asn27, Asn211, Asn269, Asn354, Asn432, Asn440, 
Asn526, Asn639 Asn713, Asn724, Asn732, Asn748, 
Asn754, Asn793, Asn910, Asn949, Asn1046, Asn1055, 
Asn1075, Asn1078, Asn1175, Asn1193, Asn1229, Asn1238, 
Asn1265, Asn1283, Asn1310, Asn1319, Asn1347, Asn1356, 
Asn1451, Asn1471, Asn1531 Asn1675, Asn1982, Asn2181 
 
Disulfide bridges 
Cys139-Cys165, Cys220-Cys301, Cys472-Cys498, Cys575-
Cys656, Cys1697-Cys1723, Cys1879-Cys2033, Cys2038-
Cys2193 
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FV circulates in plasma as a single-chain procofactor without procoagulant activity. In 
vivo the main activator of FV is thrombin, which catalyzes cleavages at R709, R1018 and 
R1545 (Fig. 2). Cleavage at R1545 seems to be critical for the activation of FV, since the 
protease RVV-V (from snake venom) is able to activate FV by cleaving exclusively at 
R1545. Cleavage by thrombin results in a rearrangement of the FV molecule. The B-
domain dissociates and the N-terminal part (heavy chain) and the C-terminal part (light 
chain) associate via non-covalent interaction mediated by a divalent metal ion [41].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic representation of FV and FVa. The box diagram of FV (A) shows the 
mosaic-like domain organisation of this molecule. FV is activated by thrombin, which catalyzes 
cleavages at R709, R1018 and R1545 as is indicated by the upper arrows (note that FV can also 
be cleaved at R1545 by the venom protease RVV-V). APC cleaves the heavy chain FVa at R306, 
R506 and R679, which is indicated by the lower arrows. Based on molecular models and x-ray 
diffraction coordinates a spatial model (B) has been developed for FV [30,31,34]. In this model 
the three A-domains are arranged in a triangular fashion with the two C-domains stretching-out 
from the A3-domain, which results in a windmill-like model. Upon activation by thrombin the 
connecting B-domain is excised from FV resulting in a FVa molecule, which consists of a heavy 
chain that is non-covalently bound to the light chain (C). The binding of FVa to phospholipid 
membranes is mediated via the light chain. Recent crystallographic data from bovine FVa 
suggest that both C-domains are positioned next to each other and serve as a platform for the A-
domains [35]. This model is depicted in panel D. 
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Activated FV (FVa) serves as a cofactor for FXa in the conversion of prothrombin to 
thrombin. This conversion occurs in the so-called prothrombinase complex, which exists 
of the serine protease FXa, the non-enzymatic cofactor FVa, Ca2+ ions and a negatively 
charged surface. Kinetic analysis has shown that FVa increases the rate of prothrombin 
activation by the prothrombinase complex about 2000-fold [42,43]. The stimulatory role of 
FVa is threefold: supporting FXa binding to negatively charged phospholipids [44], 
increasing the catalytic activity of FXa [43] and promoting the interaction of prothrombin 
with the prothrombinase complex by lowering the Km for prothrombin [45]. 
Several regions in the FVa molecule have been identified that are important for the 
interaction of FVa with the other components of the prothrombinase complex. These 
regions are summarized in Table 2.  
 
Table 2. Regions and residues in FVa important for the interaction with components of the 
prothrombinase. Based on experimental and theoretical data several regions in the FVa molecule 
have been identified that are biologically relevant. These regions are involved in the interaction 
with components of the prothrombinase complex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Residues  Component of prothrombinase complex References
 
311-331 Factor Xa  [96-98] 
493-506 Factor Xa  [99] 
467, 511, 652, 
1683 Factor Xa  [100] 
684-709 Factor Xa  [101] 
695-698 Prothrombin  [102] 
1667-1765 Non-charged phospholipids  [103] 
2063, 2064 Negatively charged phospholipids  [104,105] 
2087, 2092, 2096 Negatively charged phospholipids  [106] 
85, 1815, 1817 Ca2+  [30][31,107] 
148, 149, 1577, 
1572, 1576, 1583 Ca
2+  [31] 
96, 102, 108, 111, 
112 Ca
2+  [30,107] 
221 Interaction heavy chain and light chain of FVa  [108] 
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Inactivation of FVa 
Activated protein C plays a key role in the down-regulation of thrombin generation by 
proteolytically inactivating FVIIIa and FVa [46]. The inactivation of FVIIIa by APC 
seems less relevant, because under physiologic conditions FVIIIa inactivates also in the 
absence of APC via spontaneous dissociation [47]. In contrast, FVa is very stable and 
requires the serine protease APC for its inactivation. APC exerts its anticoagulant activity 
by cleaving the heavy chain of FVa at R306, R506 and R679 (Fig. 2) [48]. Studies using 
isolated FV have shown that inactivation of FVa by APC proceeds in a biphasic fashion 
[48,49], a rapid reaction associated with cleavage at R506 and a slow reaction associated 
with cleavage at R306. Cleavage at R506 results in a partially active FVa intermediate 
with reduced affinity for FXa, whereas cleavage at R306 results in a completely inactive 
FVa molecule, which is probably caused by a reduced affinity for FXa in combination with 
dissociation of the A2 domain [50,51]. Both cleavages are strongly dependent on the 
presence of negatively charged phospholipids [48,49]. As yet, the contribution of the APC 
cleavage at R679 to the inactivation of FVa by APC is uncertain but seems to be minor. 
Furthermore, the APC-catalyzed inactivation of FVa is strongly stimulated by the non-
enzymatic cofactor protein S, which specifically promotes the cleavage at R306 [52-54].  
 
FV and bleeding 
Deficiency of FV results in a rare bleeding disorder with a heterogeneous clinical 
phenotype. Congenital FV deficiency, also called parahaemophilia, is inherited as an 
autosomal recessive trait [55], which is generally characterized by a parallel reduction of 
FV activity and FV antigen (type I FV deficiency). Most heterozygous carriers of a 
defective FV gene are asymptomatic, but homozygous (or compound heterozygous) 
carriers show in general mild to severe haemorrhages. However, the prevalence of FV 
deficiency seems to be very low (about 1:106), which is underscored by the observation 
that affected individuals are usually found in consanguineous families.  
The search for mutations causing severe FV deficiency has been launched in 1998 
when the first molecular defect resulting in a FV null allele was reported by Guasch et al. 
[56]. During the last years an increasing number of mutations causing severe FV 
deficiency have been reported (see also [36] and [57]), but this number is still much lower 
than the collection of mutations causative for FVIII deficiency (haemophilia A database 
[58]). Currently, a database on FV mutations is under construction (supervised by Dr. H.L. 
Vos from the Hemostasis and Thrombosis Research Center, Department of Hematology, 
LUMC, Leiden) 
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FV and thrombosis 
In 1993, Dahlbäck et al. discovered a novel laboratory phenotype, which was inheritable 
and associated with venous thrombosis [59]. This plasma abnormality is defined as a poor 
anticoagulant response of plasma to exogenously added APC (i.e. APC is unable to 
prolong the clotting time of plasma) and is therefore called APC-resistance. Traditionally, 
the sensitivity of plasma to APC is calculated from two APTTs (one in the presence and 
one in the absence of APC) and expressed as a ratio of both clotting times 
(APTT+APC/APTT-APC). This ratio is called the APC-sensitivity ratio (APC-sr), which 
is divided by the APC-sr of a pooled normal plasma to obtain the normalized APC-sr (n-
APC-sr).  
Several studies have shown that congenital APC-resistance is highly frequent (~5% in 
the Caucasian population, 20-30% in unselected consecutive thrombotic patients [60] and 
over 50% in patients with a family history for thrombosis [61]), which makes this 
phenotype the most common inherited risk factor for thrombosis. The molecular basis for 
APC-resistance was found in 1994 and appeared to be a point mutation in the FV gene [62-
64]; a G→A transition at nucleotide 1691 in exon 10 of the FV gene, which predicts an 
amino-acid substitution (R506Q) at the important APC cleavage site R506. FV-506Q is 
also referred to as FV Leiden. Carriership of the FV Leiden allele explains about 90% of 
the cases in which APC-resistance is diagnosed. Epidemiological studies have estimated 
that carriership of FV Leiden is associated with 7-fold (heterozygous) and 80-fold 
(homozygous) increase of thrombotic risk compared to individuals with the normal 
genotype [65,66].  
Two mechanisms have been proposed to explain the APC resistant phenotype 
associated with FV Leiden. Initially, the APC resistant phenotype was attributed to a 
deficiency of an unknown cofactor for APC [59], which was eventually identified as factor 
V [67]. Indeed, several studies have now shown that intact FV and not FVa contains APC-
cofactor activity, at least in the APC-catalyzed degradation of FVIIIa [68,69]. More 
recently, Thorelli et al. have observed that intact FV requires cleavage at R506 by APC in 
order to express APC-cofactor function, a mechanism that is absent for FV Leiden [70]. 
After the discovery of the R506Q mutation, the APC resistant phenotype was also 
attributed to the delay of FVa inactivation due to the absence of the important APC-
cleavage at R506. At present, the contribution of each of these two mechanisms to the final 
phenotype is not clear [71].  
Besides FV Leiden, several other naturally occurring mutations in FV have been 
found, which may be associated with APC-resistance or thrombotic risk. Some of these 
mutations affect the APC-cleavage site at position R306 [72,73], but are rare compared to 
FV Leiden. The most common of these mutations is the R306G mutation (FV Hong 
Kong), which is predominantly found in Asian populations [74,75]. Whether mutations at 
R306 are associated with an APC-resistant phenotype is not clear. APC-resistant tests with 
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plasma from patients carrying a mutation at R306 do not show consistent results 
[72,73,76].  
Besides mutations at the known APC-cleavage sites also two other mutations (R485K 
and I359T) in the heavy chain of FV have been reported to be associated with mild APC-
resistance [77,78,78]. The R485K mutation has been found in an Asian population and is 
associated with mild APC-resistance, an observation that has so far not been confirmed by 
other studies. On the contrary, two independent studies have found that the R485K 
mutation is not associated with APC-resistance or thrombotic risk [73,79]. The I359T 
mutation has very recently been found in two thrombophilic brothers from Liverpool (FV 
Liverpool) and introduces a novel glycosylation signal at N357 [78]. Indications have been 
obtained that the presence of a carbohydrate side-chain at N357 impairs the APC cleavages 
at R306 and R506 and the APC-cofactor function of FV in the degradation of FVIIIa, 
which may explain the mild APC-resistance and thrombotic tendency associated with this 
mutation [80]. 
A polymorphism (A4070G) in the B-domain of FV has also been associated with 
APC-resistance and risk of venous thrombosis. This polymorphism was first described in 
1996 and predicts a His to Arg substitution at residue 1299 [81]. A number of other 
polymorphisms in the FV gene are strongly linked to the H1299R mutation, which is also 
referred to as R2-haplotype. This haplotype is widely spread amongst the Caucasian 
population and non-Caucasians with allele frequencies ranging from 0.041 to 0.102 [82-
88]. The thrombogenic phenotype associated with the carriership of the R2-haplotype is 
still a matter of debate. It has, however, been suggested that the D2194G mutation, which 
is tightly linked to the R2-haplotype, affects the plasma ratio of FV1/FV2 in favour of the 
more thrombogenic FV1 isoform [89,90]. It seems more firmly established that carriership 
of the R2-FV gene in combination with the FV Leiden gene results in an increased APC-
resistant phenotype and increased risk of venous thrombosis [82,84,91]. Most likely, 
reduced expression of R2-FV is responsible for this enhanced thrombophilic phenotype (as 
will be explained below), although it also possible that R2-FV contains reduced APC-
cofactor activity in the degradation of FVIIIa. 
Carriership of a mutation in the FV gene causing quantitative FV deficiency may also 
contribute to APC-resistance and risk of venous thrombosis. Several studies have shown 
that compound heterozygosity for FV Leiden and FV deficiency results in an APC-
resistant phenotype comparable with the homozygous carriership of the FV Leiden gene 
[92,93]. This “pseudo-homozygous” FV Leiden phenotype is rare due to the low 
prevalence of mutations causing FV deficiency. More common is the combination of the 
FV Leiden allele with FV alleles that are associated with partial FV deficiency (i.e. 
decreased FV levels), which results in a shift towards FV Leiden. An example of such a 
common FV allele associated with partial FV deficiency is the aforementioned R2-FV 
allele. Another example might be the amino-acid substitution at residue 79 (D79H), which 
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has a high allele frequency (5-15%) and has also been associated with reduced FV levels 
[94,95].   
 
Scope of this thesis 
The discovery of the R506Q mutation in FV (FV Leiden) in 1994 resulted in a renewed 
interest in the structure and function of coagulation factor V. Studies have particularly 
been focussing on the regulation of FVa activity via the anticoagulant protein C pathway. 
Initial data about the function of FV were mainly obtained from experiments using FV 
purified from plasma. However, in this experimental set-up it is only possible to study 
normal FV and FV Leiden, whereas more specific information about the structure and 
function of FV can be obtained using recombinant proteins. Therefore, in this thesis 
recombinant FV mutants were generated, purified and studied to learn more about the 
structure and function of FV with a special focus on the proteolytic degradation of FVa by 
APC via cleavages at R306, R506 and R679.  
In chapter 2 the APC resistant phenotype was studied of plasma reconstituted with 
different APC cleavage site mutants of FV, amongst which the naturally occurring FV 
Hong-Kong and FV Cambridge. Subsequently, the structural and functional implications 
of the individual APC cleavages at R306, R506 and R679 were studied by analyzing the 
time courses of inactivation of activated FV mutants by APC. For this analysis inactivation 
curves were used from FVa mutants, in which two or three APC cleavage sites were 
mutated. Data from these experiments are presented in chapter 3.  
It has been suggested that the R2-haplotype of FV is associated with reduced plasma 
FV levels and with a mild APC-resistant phenotype. In chapter 4, we assessed whether the 
D2194G mutation, which is strongly linked to the R2-haplotype of FV, is a functional 
determinant for the expression of FV and the glycosylation of the asparagine at position 
2181. 
During the study of an asymptomatic FV deficient family, it was observed that in this 
family a FV variant was segregating that was not recognized by one of the monoclonal 
antibodies (V-23) used in a FV antigen assay (ELISA) developed in our laboratory. In 
chapter 5, we report that the common D79H mutation in the heavy chain of FV is 
responsible for the strong decrease in the affinity for mAb V-23. Furthermore, some 
functional implications of the D79H mutation were investigated, because it was recently 
reported that FV-79H is associated with lower FV levels and an increased APC-resistant 
phenotype (in combination with FV Leiden). For this reason we genotyped the cases and 
controls from a large population-based case-control study on risk factors for venous 
thrombosis (Leiden Thrombophilia Study) and determined the effect of the D79H mutation 
on FV levels, n-APC-SR and risk of thrombosis.  
Finally, in chapter 6 the findings presented in this thesis are summarized and 
discussed.   
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Summary 
Recently, new missense mutations in the APC cleavage sites of human Factor V (FV) 
distinct from the R506Q (FV Leiden) mutation have been reported. These mutations affect 
the APC cleavage site at arginine 306 in the heavy chain of activated FV (FVa). Whether 
these mutations result in APC resistance and are associated with a risk of thrombosis is not 
clear. The main objective of the present study was to identify the APC resistant phenotype 
of factor V molecules with different mutations in APC cleavage sites. To study this, 
recombinant FV mutants were reconstituted in FV-deficient plasma, after which 
normalized APC-sensitivity ratios (n-APC-SRs) were measured in APTT- and RVVT-
based APC-resistance tests. The mutations introduced in FV were: R306G, R306T, 
R506Q, R679A and combinations of these mutations. Based on the APC-sensitivity ratios, 
we conclude that the naturally occurring mutations at R306 (i.e. FV Hong-Kong and FV 
Cambridge) result in a mildly reduced sensitivity for APC (n-APC-SR 0.74-0.87), whereas 
much lower values (n-APC-SR 0.41-0.51) are obtained for the mutation at R506 (FV 
Leiden). No effect on the n-APC-SR was observed for the recombinant FV mutant 
containing the single A679 mutation.  
Because reduced sensitivity for APC, not due to FV Leiden, is a risk factor for venous 
thrombosis, these data suggest that mutations at R306 might be associated with a mild risk 
of venous thrombosis. 
 
Introduction 
The protein C pathway plays an important role in the regulation of blood coagulation. In 
this pathway activated protein C (APC) exerts anticoagulant activity via proteolytic 
degradation of the heavy chains of the activated coagulation cofactors Factor VIIIa 
(FVIIIa) and Factor Va (FVa) [1]. The heavy chains of both FVIIIa and FVa contain 
several APC cleavage sites. For human FVIIIa these APC cleavage sites have been 
localized at arginine 336 and 562 [2], whereas for human FVa APC cleavage sites have 
been identified at arginine 306, 506 and 679 [3].  
Theoretically, mutations in the APC cleavage sites of FVIIIa and FVa can result in a 
reduced sensitivity towards APC and thereby change the phenotype of plasma into an 
APC-resistant phenotype [4]. No naturally occurring mutations in the APC cleavage sites 
of human FVIII have been found so far, whereas several mutations have been reported in 
APC cleavage sites of human FV. The most important mutation is FV Leiden, in which 
arginine 506 has been replaced by a glutamine [5-7]. This mutation results in APC 
resistance and is associated with an increased risk of deep-vein thrombosis [5,8,9]. 
Moreover, the high allele frequency of FV Leiden (approximately 2% in Caucasian 
populations), makes this mutation the most important heritable risk factor for venous 
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thrombosis. Besides FV Leiden, three other mutations have been found in the APC 
cleavage sites of FV. All three affect the R306 position and are less frequent than FV 
Leiden [10-12]. The most common (allele frequencies from 0% to 4%) of these mutations 
is the R306G mutation (FV Hong-Kong), which has predominantly been found in Asian 
populations [11,13-15]. Whether the naturally occurring mutations at the R306 position 
result in APC resistance and are consequently associated with thrombotic risk is not clear. 
Studies using recombinant FV, however, have shown that the mutation R306Q may result 
in a mild APC resistant phenotype [16].  
APC resistance has been defined as a poor anticoagulant response of plasma to APC. 
There is, however, no uniform theory to explain the mechanism of APC resistance in 
plasma of carriers of the FV Leiden allele. So far, APC resistance has mainly been 
attributed to delayed inactivation of activated FV Leiden by APC. More recently, an 
additional mechanism has been proposed in which FV loses its APC-cofactor function in 
the degradation of FVIIIa when arginine 506 is replaced by glutamine [17-20]. The 
contribution of each of these two mechanisms to the final phenotype is not clear.  
The main objective in the present study was to identify the APC-resistant phenotype 
of different APC-cleavage site mutants of FV reconstituted in FV-deficient plasma. To 
study this, recombinant FV mutants were constructed and expressed in COS-1 cells and 
subsequently purified. After reconstitution of these FV mutants in FV-deficient plasma 
APC-sensitivity ratios were measured using both an activated partial thromboplastin time 
(APTT) based test, which specifically probes APC-mediated FVa inactivation and cofactor 
activity of FV in FVIIIa inactivation, and a Russell’s Viper Venom time (RVVT) based 
test, which specifically probes APC-mediated FVa inactivation.  
  
Materials and methods 
Materials  
Restriction enzymes were from New England Biolabs, Beverly, MA, USA. The rapid 
ligation kit and the BM Chemiluminescence blotting substrate (POD) were obtained from 
Boehringer Mannheim, Mannheim, Germany. Plasmid isolation kits were purchased from 
Qiagen, Chatsworth, CA, USA. DNA restriction fragments were purified from agarose gel 
using the cleanmix kit (Talent, Trieste, Italy). CNBr-Sepharose and SP-Sepharose were 
obtained from Pharmacia, Uppsala, Sweden. Neutralite Avidine-HRP conjugate was from 
Eurogentec, Seraing, Belgium. Bovine Serum Albumin (BSA), benzamidine, 
phosphatidylcholine (PC), N-hydroxysuccinimidobiotine and Hepes were from Sigma (St. 
Louis, MO, USA). Dioleoylphospatidylcholine (DOPC) and Dioleoylphospatidylserine 
(DOPS) were obtained from Avanti Polar Lipids, Alabaster, Al, USA. EDTA was from 
Serva, Heidelberg, Germany. NH4CL, TRIS and CaCl2 were purchased from Merck, 
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Whitehouse Station, NJ, USA. The chromogenic substrate Pefachrome TH was obtained 
from Pentapharm Ltd., Basel, Switzerland. Cephotest (APTT) was from Nycomed, Oslo, 
Norway. LA-confirm (DRVVT) was purchased from Gradipore, North Ryde, Australia. 
 
Proteins 
RVV-V, the factor V activator from Russells Viper Venom [21], was obtained from 
Pentapharm Ltd., Basel, Switzerland. Human factor Xa was from Haematologic 
Technologies Inc., Essex, VT, USA. Human activated protein C, prothrombin and the 
sheep anti-FV polyclonal antibody were purchased from Enzyme Research Laboratories 
(South Bend, IN, USA). Monoclonal antibody (mAb) 3B1 directed against the heavy chain 
of human FV was a kind gift from Prof. B.N. Bouma. Human FV (hFV) was isolated from 
human plasma according to Nicolaes et al. [22]. For the present study we have used a 
single fraction from the FV peak in the final purification step. This fraction contained 
about 80% FV1 (Table 2). FVa1 and FVa2 were purified according to Rosing et al. [23]. 
 
Mutagenesis 
The expression vector pMT2FV (kindly provided by Dr. R.J. Kaufman), containing the 
full-length cDNA of human FV, was used as a template to introduce mutations at the Arg 
306, 506 and 679 positions in the heavy chain of FV [24]. This vector (~12 kb) was 
digested with MfeI and religated to obtain a 7 kb vector (M-fragment) in order to facilitate 
mutagenesis. This M-fragment contained the cDNA of FV coding for the first 909 amino 
acids. Mutations were introduced in the M-fragment using the Transformer Site-Directed 
Mutagenesis Kit from Clontech Laboratories, Palo Alto, CA, USA. The forward mutagenic 
oligos used for construction of the Arg306Thr, Arg306Gly, Arg506Gln, Arg679Ala 
mutants were: 
5’-CTGCCCAAAGAAAACCACGAATCTAAAGAAAATAACTCG-3’ (Arg-306-Thr),  
5’-GCCCAAAGAAAACCGGGAATCTTAAGAAAATAACTCG-3’ (Arg-306-Gly),  
5’-GCAGATCCCTGGACAGACAAGGAATACAGAGGGCAG-3’ (Arg-506-Gln),  
5’-CTACAGTCATGGCTACAGCGAAAATGCACGATCGTTTAGAACCTG-3’ (Arg-679-Ala) 
The nucleotides responsible for the missense mutations are depicted in bold and 
underlined. The additional silent mutations that serve as a marker for the mutagenic primer 
are indicated in bold (no marker was introduced in the Arg306Gly mutagenic primer). 
After mutagenesis, the presence of the mutation was confirmed by direct DNA sequencing 
using the ABI PRISM BigDye Terminator Cycle Sequencing Kit (Perkin Elmer-Cetus, 
Norwalk, CT, USA). In total 8 mutants were constructed from these mutant M fragments 
by exchange of appropriate restriction enzyme fragments (Table 1). 
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Transient expression and purification of recombinant FV 
Recombinant FV (rFV) proteins were transiently expressed in COS-1 cells using the 
calcium phosphate precipitation transfection method [25]. Twenty-four hours after 
transfection cells were washed with phosphate-buffered saline (PBS) and incubated with 
serum-free medium (Optimem Glutamax, Life Technologies Ltd, Paisley, Scotland). The 
conditioned medium was harvested after 96 h, centrifuged at 1000 rpm and frozen at 
-20°C. FV expression was measured by functional FV assay and ELISA.  
Recombinant FV proteins were isolated in a two step procedure. First, conditioned 
medium was thawed, supplemented with 10 mM benzamidine and loaded on an ion 
exchange column (SP-Sepharose fast flow), which was subsequently washed with a buffer 
containing 25 mM Hepes, 100 mM NH4Cl, 5 mM CaCl2, 10 mM benzamidine (pH 7.5), 
until the fall-through was protein free. FV was eluted from the column with elution buffer 
(25 mM Hepes, 1.5 M NH4Cl, 5 mM CaCl2, 10 mM benzamidine, pH 7.5). FV containing 
fractions were supplemented with 2 mg/ml BSA, dialyzed against a buffer containing 25 
mM Hepes, 50 mM NaCl, 5 mM CaCl2, 10 mM benzamidine (pH 7.3), pooled and applied 
at a speed of 3 ml/h to an affinity column, consisting of 1 mg mAb-3B1/ml Sepharose. The 
column was washed with 25 mM Hepes, 50 mM NaCl, 5 mM CaCl2 (pH 7.3) and eluted 
with 25 mM Hepes, 1.8 M NaCl, 5 mM CaCl2, pH 7.3. Eluted fractions were screened for 
FV (activity/antigen) and analyzed by SDS-PAGE followed by silver staining or 
immunoblotting. FV containing fractions were supplemented with 2 mg/ml BSA, dialyzed 
against 25 mM Hepes, 50 mM NaCl (pH 7.3), and stored at –80°C.   
 
Factor V activity assay 
FV activity was measured in a two-step procedure using a modification of the assay 
described by Hoekema et al. [26]. In the first step FV was completely activated by RVV-V 
(15 U/ml) in HBS-Ca (25 mM Hepes, 175 mM NaCl, 3 mM CaCl2, 5 mg/ml BSA, pH 7.5) 
during a 20 min incubation at 37°C in a final volume of 150 µl. Subsequently, 10 µl was 
transferred to a 96 wells plate, 100 µl of prothrombinase mix (HBS-Ca containing FXa and 
DOPS/PC 10:90 molar ratio) was added and after five minutes the prothrombinase reaction 
was started by addition of 25 µl prothrombin (1.47 µM) in HBS-Ca. Final concentrations 
were: FXa (125 pM), prothrombin (280 nM) and DOPS/PC (50 µM). After a 4 min 
incubation at room temperature the reaction was stopped with 50 µl TN-EDTA (50 mM 
TRIS, 175 mM NaCl, 50 mM EDTA, 5 mg/ml BSA, pH 7.9). The amount of thrombin 
formed was measured by adding 25 µl Pefachrome TH (2.2mM) on a Spectra III Thermo 
microtiter plate reader from Tecan (Salzburg, Austria). The assay was calibrated using 
dilutions of pooled normal plasma (PNP) corresponding with 0-3 nM of FV.  
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FV1/FV2 assay    
The FV1/FV2 assay was performed essentially as described by Hoekema et al. [26]. For 
each sample the Xa cofactor activity of FVa was measured at two different conditions. At 
the first condition (DOPS/DOPC 20:80 and high FXa) FVa1 and FVa2 express the same 
cofactor activity (total FV) and at the second condition (DOPS/DOPC 2.5:97.5 and low 
FXa) the cofactor activity of FVa is mainly dependent on FVa2. Purified FVa1 and FVa2 
were used to calibrate the assay.  
 
FV antigen assay 
FV light chain antigen was detected in an ELISA using two different monoclonal 
antibodies directed against the light chain of FV as described before [27]. In this ELISA, 
mAb V-6 was used as a coating antibody and biotinylated mAb V-9 as tagging antibody. 
 
SDS-PAGE and immunoblot analysis 
Polyacrylamide gel electrophoresis was performed on 3-8% gradient SDS/PAGE under 
reducing conditions according to Laemmli [28]. Gels were silver stained or subjected to 
immunoblotting. Transfer to a PVDF membrane (Millipore Corporation, Bedford, MA, 
USA) was carried out semi-dry on a blot system from Pharmacia (Uppsala, Sweden). To 
detect FV, biotinylated polyclonal antibody (sheep anti-FV) was used. Neutralite Avidin-
HRP in combination with the blotting substrate POD was used to visualise the 
immobilized biotin.  
 
Reconstitution of rFV mutants and human FV in FV-deficient plasma 
Before reconstitution factor V activity of purified rFV and hFV fractions was measured in 
the FV activity assay. Subsequently, lyophilized FV-deficient plasma (Organon Teknika, 
Durham, NC, USA) was reconstituted with purified rFV or hFV and diluted with water till 
the volume recommended by the manufacturer. We aimed at a final FV activity of 0.2 
U/ml (~4 nM). The FV clotting activities in the reconstituted plasmas were checked using 
the APTT minus APC (see APTT-based APC-resistance test). Dilutions of PNP in FV 
deficient plasma were used as standards.  
 
APC resistance tests    
The APTT based APC-sensitivity ratio (APC-SR) was measured essentially as described 
by de Ronde et al. [29] with minor modifications. Plasmas were diluted 1:5 in FV-deficient 
plasma so that the FV concentration was the same as in the reconstituted plasmas (see 
above). The final APC concentration used in this test (53 nM) gave a 3-fold increase in the 
APTT of the reference plasma containing 0.2 U/ml hFV.   
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The RVVT based APC-SR was measured in a one step clotting assay. In this test 
prothrombinase is activated by activation of factor X with RVV-X. Briefly, the test was 
performed by incubating 50 µl plasma (normal plasma diluted 1:5 in FV-deficient plasma 
or FV-deficient plasma reconstituted with purified 0.2U/ml FV) with 100 µl of 
reconstituted LA-confirm reagent (plus or minus APC) at 37°C. The clotting time was 
measured on an ACL 300 (Instrumentation Laboratory, Milan, Italy). Clot formation was 
recorded for at least 300s using the research program. The final APC concentration used in 
this test (25 nM) gave a 3-fold increase of the RVVT of the plasma containing 0.2 U/ml 
hFV. All APC-sensitivity ratios were normalized by dividing them by the APC-SR of the 
reference plasma containing 0.2 U/ml hFV.  
Finally, it should be noted that both the APTT and RVVT are independent of the 
actual FV1/FV2 ratio, because in these assays high phospholipid concentrations are used.  
 
Results 
Expression and purification of recombinant factor V mutants 
In order to study the APC resistant phenotype of APC cleavage-site mutants of FV in 
plasma, different rFV mutants were constructed with mutations in one, two or three APC 
cleavage sites. In analogy to the naturally occurring FV Hong-Kong, FV Cambridge and 
FV Leiden a glycine or a threonine was introduced at the R306 cleavage site and a 
glutamine at the R506 position. At the R679 position a neutral amino acid was introduced 
by substituting the arginine by an alanine. Double and triple mutants were obtained by 
exchanging restriction enzyme fragments containing single mutations (Table 1).  
After transfection in COS-1 cells, conditioned media containing the rFV molecules 
were collected after 96h and frozen at -20ºC. Factor V expression levels (activity and 
antigen) of the wild type and the APC cleavage site mutants were similar and varied 
between 0.2 and 1 nM. After thawing and pooling of conditioned media, rFV proteins were 
purified by ion-exchange- and immunoaffinity-chromatography. 
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Table 1. Factor V molecules used in this study. The recombinant proteins were named after 
the amino acids present at the APC cleavage sites at the positions 306, 506 and 679 using the 
one letter code for amino acids. The mutated positions are bold and underlined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characterization of (r)FV preparations 
The purity of the isolated rFV fractions was checked by SDS-PAGE (Fig. 1). In all 
purified rFV preparations the 330 kD band, corresponding to the single-chain form of FV, 
was present. In addition, main bands of 220 kD and 140 kD were visible. Immunoblotting 
using a polyclonal anti-FV antibody gave identical patterns (Fig. 2), with the exception 
that the 220 kD band stained more intensively on the immunoblot. Figure 2 also shows that 
the isolation procedure does not affect the band pattern of recombinant FV-RQA and 
plasma factor V. The patterns shown for rFV-RQA are representative for the other 
recombinant FV molecules. SDS-PAGE patterns similar to those of Fig. 2 have been 
presented by others for plasma FV or recombinant FV [30-33]. Incubation of conditioned 
medium for more than 24h at 37ºC did not change the pattern of FV bands. Besides, there 
was no obvious relation between the SDS-PAGE pattern and the specific activity of the 
rFV preparations (compare Fig. 1 and Table 2). Hence, it is likely that these bands are not 
the products of proteolytic degradation, but correspond to proteins secreted from COS-1 
cells into the conditioned medium or in plasma. All bands were susceptible to thrombin 
cleavage, strongly suggesting that they are intermediate forms of FV. After thrombin 
cleavage a single heavy chain (~105 kD) and a single light chain (~71 kDa) could be 
distinguished (data not shown). 
 
Factor V Mutation Comments 
hFV No mutations 
 
FV isolated from human 
plasma 
rFV-wt No mutations “FV wild type” 
rFV-GRR R306G “FV Hong-Kong” 
rFV-TRR R306T “FV Cambridge” 
rFV-RQR R506Q “FV Leiden” 
rFV-RRA R679A Not found in vivo 
rFV-RQA R506Q, R679A R306 intact 
rFV-GRA R306G, R679A R506 intact 
rFV-GQR R306G, R506Q R679 intact 
rFV-GQA R306G, R506Q, R679A No APC cleavage sites left 
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The specific activities of the rFV proteins in conditioned media were similar to that of 
plasma FV. The activity/antigen ratio was approximately one for all recombinant FV 
proteins in the conditioned media, but was in general slightly lower after purification 
(Table 2). However, after reconstitution in FV deficient plasma FV activity/antigen ratios 
were partially restored, suggesting that part of the reduction in specific activity of the 
isolated preparations might be due to incomplete recovery of FV in the prothrombinase-
based assay. 
Figure 1. Purified recombinant Factor V mutants analyzed on a 
silver stained SDS-PAGE gel (3-10%). Fractions were prepared 
directly after the elution of the 3B1 column before addition of 
BSA. Each lane was loaded with approximately 0.2 µg of FV. 
Lane 1 to 9 contain respectively, rFV-GRR, rFV-TRR, rFV-RQR, 
rFV-RRA, rFV-GQR, rFV-RQA, rFV-GRA, rFV-GQA and hFV.   
 
 
330 kD - 
1       2       3        4        5       6       7        8       9 
140 kD -  
       
330 kD- 
140 kD -  
1 2 3 4
Figure 2. Immunoblot analysis of plasma factor V and recom-
binant factor V before and after purification. Samples were
separated on a 3-8% SDS-PAGE gel and detected with polyclonal
antibody against human FV. Each lane contained about 10 ng of FV.
Lane 1 to 4: normal plasma, FV isolated from human plasma, freshly
collected rFV-RQA in conditioned medium and isolated rFV-RQA. 
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Relative amounts of FV1 and FV2 present in used FV preparations 
Plasma contains two isoforms of FV (FV1 and FV2) [23]. The difference between these 
forms is thought to be due to partial glycosylation of the light chain [34,35]. As a result, 
the light chain is heterogeneous both in size and in affinity for negatively charged 
phospholipid vesicles. The dominant form in plasma is FV2, which is less glycosylated 
than FV1 and has a higher affinity for binding to negatively charged phospholipids.  
To identify which form of FV was expressed in COS-1 cells, FV1/FV2 assays were 
performed in the conditioned media containing different rFV mutants. After complete 
activation with thrombin the recombinant FV mutants resembled FVa2 with respect to its 
functional activity in prothrombin activation (Table 2). This observation was confirmed by 
Mono S column chromatography of conditioned medium containing activated rFV-wt: the 
activated rFV-wt eluted as a single peak at the same molarity (~700mM NH4Cl) as 
previously reported for FVa2 (data not shown) [23].  
 
Table 2. Characterization of normal plasma, plasma derived FV and rFV mutants used 
in this study before and after reconstitution in FV deficient plasma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Factor V 
 
Activity/ 
Antigen %FV2
 
n-ACP-SR 
(APTT-
based) 
n-APC-SR 
(RVVT-based) 
Normal plasma 1.00 62% 1.00 (0.02) 1.00 (0.06) 
hFV 0.90 20% 1.00 (0.06) 1.00 (0.06) 
rFV-wt 0.95 122% 1.09 (0.05) 0.97 (0.03) 
rFV-GRR 0.62 92% 0.76 (0.01) 0.84 (0.02) 
rFV-TRR 0.60 108% 0.74 (0.02) 0.79 (0.00) 
rFV-RQR 0.51 101% 0.44 (0.00) 0.43 (0.01) 
rFV-RRA 0.62 105% 1.10 (0.07) 1.15 (0.06) 
rFV-RQA 0.34 86% 0.27 (0.00) 0.36 (0.01) 
rFV-GRA 0.61 104% 0.69 (0.01) 0.79 (0.01) 
rFV-GQR 0.62 72% 0.27 (0.00) 0.37 (0.01) 
rFV-GQA 0.49 94% 0.31 (0.01) 0.38 (0.00) 
 
Activity and antigen levels were determined in purified fractions. The FV1/FV2 assay was 
performed in conditioned medium. The average results of two or three independent 
measurements are shown (average standard deviation 22.3%). All APC ratios were 
normalized against the ratio of FV-deficient plasma reconstituted with purified human FV 
(0.2 U/ml). Means and standard deviations of three independent tests (APTT and RVVT-
based) are shown. 
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Normalized APC-sensitivity ratios of recombinant factor V mutants reconstituted in FV-
deficient plasma 
After purification the recombinant APC cleavage site mutants of FV were reconstituted in 
FV-deficient plasma aiming at a final FV activity of 0.2 U/ml FV. Using an APTT based 
FV clotting assay we found that the mean FV clotting activity was 0.21 U/ml (range 0.07-
0.35 U/ml). In this range APC-SRs are virtually independent of the FV concentration [29]. 
The sensitivity of the FV mutants to APC was determined by measuring the n-APC-SR of 
the reconstituted plasmas in an APTT and a RVVT test in the presence and absence of 
APC.  
First, the range of n-APC-SRs in our experimental set up was determined by using 
plasma from heterozygous and homozygous FVL carriers diluted 1:5 in FV deficient 
plasma in both the APTT- and the RVVT-based APC resistance tests. After normalization 
against normal pooled plasma (1:5 diluted) homozygous FVL carriers showed very similar 
n-APC-SRs in both tests, 0.37 in the RVVT-based test and 0.39 in the APTT-based test. 
The n-APC-SR for heterozygous FVL plasma was slightly lower in the RVVT-based test 
(0.44) than in the APTT-based test (0.51). 
In Table 2 the n-APC-SRs are shown for plasmas containing the APC cleavage site 
mutants of factor V. The APC-sensitivity ratios were normalized against the sensitivity 
ratio of plasma containing 0.2 U/ml purified human factor V. The first observation is that 
the n-APC-SRs obtained by APTT and RVVT based tests are very similar. Further, the n-
APC-SR measured for plasma containing hFV is the same as that for plasma with rFV-wt, 
whereas rFV-RQR renders the reconstituted plasma almost completely resistant to APC. 
The two different mutations at the R306 position resulted in similarly mildly reduced n-
APC-SRs. The introduction of an alanine at the R679 position did not affect the sensitivity 
of rFV to APC in these tests.  
With the exception of the rFV-GRA mutant the double and triple mutants were 
completely resistant to APC (there was no prolongation of the clotting time after addition 
of APC) resulting in very low n-APC-SRs. The plasma containing rFV-GRA showed only 
mildly reduced n-APC-SRs, which were slightly lower than the n-APC-SR of plasmas 
containing rFV mutants with single mutations at the 306 position. 
 
The n-APC-SR of plasmas containing rFV-GRR, rFV-TRR or rFV-RQR mixed with plasma 
containing rFV-wt  
The plasmas used in the previous tests were all reconstituted with one type of rFV, thus 
resembling the homozygous state of the different mutations. Until now, homozygous 
carriers of the FV Hong-Kong or FV Cambridge have not been reported. Probably these 
are very rare considering the low prevalence of these mutations. Reconstituted plasmas 
containing rFV Hong-Kong or rFV Cambridge were mixed 1 to 1 with plasma containing 
APC-resistant phenotype of FV mutants 
 
 
41   
rFV-wt to simulate plasma of heterozygous carriers of these mutations. The n-APC-SRs of 
these plasmas are shown in Table 3. It is evident that the n-APC-SRs (~0.85) of the 
plasmas containing rFV-GRR or rFV-TRR combined with rFV-wt are only mildly 
reduced, whereas the n-APC-SR of the plasma containing rFV-RQR and rFV-wt is 
considerably reduced (0.51). 
 
Table 3. Normalized APC-sensitivity ratios of plasmas containing naturally occurring FV 
mutants mixed 1 to 1 with plasma containing rFV-wt simulating the heterozygous plasma 
state. All ratios were normalized against the ratio of FV-deficient plasma reconstituted with 
purified human FV (0.2 U/ml). 
 
Factor V APTT-based* RVVT-based* 
hFV 1.00 (0.11) 1.00 (0.11) 
rFV-GRR/rFV-wt 0.85 (0.01) 0.85 (0.03) 
rFV-TRR/rFV-wt 0.86 (0.02) 0.81 (0.03) 
rFV-RQR/rFV-wt 0.51 (0.01) 0.51 (0.01) 
 
* Mean (SD) of three different experiments. 
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Discussion   
Recently, three missense mutations in APC cleavage sites of human FV have been found 
distinct from the R506Q mutation [10-12]. All three mutations are located at the R306 
position and have predominantly been found in Asian populations. The most prevalent 
mutation is the R306G, for which allele frequencies have been reported as high as 4% 
[11,36]. However, the effect on the sensitivity to APC in carriers of these mutations has 
not yet been clearly defined. One objective in this study was to identify the APC resistant 
phenotype of these naturally occurring mutants by using recombinant FV mutants 
reconstituted in FV-deficient plasma at a concentration of ~0.2 U/ml. This concentration is 
commonly used in the so-called modified APC-resistance test [37]. In addition to mutants 
with naturally occurring mutations at position R306 also other APC cleavage site mutants 
of FV were screened with mutations at one, two or three APC cleavage sites. 
Characterization of the rFV molecules revealed that transfected COS-1 cells not only 
expressed single chain FV but also a number of FV related fragments, which could be 
visualized both by silver staining and immunoblotting. Very similar patterns were obtained 
after immunoblotting of human plasma, factor V isolated from human plasma, conditioned 
medium containing recombinant factor V and isolated recombinant FV (Fig. 2). No 
evidence was obtained that suggested that rFV was proteolytically degraded during 
purification. Most likely, the observed FV forms originate from partial intracellular 
processing of the B domain.  
After reconstitution at 0.2 U/ml (range 0.07-0.35 U/ml) in FV-deficient plasma the 
sensitivity to APC of rFV-wt was identical to that of FV purified from human plasma in 
both the APTT- and the RVVT-based APC-resistance test (Table 2). Under the same 
conditions rFV-RQR showed a strongly reduced n-APC-SR (~0.43), which is similar to the 
ratio obtained with plasma of a homozygous FV Leiden carrier after 5-fold dilution in FV-
deficient plasma. This observation demonstrated that rFV mutants reconstituted at a 
concentration of 0.2 U/ml in FV-deficient plasma provide a valid model to study the APC 
resistant phenotype of rFV mutants and is independent of the relative amount FV2 
reconstituted in plasma.  
Interestingly, n-APC-SRs were almost identical in the APTT and the RVVT tests. 
This suggests that the final APC resistant phenotype of FV mutants is equal in both the 
APTT and the RVVT regardless of any contribution of APC-cofactor function of FV in the 
degradation of FVIIIa. This may seem contradictory to other reports on the APC-cofactor 
activity of FV [18,38,39], but in these studies no clot-based experiments were performed. 
Alternatively, it could be that FV expresses APC-cofactor activity in the inactivation of 
FVa instead of FVIIIa. In theory, the contribution of this mechanism would be the same in 
both the APTT and the RVVT test.  
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In reconstituted plasmas no difference in APC-sensitivity was observed between 
plasmas containing rFV-R306G or rFV-R306T. Both plasmas showed a mildly reduced n-
APC-SR of about 0.80 in both tests (Table 2). When these plasmas were mixed 1 to 1 with 
plasma containing rFV-wt (representing the heterozygous state of these mutations) the n-
APC-SRs increased to approximately 0.85 (Table 3), which is still lower than the n-APC-
SR of plasma containing rFV-wt. The n-APC-SR of plasma containing rFV-RQR was 
much lower (circa 0.44), whereas the n-APC-SR of plasma containing rFV-wt and rFV-
RQR in 1:1 ratio was still strongly reduced (0.51). Introduction of G306 in rFV-RQR 
resulted in a further decrease of the n-APC-SR in both the APTT and the RVVT test (from 
0.44 to 0.27 and from 0.43 to 0.37, respectively). Together these data suggest that cleavage 
at position R506 is the most important step in the APC-mediated down regulation of clot 
formation. The role of the R306 cleavage seems to be minor. These observations indicate 
that models for APC-catalyzed inactivation of FVa, derived from experiments with 
purified human FV and FV Leiden, which show that inactivation of FVa proceeds via a 
rapid cleavage at R506 and is completed via a slower cleavage at R306, can be applied to 
plasma systems [16,22,40-42].  
The question whether mutations at the R306 would have an effect on the risk of 
venous thrombosis can not be answered yet. However, a mildly reduced sensitivity for 
APC, not caused by FV Leiden, has been demonstrated to be a risk factor for venous 
thrombosis [43]. Therefore we hypothesise that mutations at the R306 position in FV 
might also be associated with a moderate increase of the risk of venous thrombosis. Our 
data indicate that it might be informative to check for a mutation at the R306 position 
when patients show n-APC-SRs at or slightly below the limit of the ranges established for 
homozygous R506 or heterozygous Q506 carriers.   
No naturally occurring mutations in the APC cleavage site at R679 have been reported 
so far. Introducing a R679A mutation did not affect the APC resistant phenotype of FV, as 
was demonstrated by n-APC-SRs of 1.10 and 1.15 for plasma reconstituted with rFV-RRA 
(Table 2). Surprisingly, introduction of the 679A mutation in rFV-RQR resulted in a 
decrease of the n-APC-SR in both the APTT and the RVVT (from 0.44 to 0.27 and from 
0.43 to 0.36, respectively). This effect was not observed when the A679 mutation was 
introduced in rFV-GRR (compare n-APC-SRs of rFV-GRR with rFV-GRA). The reason 
for this difference is presently not known. Together the data show that in these clotting 
tests the role of cleavage at the R679 in the inactivation of FVa by APC is even smaller 
than the role of cleavage at the R306 site.  
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Summary 
Activated protein C (APC) exerts its anticoagulant activity via proteolytic degradation of 
the heavy chains of activated factor VIII (FVIIIa) and activated factor V (FVa). So far, 
three APC cleavage sites have been identified in the heavy chain of FVa: R306, R506 and 
R679. To obtain more insight in the structural and functional implications of each 
individual cleavage, recombinant factor V mutants were constructed in which two or three 
of the APC-cleavage sites were mutated. After expression in COS-1 cells, rFV mutants 
were purified, activated with thrombin and inactivated by APC. During this study we 
observed that activated rFV-GQA (rFVa-GQA) -in which the arginines at positions 306, 
506 and 679 were replaced by glycine, glutamine and alanine, respectively- was still 
inactivated by APC. Further analysis showed that the inactivation of rFVa-GQA by APC 
was phospholipid dependent and sensitive to an inhibitory monoclonal antibody against 
protein C. Inactivation proceeded via a rapid phase (kx1 = 5.4 x 104 M-1s-1) and a slow 
phase (kx2 = 3.2 x 103 M-1s-1). Analysis of the inactivation curves showed that the rapid 
phase yielded a reaction intermediate which retained ~80% of the original FVa activity, 
whereas the slow cleavage resulted in formation of a completely inactive reaction product. 
Inactivation of rFVa-GQA was accelerated by protein S, most likely via stimulation of the 
slow phase. Immunoblot analysis using a monoclonal antibody recognizing an epitope 
between R306 and R506 indicated that during the rapid phase of inactivation a fragment of 
80 kD was generated that resulted from cleavage at a residue very close to R506. The slow 
phase was associated with the formation of fragments resulting from cleavage at a residue 
1.5-2 kD carboxyterminal to R306. Our observations may explain the unexpectedly mild 
APC resistance associated with mutations at R306 (FV HongKong and FV Cambridge) in 
the heavy chain of FV. 
 
 
 
 
 
 
 
1Abbreviations used in chapter III 
APC, activated protein C; DOPS, dioleoylphospatidylserine; DOPC, dioleoylphospatidylcholine; FV, factor V;
FVa, activated factor V; rFV, recombinant FV, rFV∆B-GQA, recombinant factor V with a partial deletion of the 
B-domain containing the following mutations, R306G, R506Q, R679A; rFVa-GQA, activated rFV∆B-GQA; 
FXa, activated factor X; TN-EDTA, buffer containing 50 mM TRIS, 175 mM NaCl, 20 mM EDTA, 0.5 mg/ml
ovalbumin, pH 7.9. 
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Introduction 
Human blood coagulation factor V (FV)1 is the inactive precursor of activated factor V 
(FVa), the non-enzymatic cofactor of the serine protease factor Xa (FXa) . FVa is formed 
via limited proteolysis of its single-chain precursor FV (Mr ~330 kD) by thrombin. It 
consists of a heavy chain (Mr ~105 kD) and light chain (Mr 71-74 kD), which are held 
together via a Ca2+ ion. FVa is an essential part of the prothrombinase complex, which 
comprises FVa, FXa, calcium ions and a negatively charged membrane surface. In this 
complex FVa acts as a non-enzymatic cofactor that accelerates FXa-catalyzed prothrombin 
activation 103-105 fold [3-5].  
Proteolytic inactivation of FVa by activated protein C (APC) is an essential reaction in 
the anticoagulant protein C pathway [6], which is important in the regulation of thrombin 
formation and in the inhibition of acute inflammation triggered by coagulation [7]. 
Congenital deficiencies in this pathway are associated with thrombotic disease [8,9]. 
Inactivation of FVa activity by APC is associated with cleavage of three peptide bonds in 
the heavy chain of FVa, which have been localized at R306, R506 and R679 [10].  
Several mutations have been reported in the APC cleavage sites of human FV. The 
most important one is FV Leiden (FVL), in which arginine 506 has been replaced by 
glutamine [11-13]. This mutation results in the laboratory phenotype of APC resistance 
and is associated with an increased risk of deep-vein thrombosis [11,14,15]. The high 
allele frequency of FVL (2-7% in Caucasian populations [16]), makes this mutation the 
most important heritable risk factor for venous thrombosis. Besides FVL, three other 
mutations have been found in the APC cleavage sites of FV. All three affect the R306 
position and are much less frequent than FV Leiden [17-20]. There are no indications that 
the mutations at R306 are associated with an increased risk of venous thrombosis [18,21]. 
Moreover, the effect of these mutations on the sensitivity to APC is not entirely clear. 
Studies using recombinant FV have shown that mutations at R306 result in an 
unexpectedly mild APC resistant phenotype [22-24].  
Several studies have been performed to obtain more insight in the complex 
mechanism of APC-catalyzed FVa inactivation. These investigations demonstrated that 
cleavage of the heavy chain of FVa by APC is stimulated by negatively charged 
phospholipids [25-27] and protein S [27-29], which is a non-enzymatic cofactor of APC. 
In the presence of negatively charged phospholipids the inactivation of FVa by APC 
proceeds via a rapid and a slow phase, which are associated with cleavages at R506 and 
R306, respectively [10,30]. Cleavage at R506 yields a reaction intermediate with reduced 
FVa activity, which is completely inactivated by the subsequent cleavage at R306. 
Inactivation of activated FVL is monophasic and associated with cleavage at R306, which 
was stimulated ~20-fold by protein S [31]. In the presence of negatively charged 
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phospholipids the contribution of the cleavage at R679 to the inactivation of FVa seems to 
be minor and is difficult to assess [30].  
The original objective of the present study was to investigate the functional and 
structural implications of each individual APC cleavage in more detail. Recombinant 
factor V mutants were constructed in which a major part of the B-domain (rFV∆B) was 
removed and two or three of the APC-cleavage sites were mutated. After expression in 
COS-1 cells, rFV mutants were purified, activated with thrombin and inactivated by APC. 
Interestingly, rFVa-GQA (rFVa in which the arginines at positions 306, 506 and 679 were 
replaced by glycine, glutamine and alanine, respectively) was still inactivated by APC. In 
this paper we report on the mechanism of APC-catalyzed inactivation of rFVa -GQA. 
 
Experimental Procedures 
Materials  
Restriction enzymes were from New England Biolabs, Beverly, MA, USA. Rapid ligation 
kit and BM Chemiluminescence blotting substrate (POD) were obtained from Boehringer 
Mannheim, Mannheim, Germany. Plasmid isolation kits were purchased from Qiagen, 
Chatsworth, CA, USA. DNA restriction fragments were purified from agarose gel using 
the cleanmix kit (Talent, Trieste, Italy). CNBr-Sepharose and SP-Sepharose were obtained 
from Pharmacia, Uppsala, Sweden. Bovine serum albumin (BSA), 98% fatty free, was 
from ICN Biomedicals (Aurora, Ohio, USA). Ovalbumin, benzamidine, 
phosphatidylcholine (PC), N-hydroxysuccinimidobiotine and Hepes were from Sigma (St. 
Louis, MO, USA). Dioleoylphospatidylcholine (DOPC) and dioleoylphospatidylserine 
(DOPS) were obtained from Avanti Polar Lipids, Alabaster, Al, USA. EDTA was from 
Serva, Heidelberg, Germany. NH4Cl, TRIS and CaCl2 were purchased from Merck, 
Whitehouse Station, NJ, USA. Chromogenic substrate S-2238 was obtained from 
Chromogenix, Uppsala, Sweden. APMSF was from Roche Diagnostics, Mannheim, 
Germany. 
 
Proteins 
Human activated protein C (APC), protein S, prothrombin and thrombin were purchased 
from Enzyme Research Laboratories (South Bend, IN, USA). The APC concentration was 
determined from APC antigen and activity measurements. APC antigen was measured by 
ELISA using IgG fractions of rabbit anti–human protein C (DakoCytomation Denmark 
A/S, Glostrup, Denmark), whereas APC activity was measured with S2366 using the 
kinetic parameters reported by Sala et al. [32]. Human factor Xa, monoclonal antibodies 
AHV-5146 and AHV-5112 were from Haematologic Technologies Inc., Essex, VT, USA. 
Monoclonal antibody 3B1 directed against the heavy chain of human FV was a kind gift 
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from Prof. B.N. Bouma. Goat-anti-mouse IgG conjugated with horse-radish peroxidase 
(GAMPO) was from Bio-Rad Laboratories Inc., Hercules, CA, USA. NeutraliteTM Avidin-
HRP conjugate was from Southern Biotechnology Associated, Inc., Birmingham, AL, 
USA. Human FV Leiden (FVL) was isolated from human plasma according to Nicolaes et 
al. [30]. 
 
FV antigen assay 
FV light chain antigen was measured by ELISA using two different monoclonal antibodies 
directed against the light chain of FV [33]. In this ELISA, mAb V-6 was used as coating 
antibody and biotinylated mAb V-9 as tagging antibody.  
 
Mutagenesis 
In this study expression vectors (pMT2) were used containing the cDNA of FV in which 
two or three APC-cleavage sites were mutated [23,34]. In these mutants the arginines at 
position 306, 506 or 679 were replaced by glycine, glutamine and alanine, respectively 
(see Table 1). The vectors were used to construct FV expression vectors lacking a major 
part of the B-domain (deletion from amino acid 827 to 1499) as described before [35]. B-
domainless constructs, labelled pMT2FV∆B, were checked by direct DNA sequencing 
using the CEQ2000TM Dye Terminator Cycle Sequencing Kit from Beckman Coulter Inc., 
Fullerton, CA, USA.  
  
Transient expression and purification of rFV∆B mutants 
B-domainless recombinant FV (rFV∆B) mutants were transiently expressed in COS-1 cells 
(175 cm2 culture flasks) using Fugene 6 Transfection Reagent from Roche Molecular 
Biochemicals, Hague Road, IN, USA. Twenty-four hours after transfection cells were 
washed with phosphate-buffered saline (PBS) and incubated with serum-free medium 
(Optimem Glutamax, Life Technologies Ltd., Paisley, Scotland). Conditioned medium was 
harvested after 72h, centrifuged for 20 min at 3000 rpm (4°C) and frozen at -20°C. FV 
expression was measured by functional FV assay and ELISA.  
Recombinant FV∆B mutants were isolated in a two-step procedure essentially as 
previously described [35]. Briefly, conditioned medium was thawed, supplemented with 
10 mM benzamidine and loaded on an ion exchange column (SP-Sepharose fast flow), 
which was subsequently washed with 25 mM Hepes, 100 mM NH4Cl, 5 mM CaCl2, 10 
mM benzamidine (pH 7.5), until the fall-through was protein free. Recombinant FV∆B 
was eluted from the column with 25 mM Hepes, 1.5 M NH4Cl, 5 mM CaCl2, 10 mM 
benzamidine, pH 7.5. Fractions containing FVa activity were supplemented with 2 mg/ml 
ovalbumine, dialyzed against a buffer containing 25 mM Hepes, 50 mM NaCl, 5 mM 
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CaCl2, 10 mM benzamidine (pH 7.3), pooled and applied at a speed of 3 ml/h to an affinity 
column, consisting of 1 mg mAb-3B1/ml Sepharose. The column was washed with 25 mM 
Hepes, 50 mM NaCl, 5 mM CaCl2 (pH 7.3) and eluted with 25 mM Hepes, 1.8 M NaCl, 5 
mM CaCl2, pH 7.3. Eluted fractions were screened for FV (activity/antigen) and analyzed 
by SDS-PAGE and immunoblotting. FV containing fractions were supplemented with 2 
mg/ml ovalbumin, dialyzed against 25 mM Hepes, 50 mM NaCl (pH 7.3), and stored at –
80°C.   
 
Factor Va activity assay 
FVa activity was measured in a two step procedure as previously described [35]. This 
assay was calibrated using dilutions of pooled normal plasma corresponding with 0-3 pM 
of FV. 
 
Inactivation of FVa by APC 
FVa (~1nM) was incubated with APC (see legends) in 25 mM Hepes (pH 7.5), 175 mM 
NaCl, 3 mM CaCl2, 5 mg/ml BSA, 24.5 µM phospholipids (DOPS:DOPC 10:90). At 
different time intervals 10 µl samples were transferred to 240 µl of prothrombinase mix 
(containing 25 mM Hepes (pH 7.5), 175 mM NaCl, 3 mM CaCl2, 0.5 mg/ml ovalbumin, 
FXa, prothrombin and DOPS/DOPC 10:90 molar ratio) yielding final concentrations of 5 
nM FXa, 540 nM prothrombin and 50 µM DOPS/DOPC vesicles. After 3 min incubation 
at 37°C prothrombin activation was stopped by subsampling 40 µl in 460 µl TN-EDTA 
(50 mM TRIS, 175 mM NaCl, 20 mM EDTA, 0.5 mg/ml ovalbumin, pH 7.9). 
Subsequently, 200 µl of this mix were transferred to a 96-wells plate and 25 µl of 
chromogenic substrate S-2238 (2.35 mM) was added, after which the amount of thrombin 
formed was measured kinetically on a Spectra III Thermo microtiter plate reader from 
Tecan (Salzburg, Austria). Under these conditions the formation of thrombin was linearly 
dependent on the FVa concentration present in the prothrombinase mixture. The FVa 
activity measured before the addition of APC (t=0) was set at 100%.  
 
Curve fitting of time courses of FVa inactivation 
Time courses of APC-catalyzed FVa inactivation were obtained by measuring loss of FVa 
activity as a function of time. Data reported in this paper indicate that inactivation of the 
activated rFV∆B-GQA mutant by APC proceeds via two pathways: 
ViVaVa kB
k →→ 21    (1) 
ViVa k→ 3     (2) 
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This model is similar to the inactivation of plasma FVa via cleavages at R506 and R306 
[30]. k1, k2 and k3 are pseudo first-order rate constants for cleavage at the as yet unidentified 
cleavage sites Rx1 and Rx2. 
Under first order conditions, i.e. conditions at which the inactivation rate is directly 
proportional to the factor Va and APC concentration, the loss of FVa cofactor activity is 
described by the following equation [30]: 
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In this equation Vat is the FVa activity at time t, Va0 is the FVa activity at time zero, B is 
the activity of the FVa intermediate generated after cleavage at Rx1. k1, k2 and k3 are the 
observed pseudo first-order rate constants, from which the second-order rate constants 
were calculated as follows: kx1= k1/[APC], kx2= (k2-k’s)/[APC] and k’x2= (k3-ks) /[APC], in 
which k’s and ks are the first-order rate constants of spontaneous inactivation of the FVa 
intermediate (FVaB) and intact FVa, respectively. 
  
SDS-PAGE and immunoblot analysis 
Polyacrylamide gel electrophoresis was performed on SDS/PAGE (TRIS/HCl prefab gels, 
Gradipore, French Forest, Australia) under reducing conditions according to Laemmli [36]. 
Protein transfer to PVDF membranes (Millipore Corporation, Bedford, MA, USA) was 
carried out semi-dry on a blot system from Pharmacia (Uppsala, Sweden). To detect FV, 
murine monoclonal antibodies against the heavy and light chain (AHV-5146 and AHV-
5112, respectively) were used. GAMPO in combination with the blotting substrate POD 
was used to visualise the immobilized antibodies. Both antibodies were checked for any 
cross-reaction with BSA present in the FV fractions and were found negative. 
Visualization with AHV5146 was optimized to detect low molecular degradation 
fragments from the heavy chain. Due to the high sensitivity of this procedure small 
amounts of intact heavy chains still show significant staining (see also reference [37]).  
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Figure 1. Schematic representation of fragments generated during APC-mediated 
proteolysis of the heavy chain of activated rFV∆B mutants with a single APC cleavage site. 
Three rFV∆B double mutants were prepared for this study in each of which only one APC-
cleavage site was left. Based on previous reports APC-mediated cleavage should generate 
fragments with molecular weights as indicated [10,30].    
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Results 
Expression and purification of recombinant factor V mutants 
Recombinant FV∆B mutants were constructed with mutations either in two or in three of 
the known APC cleavage sites (R306, R506, R679). In analogy to the naturally occurring 
FV HongKong (R306G) and FV Leiden (R506Q) mutations R306 was replaced by glycine 
and R506 by glutamine, whereas R679 was replaced by alanine (Table 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After transfection of COS-1 cells, conditioned media containing the rFV∆B molecules 
were collected, centrifuged and stored at -20ºC. Factor V expression levels (activity and 
antigen) of rFV∆B-wt and its mutants were similar and ranged (depending on the 
transfection efficiency) between 0.2 and 4 nM. After thawing and pooling of conditioned 
media, rFV∆B proteins were purified by ion-exchange- and immunoaffinity-
chromatography. The rFV∆B mutants were activated with thrombin and analyzed by SDS-
PAGE followed by silverstaining or immunoblotting. Both detection methods showed two 
dominant bands with a MW of 105 kD and 71 kD, which corresponded to the expected 
MW of the heavy and light chain of factor Va, respectively (data not shown). Apart from 
these two bands also variable amounts of 90 kD fragment were observed, which was most 
likely the result of thrombin cleavage at R643 [38]. The specific activities 
(activity/antigen) of the purified rFV mutants were slightly lower than in conditioned 
medium, being around 0.7.  
 
Table 1. Factor V molecules used in this study. Recombinant proteins were named after the 
amino acids present at the APC cleavage sites at positions 306, 506 and 679 using the one letter 
code for amino acids. The symbol ∆B indicates that a major part of the B-domain (∆ 827-1499) is 
lacking. Mutated positions are bold and underlined.  
 
 
Factor V 
 
Mutation Comments 
hFV Leiden R506Q FV isolated from homozygous FV Leiden carrier 
rFV∆B-wt No mutations “wild type FV” 
 rFV∆B-RQA R506Q, R679A R306 intact 
rFV∆B-GRA R306G, R679A R506 intact 
rFV∆B-GQR R306G, R506Q R679 intact 
rFV∆B-GQA R306G, R506Q, R679A No APC cleavage sites left 
Chapter IIIa 
 
 
 
 60 
Stability of activated rFV∆B mutants 
Recombinant FV∆B proteins were activated with 9 nM thrombin for 20 min at 37°C and 
incubated in the absence or presence of phospholipids. The stability of the activated 
rFV∆B mutants was assessed by following the loss of FVa activity as a function of time in 
a reaction mixture that did not contain APC. The first-order rate constants for spontaneous 
inactivation of activated rFV∆B-wt and the activated rFV∆B mutants were approximately 
similar, being around ~3.0 x 10-5 s-1, which corresponds to a spontaneous loss of FVa 
activity of ~0.2% per min. The presence of phospholipids did not influence the stability of 
the activated rFV molecules.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APC-catalyzed inactivation of activated rFV∆B-GQA   
Preliminary experiments showed that apart from the activated rFV∆B double mutants 
(rFV∆B-RQA, rFV∆B-GRA, rFV∆B-GQR) also the activated triple mutant rFVa-GQA 
was inactivated by APC and that this inactivation was strongly dependent on the presence 
of negatively charged phospholipids (Fig. 2). In the absence of phospholipids inactivation 
of rFVa-GQA by 20 nM APC was only slightly faster than the spontaneous loss of activity. 
Preincubation of APC with a monoclonal antibody against protein C (C12), which 
blocks the active site of APC, or with APMSF (a non-specific inhibitor of serine 
proteases), inhibited the activation of rFVa-GQA by APC, whereas preincubation with a 
monoclonal antibody against protein S (S18) did not affect the rate of inactivation (Table 
3). This indicates that the loss of FVa activity observed in the presence of APC and 
phospholipids (Fig. 2) was indeed mediated by APC and not a contaminating protease.  
Table 2. Stability of activated rFV∆B mutants in the absence or presence of phospholipids. 
Spontaneous inactivation rates (ks) were obtained by fitting time courses (30 hours) of rFVa 
inactivation with a single exponential. Incubation conditions were similar to those for FVa 
inactivation in the presence of APC (~1 nM FVa in 25 mM Hepes (pH 7.5), 175 mM NaCl, 3 
mM CaCl2, 5 mg/ml BSA +/- 24.5 µM phospholipids (10:90 DOPS:DOPC) at 37°C). 
 
   
Activated Factor V 
 
ks (s-1) 
+ phospholipids 
ks (s-1) 
- phospholipids 
rFV∆B-wt 3.3 x 10-5 3.7 x 10-5 
rFV∆B-RQA 5.4 x 10-5 6.4 x 10-5 
rFV∆B-GRA 2.9 x 10-5 3.3 x 10-5 
rFV∆B-GQR 3.1 x 10-5 2.6 x 10-5 
rFV∆B-GQA 3.8 x 10-5 4.6 x 10-5 
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Figure 2. Effect of phospholipids on the inactivation of activated rFV∆B-GQA by 
APC.  1 nM of activated rFV∆B-GQA was incubated with 20 nM APC in the presence 
(●) or in the absence () of 24.5 µM phospholipid vesicles (DOPS/DOPC, 10/90) in 25 
mM Hepes (pH 7.5), 175 mM NaCl, 3 mM CaCl2 and 5 mg/ml BSA at 37°C. At the 
indicated time points FVa activity was measured as described in “Experimental 
Procedures”. In the presence of phospholipids vesicles the activated rFV∆B-GQA was 
also incubated without APC (▲) to determine spontaneous inactivation under these 
conditions. 
Table 3. Effect of APC inhibitor C12 on APC-catalyzed loss of FVa activity of activated 
rFV∆B-GQA. Activated rFV∆B-GQA was incubated for 180 min at 37°C in 25 mM Hepes 
(pH 7.5), 175 mM NaCl, 3 mM CaCl2, 5 mg/ml BSA with 20 nM APC, which had been 
preincubated with anti-protein C antibody C12 (~60 µg/ml), anti-protein S antibody S18 (~60 
µg/ml) or APMSF (80µM). The remaining FVa activity is shown. 
 
  
Condition 
 
-APC1 + APC + APC/  C12 
+ APC/ 
S18 
+ APC/ 
APMSF 
FVa activity 
(%) 100 32 75 34 81 
 
1Residual FVa activity determined after 180 min in the absence of APC was set at 100% 
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Inactivation of activated rFV∆B-GQA with increasing APC concentrations 
The results presented above indicate that the inactivation of rFVa-GQA by APC results 
from one or more proteolytic cleavages at as yet unidentified cleavage sites. To learn more 
about the mechanism of inactivation, rFVa-GQA was incubated with increasing 
concentrations of APC under pseudo-first order conditions. Increasing the APC 
concentration resulted in an acceleration of FVa inactivation (Fig. 3a). The FVa 
inactivation curves could not be fitted with a single exponential (data not shown), 
indicating that inactivation involves at least two different reactions, a rapid reaction 
resulting in a partially active FVa molecule that is subsequently completely inactivated via 
a slow reaction. Since the rate constant for the second reaction was much lower than that 
for the first reaction, it was possible to calculate the pseudo-first order rate constant (k2) for 
the second reaction and the activity of the FVa intermediate (FVaB) from semi-logarithmic 
plots (Fig. 3b). The slope of the lines yields k2 at different APC concentrations and the 
intercept at the y-axis yields an estimate for the FVa activity remaining in the intermediate 
(FVaB), which was found to be ~80%. Fig. 3c shows that the pseudo-first order rate 
constant k2 obtained for the second, slow reaction is a linear function of the APC 
concentration, which enabled calculation of the second-order rate constant (kx2 = 3.2 x 103 
M-1s-1) for the second cleavage reaction. The line extrapolated to a rate constant of 5.6 x 
10-5 s-1 at [APC] = 0 (intercept of the line with the y-axis), which most likely reflects the 
spontaneous loss of activity of the reaction intermediate FVaB (represented as k’s). This 
rate constant is close to that determined for native rFVa (ks ~3.0 x 10-5 s-1).   
The time courses of inactivation of rFVa-GQA by APC (Fig. 3a) were further 
analyzed in a random ordered two-step model (Equation 3 in Experimental Procedures), in 
which rFVa-GQA is rapidly cleaved by APC resulting in an intermediate (FVaB) with 
slightly lower FVa activity, while a much slower cleavage in FVa and FVaB results in the 
formation of a FVa derivate that is completely inactive. This model is similar to that 
proposed by Nicolaes et al. [30] for the inactivation of plasma FVa via cleavages at R506 
(fast reaction) and R306 (slow reaction). Using the pseudo-first order rate constants (k2) 
and B calculated from Fig. 3b and 3c, the pseudo-first order rate constants k1 and k3 were 
calculated by fitting the experimental data (Fig. 3a) to Equation 3. Like k2, also k1 and k3 
increased with higher APC concentrations (Fig. 3d and 3e), which indicates that the rapid 
and slow inactivation phases both are associated with APC-mediated cleavages at two as 
yet unidentified cleavage sites, designated Rx1 (kx1) and Rx2 (kx2, k’x2). From these plots 
the second-order rate constants were calculated (see Experimental Methods). The second-
order rate constant of the first reaction (kx1 = 5.4 x 104 M-1s-1) appeared to be ~20-fold 
higher than that of the second reaction (compare with kx2 and k’x2 in Table 4). These rate 
constants are much lower than those reported for APC-catalyzed cleavage at R306 (k306 = 
2.3 x 106 M-1s-1) and R506 (k506 = 4.3 x 107 M-1s-1) [30].  
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Figure 3. Inactivation of activated rFV∆B-GQA with different APC concentrations. Activated
rFV∆B-GQA (1 nM) was incubated with 0 nM (x), 20 nM (), 40 nM (♦), 60 nM (▲) or 80 nM
(●) APC in the presence of 24.5 µM phospholipid vesicles (DOPS/DOPC, 10/90) in 25 mM Hepes
(pH 7.5), 175 mM NaCl, 3 mM CaCl2 and 5 mg/ml BSA at 37°C. At the indicated time intervals
FVa activity was measured as described in “Experimental Procedures”. Data are presented as
means +/- SD. The solid lines in Fig 3a represent exponential curves obtained by fitting the data to
equation 3 (using k2 and B obtained from Fig. 3b) with nonlinear least-squares regression of the
data. The pseudo first-order rate constants of the second slow phase (k2) and the activity of the
reaction intermediate (B) were estimated from the plots in Fig 3b. The slope of the lines from 90 to
180 min represents k2, while the intercept of these lines with the Y-axis represents the activity of
the reaction intermediate (B). In Fig. 3c the pseudo first-order rate constants of k2 (s-1) have been
plotted versus the APC concentration. The slope of this line corresponds to the second-order rate
constant kx2. The pseudo first-order rate constants for k1 (s-1) and k3 (s-1) were obtained by fitting
the experimental data to equation 3, in which k2 (s-1) and B were fixed. In Fig. 3d the pseudo first-
order rate constants of k1 (s-1) have been plotted versus the APC concentration. From the slope of
this line the second-order rate constant kx1 was determined. In Fig. 3e the pseudo first-order rate
constants of k3 (s-1) have been plotted versus the APC concentration. The slope of this line
represents the second-order rate constant k’x2. 
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Effect of protein S on the APC-catalyzed inactivation of activated rFV∆B-GQA 
Previous studies have shown that in the presence of saturating concentrations of protein S 
(490 nM) the inactivation of FVa by APC is accelerated by selective stimulation of the 
cleavage at R306 [31]. The inactivation of rFVa-GQA by APC was also strongly 
stimulated in the presence of 490 nM protein S (Fig. 4). The time course of inactivation of 
rFVa-GQA by APC in the presence of protein S suggests that the acceleration of FVa 
inactivation was mainly due to an increased rate of the slow cleavage reaction (cleavage at 
Rx2). Acceleration of the rapid reaction (cleavage at Rx1) will hardly contribute to the 
final inactivation curve, because the intermediate formed after cleavage at Rx1 (FVaB) still 
has a high FVa activity. Assuming that kx1 (5.4 x 104 M-1s-1) and B (0.82) were not affected 
by the addition of protein S, k2 and k3 were determined by fitting the data to equation 3 
(Table 4). The second-order rate constant k’x2 (calculated from k3) was ~1.5 x 105 M-1s-1, 
which indicates that protein S stimulates the APC-catalyzed cleavage at Rx2 about 50-fold.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Second-order rate constants for inactivation of activated rFV∆B-GQA by 
APC via peptide bond cleavages at unidentified cleavage sites (Rx1 and Rx2). The 
second-order rate constants (M-1s-1) in the absence of protein S were calculated from the 
slopes of the plots of the pseudo first-order rate constants versus the APC concentrations 
(Fig. 3c,d,e). The second-order rate constants in the presence of protein S were measured 
at a single APC concentration of 20 nM. The pseudo-first order rate constants k2 and k3 
were determined by fitting the data to equation 3 (Fig. 4), assuming that kx1 (5.4 x 104 M-
1s-1) and B (0.82) were not affected by the presence of protein S (see text). The second-
order rate constants kx2 and k’x2 were calculated from the pseudo first-order rate constants 
as described under Experimental Procedures). 
 
Rate constants - protein S + protein S 
kx1 (M-1s-1) 5.4 x 104 5.4 x 104 
kx2 (M-1s-1) 3.2 x 103 8.1 x 104 
k’x2 (M-1s-1) 2.6 x 103 1.5 x 105 
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SDS-PAGE analysis of APC-catalyzed inactivation of activated rFV∆B-GQA 
APC-mediated proteolysis of the heavy and light chain of rFVa-GQA was monitored by 
SDS-PAGE and immunoblotting. In this procedure, heavy chain fragments were detected 
by monoclonal antibody AHV-5146, which recognizes an epitope between R306 and 
R506. Experiments with synthetic peptides identified the epitope for AHV-5146 between 
residues 427 and 440 (unpublished results). FVa light chains were detected by mAb AHV-
5112. During the inactivation of rFVa-GQA with 20 nM APC no degradation of the light 
chain was observed (data not shown). Analysis of the heavy chain, however, revealed the 
generation of several fragments, which could be associated with the loss of FVa activity 
(Fig. 5). The initial phase of inactivation (0-30 min) was associated with generation of a 
fragment of ~80 kD, whereas the second slow phase was associated with the generation of 
a doublet of 55/60 kD and fragments of 45 kD and 30 kD (Fig 5). Note that besides the 
heavy chain fragment of 105 kD (intact heavy chain from position 1 to 709) also a 
fragment of ~90 kD was detected, which was already present before addition of APC. 
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Figure 4. Effect of protein S on the APC-catalyzed inactivation of activated rFV∆B-
GQA. 1 nM of activated rFV∆B-GQA was incubated at 37°C with 20 nM APC in the
absence () or in the presence (●) of 490 nM protein S (in 25 mM Hepes (pH 7.5), 175 mM
NaCl, 3 mM CaCl2, 5 mg/ml BSA and 24.5 µM phospholipid vesicles, DOPS/DOPC, 10/90).
At indicated time points FVa activity was measured as described in “Experimental
Procedures”. Data are presented as means +/- SD. The fitted curves (solid lines) were
obtained after fitting the data with equation 1 using non-linear least-squares regression.  
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Most likely, this fragment was formed during the activation with thrombin, which can 
cleave the heavy chain of FVa at R643 [38].  
In the presence of protein S the loss of FVa activity was essentially associated with the 
generation of a 60 kD fragment (Fig. 5c). After 15 min also 45 kD and faint 30 kD 
fragments were generated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     A 
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Localization of potential APC cleavage sites in rFV∆B-GQA 
The experimental data and the amino acid sequence of FV were used to localize potential 
APC-cleavage sites in the heavy chain of rFVa-GQA. The rapid cleavage at Rx1 in the 
absence of protein S was associated with formation of a 80 kD fragment (Fig. 5a/b), which 
still contained ~80% FVa activity. Such a fragment may result from a cleavage in a region 
150-200 amino acids from either the N- or the C-terminus of the heavy chain. Since the N-
terminal region (residue 150 to 200) contains no arginines and only a few lysines, whereas 
the region between residues 499 and 513 contains a surface-exposed loop with several 
arginines and lysines [39], it is likely that Rx1 is positioned in the region surrounding 
Q506. Cleavage in this region will result in the formation of a 80 kD fragment from both 
the 105 kD and 90 kD heavy chains and is also compatible with the high activity of the 
intermediate (FVaB~80%) after cleavage at Rx1. Consequently, the slow cleavage (Rx2), 
    C 
 
Figure 5. Immunoblot analysis of APC-catalyzed inactivation of activated rFV∆B-
GQA. 1 nM of activated rFV∆B-GQA was incubated at 37°C in an inactivation mixture
containing 20 nM APC and 24.5 µM phospholipid vesicles (DOPS/DOPC, 10/90) in 25
mM Hepes (pH 7.5), 175 mM NaCl, 3 mM CaCl2 and 5 mg/ml BSA. At indicated time
points samples were drawn from the inactivation mixture and subjected to 8% (Fig. 5a)
and 4-15% (Fig. 5b) SDS-PAGE under reducing conditions followed by immunoblot
analysis. Fragments from the heavy chain were visualized with mAb AHV-5146 (epitope
between R306 and R506). The same procedure was also performed in the presence of 490
nM protein S, after which the samples were subjected to 8% SDS/PAGE and immunoblot
analysis (Fig. 5c).    
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which results in complete inactivation, should be positioned in the region of G306. This 
would explain the generation of the observed 60 kD fragment (cleavage in the intact heavy 
chain of 105 kD) and the 30 kD fragment (cleavage in the intermediate fragment of 80 
kD). A cleavage near position 306 can also explain the generation of a 45 kD fragment 
(cleavage in heavy chain fragment of 90 kD), which has been described before [38]. 
Furthermore, a location of Rx2 close to R306 is compatible with the stimulation of k’x2 by 
protein S (formation of 60 kD fragment in Fig. 5c), because cleavage at R306 is also 
stimulated by protein S [31]. 
More information about the position of Rx1 and Rx2 was obtained from experiments 
in which the activated double mutants rFV∆B-GRA (R506 present) and rFV∆B-RQA 
(R306 present) were incubated with APC. Inactivation of activated rFV∆B-GRA with APC 
(20 nM) generated an expected fragment of 75 kD (1-506), which was gradually cleaved 
into a 30 kD fragment (data not shown), suggesting that in the region of G306 indeed 
another APC cleavage site (Rx2) is present. The generation of this 30 kD fragment was 
strongly accelerated in the presence of protein S (Fig. 6a). Inactivation of activated 
rFV∆B-RQA with 20 nM APC generated fragments with the expected sizes of 60 kD (307-
709) and 45 kD (307-643), which were both accelerated in the presence of protein S (Fig. 
6b). These fragments were no longer susceptible to APC cleavage in the Q506 region, 
which may be due to dissociation of the 307-643 and the 307-709 fragments after cleavage 
at R306 [40].  
Finally, the position of Rx2 could be estimated more precisely by comparing the 
mobility of the 30 kD fragments, which are the final products formed after inactivation of 
activated rFV∆B-wt, rFV∆B-GRA and rFV∆B-GQA by APC (Fig. 7). The final fragment 
generated during the inactivation of rFV∆B-wt has an expected MW of 30 kD, 
corresponding to fragment 307-506. The fragment generated from the inactivation of 
activated rFV∆B-GRA, most likely corresponding to position Rx2-506, was about 28 kD 
suggesting that the position of Rx2 is about 10-20 amino acids carboxy-terminal to residue 
306. Consequently, the position of Rx1 should be very close to residue 506, because the 
final product in the inactivation of rFV∆B-GQA (Rx2-Rx1) also has a MW of 28 kD. 
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 Figure 6. Immunoblot analysis of APC-catalyzed inactivation of activated rFV∆B-GRA
and rFV∆B-RQA in the presence of protein S. 1 nM of activated rFV∆B-GRA (Fig. 6a)
was incubated at 37°C in an inactivation mixture containing 20 nM APC, 490 nM protein S
and 24.5 µM phospholipid vesicles (DOPS/DOPC, 10/90) in 25 mM Hepes (pH 7.5), 175
mM NaCl, 3 mM CaCl2 and 5 mg/ml BSA. 1 nM of rFV∆B-RQA (Fig. 6b) was incubated
using the same conditions with 6 nM APC. At indicated time points samples were drawn
from the inactivation mixture and subjected to 4-15% SDS-PAGE under reducing conditions
followed by immunoblot analysis. Fragments from the heavy chain were visualized with
mAb AHV-5146 (epitope between R306 and R506). In the blot of rFV∆B-GRA (Fig. 6a) a
small band with a MW around 50 kD was observed, which appeared to be present in all time
samples. Most likely, purified samples of this FV mutant were enriched with some IgG
during the purification procedure, which could also be stained.          
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Cleavage of Rx1 in activated FV Leiden 
Theoretically, cleavage at Rx1 (located in the region of residue 506) may serve as an 
alternative for a cleavage at R506. To check this, purified plasma FV Leiden was activated 
and inactivated using the same conditions as for the rFV∆B mutants and subsequently 
subjected to analysis by SDS-PAGE and immunoblotting (Fig. 8). The immunoblot 
showed a very similar cleavage pattern as observed for the activated rFV∆B-RQA mutant 
starting with a heavy chain doublet of 105 kD and 90 kD. Initially a 50/60 kD doublet was 
generated, which was most likely the result of cleavage at R306 in the 1-679 and 1-709 
fragments. Also a fragment of 45 kD was generated, which was probably produced by 
cleavage of the 90 kD fragment resulting in a fragment from residue 307 to 643. The 
fragments were not further cleaved at Rx1, analogous to what was observed during 
inactivation of activated rFV∆B-RQA. This might be the result of dissociation of the 
domain carboxy-terminal to R306 (A2 domain).  
 
 Figure 7. Comparison of 30 kD fragments generated during the APC-catalyzed 
inactivation of activated rFV∆B-GQA, rFV∆B-wt and rFV∆B-GRA. The sample 
containing rFVa-GQA was the same as used in Fig. 5b (T = 90 min). The sample containing
activated rFV∆B-wt was drawn after 30 min from an inactivation mixture containing 1 nM
rFV∆B-wt, 0.15 nM APC, 490 nM protein S and 24.5 µM phospholipid vesicles
(DOPS/DOPC, 10/90) in 25 mM Hepes (pH 7.5), 175 mM NaCl, 3 mM CaCl2 and 5 mg/ml 
BSA at 37°C. The sample containing rFV∆B-GRA was the same as used in Fig. 6a (T = 30 
min). Samples were subjected to 12-20% SDS-PAGE under reducing conditions followed by 
immunoblot analysis. Fragments from the heavy chain were visualized with mAb AHV-5146 
(epitope between R306 and R506). The 30 kD fragments represent the following cleavage
products: rFV∆B-GQA, Rx2-Rx1; rFV∆B-wt, 307-506 and rFV∆B-GRA, Rx2-506. 
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Figure 8. Immunoblot analysis of APC-catalyzed inactivation of activated plasma
FV Leiden in the presence of protein S. 1 nM of activated FV Leiden was incubated
at 37°C in an inactivation mixture containing 6 nM APC, 490 nM protein S and 24.5
µM phospholipid vesicles (DOPS/DOPC, 10/90) in 25 mM Hepes (pH 7.5), 175 mM
NaCl, 3 mM CaCl2 and 5 mg/ml BSA. At indicated time points samples were drawn
from the inactivation mixture and subjected to 4-15% SDS-PAGE under reducing
conditions followed by immunoblot analysis. Fragments from the heavy chain were
visualized with mAb AHV-5146 (epitope between R306 and R506).     
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Discussion 
To obtain more insight in the functional and structural implications of the individual 
cleavages at R306, R506 or R679 in the heavy chain of FVa by APC, recombinant FV 
mutants were generated in which two or three of these APC-cleavage sites had been 
mutated. Because the B-domain of FV has no crucial role in the APC-catalyzed 
inactivation of FVa, we used mutants lacking a major part of the B-domain in order to 
increase the yield of rFV mutants. The expression of these B-domainless mutants was 
about 10 times higher than that of the full-length constructs, which is in line with previous 
studies [35,41]. Initial inactivation experiments with the purified recombinant proteins 
showed that rFVa-GQA (in which the known APC cleavage sites R306, R506 and R679 
have been mutated) was still inactivated by APC, although at a much lower rate than 
normal FVa. The main objective of this study was to learn more about the mechanism 
underlying this unexpected observation.  
All activated B-domainless rFV mutants used in this investigation were stable under 
the conditions chosen to study FVa inactivation by APC (Table 2). Also the presence of a 
heavy chain fragment of 90 kD (most likely representing fragment 1-643 [38] generated 
during the activation with thrombin) did not affect the stability of the activated rFV 
molecules. The inactivation of rFVa-GQA by APC is dependent on negatively charged 
phospholipids (Fig. 2) and is inhibited by a monoclonal antibody against protein C (Table 
3), indicating that the observed inactivation is mediated by APC. 
Kinetic analysis of the inactivation of rFVa-GQA by APC revealed that under pseudo-
first order conditions (FVa concentration ranging from 1 to 5 nM [30]) rFVa-GQA was 
inactivated in a biphasic reaction, indicating that analogous to the inactivation of normal 
FVa also the inactivation of rFVa-GQA was associated with at least two cleavages 
(designated Rx1 and Rx2). This conclusion is supported by SDS-PAGE analysis of the 
reaction products (Fig. 5). During inactivation of rFVa-GQA a FVa intermediate (FVaB) 
with ~80% of the original FVa activity was formed via rapid cleavage at Rx1. This 
intermediate was completely inactivated via a second slow cleavage at Rx2. The calculated 
second-order rate constant of the rapid reaction (kx1 = 5.4 x 104 M-1.s-1) was approximately 
20-fold higher than that of the slow reaction (kx2 = 3.2 x 103 M-1.s-1 and k’x2 = 2.6 x 103 
M-1.s-1). The rate constant of the rapid reaction is 50 and 1000-fold lower than those 
reported for cleavage at R306 and R506, respectively [30], but is somewhat higher than the 
second-order rate constant for cleavage at R679, which has been estimated at 7.6 x 103 
M-1.s-1 [30]. Therefore, the knowledge of the existence of additional cleavage sites for 
APC, one close to residue 306 and one close to residue 506, is important for the 
determination of the kinetic parameters for cleavage at the individual sites R306, R506 or 
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R679 and need to be taken into account (especially in the case of analysis of cleavage at 
R679). 
Protein S strongly stimulated the inactivation of rFVa-GQA by APC (Fig. 4). Kinetic 
analysis revealed that the slow cleavage at Rx2 (k’x2) that fully inactivates rFVa-GQA was 
stimulated about 50-fold by protein S (Table 4). In this analysis we assumed that cleavage 
at Rx1 was not affected by protein S. This is supported by the observation that in the 
presence of protein S (Fig. 5c) mainly a 60 kD fragment (cleavage at Rx2) was generated 
by APC instead of the 80 kD fragment observed in the absence of protein S. Moreover, 
under the experimental conditions used acceleration of the cleavage at Rx1 by protein S 
would hardly contribute to the final inactivation curve due to the high FVa activity 
associated with the intermediate formed after cleavage at Rx1.  
To localize the position of the cleavage sites Rx1 and Rx2, the fragments generated 
during the APC-catalyzed degradation of rFVa-GQA were analyzed by SDS-PAGE and 
immunoblotting using an antibody with an epitope between residue 306 and 506 on the 
heavy chain of FVa. At time zero of the inactivation curves also some 90 kD fragment was 
present in the activated rFV∆B mutants (Fig. 5, 6) and activated FV Leiden (Fig. 8) apart 
from the expected 105 kD heavy chain fragment. SDS-PAGE analysis of the time courses 
of thrombin activation revealed that this fragment was the result of cleavage by thrombin 
(data not shown), most likely at R643 [38]. Due to the high sensitivity of the detection 
method it was not possible to quantify the relative amounts of 105 kD and 90 kD 
fragments. However, under the conditions used no effect of the cleavage at R643 on the 
FVa activity was observed (data not shown).  
Positioning of Rx1 and Rx2 close to residue 506 and 306, respectively, would best fit 
the experimental data obtained via immunoblot and kinetic analysis. A position of Rx1 
near residue 506 would explain the generation of a fragment of ~80 kD during the initial 
phase of the inactivation of rFVa-GQA by APC (Fig 5a). It also would explain the 
relatively high FVa activity of the intermediate formed after cleavage at Rx1, because 
cleavage of factor Va at R506 also results in the formation of an intermediate with 
relatively high factor Va activity [30,37]. Location of Rx2 near residue 306 would explain 
the formation of peptides of 60 kD and 45 kD (from the heavy chains fragments of 105 kD 
and 90 kD, respectively) and 30kD (from the 80 kD intermediate) during the second slow 
inactivating phase. A position of Rx2 close to residue 306 is also compatible with the 
observation that the cleavage at Rx2 is stimulated by protein S (Table 4), because protein S 
exerts its stimulatory effect on the inactivation of normal FVa by selectively stimulating 
the cleavage at R306 [31]. A more detailed localization of the position of Rx2 was 
obtained by comparing the 30 kD fragment (residues 307-506) generated in the 
inactivation of rFV∆B-wt with the fragment (Rx2-506) generated during the inactivation of 
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activated rFV∆B-GRA by APC, when cleavage at R506 is followed by cleavage at Rx2 
(Fig. 7). The fragment of Rx2-506 was about 1.5 kD smaller than the fragment of 307-506 
indicating that the position of Rx2 is localized 10-20 residues carboxy-terminal to residue 
306. This confines the candidates for the position of Rx2 to the residues R316, R317, K320 
and R321. Consequently, the position of Rx1 should be very close to residue 506, because 
the Rx2-Rx1 fragment produced during the inactivation of rFVa-GQA has the same 
molecular weight as the Rx2-506 fragment (Fig. 7). This would make residues R505 and 
R510 strong candidates for the location of Rx1. However, the localization of Rx1 at R505 
seems less likely, because this residue is positioned in a putative Xa binding site (493-506) 
[42]. Hence, cleavage at R505 would likely result in a FVa intermediate with a lower FVa 
activity than the 80% activity calculated for the intermediate after cleavage at Rx1. 
Currently, attempts are made to produce sufficient amounts of rFV∆B-GQA to identify the 
precise location of Rx1 and Rx2 by N-terminal sequencing.  
Interestingly, the degradation patterns of the activated rFV∆B-RQA and rFV∆B-GRA 
mutants (Fig 6) confirmed some of the structural implications of cleavage at R306 or 
R506. The final fragments in the APC-mediated degradation of activated rFV∆B-RQA 
were 60 kD and 45 kD (Fig. 6b), which indicated that after cleavage at R306, Rx1 was no 
longer susceptible to APC cleavage. This might be explained by the dissociation of the 60 
kD and 45 kD fragments from the FVa heterotrimer, a mechanism that has been proposed 
as explanation for the low FVa activity after cleavage at R306 [40]. In contrast, the final 
fragment in the degradation of activated rFV∆B-GRA was 30 kD, which indicates that Rx2 
can still be cleaved by APC after cleavage at R506.  
This is the first time that APC cleavage sites are reported in the heavy chain of FVa 
different from the sites at R306, R506 and R679. During the inactivation of plasma FVa by 
APC, cleavage at Rx1 or Rx2 will hardly occur, because the second-order rate constants 
are much lower than those reported for cleavage at R506 and R306, even in the presence of 
protein S. This might explain why the sites of Rx1 and Rx2 have not been identified before 
in studies using normal FVa [10,30]. Also, no novel APC-cleavage sites have been 
observed in studies using rFV molecules in which R306 and R506 had been mutated 
[22,24,37,43]. However, the conditions used in these studies were such (much lower APC 
concentrations and shorter incubation time) that cleavages at Rx1 and Rx2 could not be 
detected. 
During the present study we observed that Rx1 is not cleaved by APC as an alternative 
for R506 during the inactivation of activated FV Leiden (Fig. 7), most likely because of 
dissociation of the A2 domain after cleavage at R306. Inactivation of activated rFV∆B-
GRA on the other hand clearly demonstrated that cleavage at Rx2 may occur as an 
alternative for cleavage at R306. Therefore, cleavage at Rx2 may be relevant in the APC-
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catalyzed inactivation of activated FV Hongkong or FV Cambridge and may explain the 
unexpected mild APC resistant phenotype associated with the carrier-ship of these FV 
mutants. 
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Summary 
Inactivation of Factor Va (FVa) by activated protein C (APC) is associated with 
proteolytic cleavage of three peptide bonds in the heavy chain of FVa, which have been 
localized at R306, R506 and R679. Current knowledge of the complex mechanism of 
APC-catalyzed inactivation of FVa has mainly emerged from studies using (purified) 
plasma Factor V (FV) and is limited. The main objective of the present study was to obtain 
detailed information on the contribution of each individual cleavage to the kinetics of 
APC-catalyzed inactivation of FVa. For this reason B-domainless recombinant factor V 
mutants (rFV∆B) were generated in which two of the three known APC-cleavage sites 
were mutated. These FV mutants were purified, activated with thrombin and incubated 
with APC, after which time courses of APC-catalyzed inactivation of the FVa mutants 
were followed and analyzed. Our data show that APC-mediated cleavage at R506 occurs at 
a 100-fold and 2000-fold higher rate than cleavage at R306 or R679, respectively. Like the 
cleavages at R506 and R306, the APC-catalyzed cleavage at R679 was also stimulated by 
the presence of negatively charged phospholipids, but the effect was not very strong. 
Protein S stimulates both the APC-mediated cleavages at R306 and R506, although this 
stimulation is much stronger for cleavage at R306. The effect of protein S on the APC-
mediated cleavage at R679 remains to be elucidated. Finally, our results demonstrate that 
cleavages at the individual APC cleavage sites have different effects on the residual FVa 
activities of the reaction intermediates being, 85% (FVa679), 60-75% (FVa506) and 10% 
(FVa306) as measured with 5 nM FXa in the prothrombinase assay. These data suggest that 
the physiological relevance of the APC-catalyzed cleavage at R679 is less important than 
cleavage at the as yet unidentified cleavage site Rx2, which is located near position 306. 
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Introduction 
Activation and inactivation of human blood coagulation factor V (FV) are important 
processes in the regulation of blood coagulation. Thrombin is the main activator of FV. It 
generates via limited proteolysis an activated factor V (FVa) molecule, which consists of a 
heavy chain (Mr ~105 kD) and light chain (Mr 71-74 kD), held together via a Ca2+ ion. FVa 
exerts its procoagulant function by serving as a non-enzymatic cofactor of the serine 
protease factor Xa (FXa) by accelerating prothrombin activation 103-105 fold [1-3]. 
Inactivation of FVa activity is catalyzed by activated protein C (APC) and is associated 
with proteolysis of three peptide bonds in the heavy chain of FVa, which have been 
localized at R306, R506 and R679 [4]. Proteolytic inactivation of FVa is an essential 
reaction in the so-called anticoagulant protein C pathway [5].  
Several mutations have been reported in the APC cleavage sites of human FV, from 
which the R506Q (FV Leiden) is the most important [6-8]. This mutation results in the 
plasma phenotype of APC resistance and is associated with a 3-7 fold increased risk of 
deep-vein thrombosis [6,9,10]. The high frequency of the FV Leiden allele (2-7% in 
Caucasian populations [11]), -makes this mutation the most important heritable risk factor 
for venous thrombosis. Besides FV Leiden, three other mutations have been found in the 
APC cleavage sites of FV. All three affect the R306 position and are much less frequent 
than FV Leiden [12-15]. There are no indications that mutations at R306 are associated 
with an increased risk of venous thrombosis [13,16]. The effect of these mutations on the 
plasma sensitivity to APC is not entirely clear. Studies using recombinant FV (rFV) have 
shown that mutations at R306 result in an unexpectedly mild APC-resistant phenotype [17-
19].  
Our current knowledge of the complex mechanism of APC-catalyzed FVa inactivation 
has mainly been obtained from studies using (purified) plasma FV. These studies have 
demonstrated that cleavage of the heavy chain of FVa by APC is stimulated by negatively 
charged phospholipids [20-22] and protein S [22-24], the non-enzymatic cofactor of APC. 
In the presence of negatively charged phospholipids and Ca2+ ions the inactivation of FVa 
by APC proceeds via a rapid and a slow phase, associated with cleavages at R506 and 
R306, respectively [4,25]. Cleavage at R506 yields a reaction intermediate with reduced 
FVa activity, which is completely inactivated by the subsequent cleavage at R306. 
Inactivation of activated FV Leiden is monophasic and associated with cleavage at R306, 
which is stimulated ~20-fold by protein S [26]. In the presence of negatively charged 
phospholipids the contribution of the cleavage at R679 to the inactivation of FVa seems to 
be minor, but has been difficult to assess [25].  
More detailed information about the functional and structural implications of each 
individual APC cleavage can be obtained by using recombinant FV mutants in which two 
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of the three APC-cleavage sites have been mutated, an approach which has successfully 
been used by Norstrøm et al. [27]. Recently, we have also generated rFV mutants in which 
two or three of the known APC cleavage sites were mutated [28]. During this study we 
noticed that rFVa is still inactivated by APC in the absence of R306, R506 and R679 via 
proteolysis at alternative cleavage sites in the heavy chain of FVa, designated Rx1 and Rx2 
[28]. The second order rate constants for these alternative cleavages as well as their effect 
on FVa activity have been determined [28]. The main objectives of the present study was 
to use the knowledge of the APC-dependent cleavage at the alternative sites (Rx1 and Rx2) 
in the analysis and interpretation of APC-mediated inactivation of rFVa which contained 
one of the three known APC-cleavage sites (R306, R506 or R679)  
 
Experimental Procedures  
Materials  
Restriction enzymes were from New England Biolabs, Beverly, MA, USA. Rapid ligation 
kit and BM Chemiluminescence blotting substrate (POD) were obtained from Boehringer 
Mannheim, Mannheim, Germany. Plasmid isolation kits were purchased from Qiagen, 
Chatsworth, CA, USA. DNA restriction fragments were purified from agarose gel using 
the cleanmix kit (Talent, Trieste, Italy). CNBr-Sepharose and SP-Sepharose were obtained 
from Pharmacia, Uppsala, Sweden. Bovine serum albumin (BSA), 98% fatty free, was 
from ICN Biomedicals (Aurora, Ohio, USA). Ovalbumin, benzamidine, 
phosphatidylcholine (PC), N-hydroxysuccinimidobiotine and Hepes were from Sigma (St. 
Louis, MO, USA). Dioleoylphospatidylcholine (DOPC) and dioleoylphospatidylserine 
(DOPS) were obtained from Avanti Polar Lipids, Alabaster, Al, USA. EDTA was from 
Serva, Heidelberg, Germany. NH4Cl, TRIS and CaCl2 were purchased from Merck, 
Whitehouse Station, NJ, USA. Chromogenic substrate S-2238 was obtained from 
Chromogenix, Uppsala, Sweden. APMSF was from Roche Diagnostics, Mannheim, 
Germany. 
 
Proteins 
Human activated protein C (APC), protein S, prothrombin and thrombin were purchased 
from Enzyme Research Laboratories (South Bend, IN, USA). The APC concentration was 
determined from APC antigen and activity measurements. APC antigen was measured by 
ELISA using IgG fractions of rabbit anti–human protein C (DakoCytomation Denmark 
A/S, Glostrup, Denmark), whereas APC activity was measured with S2366 using the 
kinetic parameters reported by Sala et al. [29]. Human factor Xa, monoclonal antibodies 
AHV-5146 and AHV-5112 were from Haematologic Technologies Inc., Essex, VT, USA. 
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Monoclonal antibody 3B1 directed against the heavy chain of human FV was a kind gift 
from Prof. B.N. Bouma. Goat-anti-mouse IgG conjugated with horse-radish peroxidase 
(GAMPO) was from Bio-Rad Laboratories Inc., Hercules, CA, USA. NeutraliteTM Avidin-
HRP conjugate was from Southern Biotechnology Associated, Inc., Birmingham, AL, 
USA. Human FV Leiden (FVL) was isolated from human plasma according to Nicolaes et 
al. [25]. 
 
FV antigen assay 
FV light chain antigen was measured by ELISA using two different monoclonal antibodies 
directed against the light chain of FV [30]. In this ELISA, mAb V-6 was used as coating 
antibody and biotinylated mAb V-9 as tagging antibody.  
 
Mutagenesis 
In this study FV expression vectors (pMT2) were used containing the cDNA of FV in 
which two or three APC-cleavage sites have been mutated and a major part of the B-
domain (deletion from amino acid 827 to 1499) was lacking (these mutants have been 
described before [28,31]). In these mutants the arginines at position 306, 506 or 679 were 
replaced by glycine, glutamine and alanine, respectively (see Table 1). 
  
Transient expression and purification of rFV∆B mutants 
B-domainless recombinant FV (rFV∆B) mutants were transiently expressed in COS-1 cells 
(175 cm2 culture flasks) using Fugene 6 Transfection Reagent from Roche Molecular 
Biochemicals, Hague Road, IN, USA. Twenty-four hours after transfection cells were 
washed with phosphate-buffered saline (PBS) and incubated with serum-free medium 
(Optimem Glutamax, Life Technologies Ltd., Paisley, Scotland). Conditioned medium was 
harvested after 72h, centrifuged for 20 min at 3000 rpm (4°C) and frozen at -20°C. FV 
expression was measured by functional FV assay and ELISA.  
Recombinant FV∆B mutants were isolated in a two-step procedure essentially as 
previously described [32]. Briefly, conditioned medium was thawed, supplemented with 
10 mM benzamidine and loaded on an ion exchange column (SP-Sepharose fast flow), 
which was subsequently washed with 25 mM Hepes, 100 mM NH4Cl, 5 mM CaCl2, 10 
mM benzamidine (pH 7.5), until the fall-through was protein free. Recombinant FV∆B 
was eluted from the column with 25 mM Hepes, 1.5 M NH4Cl, 5 mM CaCl2, 10 mM 
benzamidine, pH 7.5. Fractions containing FVa activity were supplemented with 2 mg/ml 
ovalbumine, dialyzed against a buffer containing 25 mM Hepes, 50 mM NaCl, 5 mM 
CaCl2, 10 mM benzamidine (pH 7.3), pooled and applied at a speed of 3 ml/h to an affinity 
column, consisting of 1 mg mAb-3B1/ml Sepharose. The column was washed with 25 mM 
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Hepes, 50 mM NaCl, 5 mM CaCl2 (pH 7.3) and eluted with 25 mM Hepes, 1.8 M NaCl, 5 
mM CaCl2, pH 7.3. Eluted fractions were screened for FV (activity/antigen) and analyzed 
by SDS-PAGE and immunoblotting. FV containing fractions were supplemented with 2 
mg/ml ovalbumin, dialyzed against 25 mM Hepes, 50 mM NaCl (pH 7.3), and stored at –
80°C.   
 
Factor Va activity assay 
FVa activity was measured in a two-step procedure as previously described [32]. This 
assay was calibrated using dilutions of pooled normal plasma corresponding with 0-3 pM 
of FV. 
 
Inactivation of FVa by APC 
FVa (~1nM) was incubated with APC (see legends) in 25 mM Hepes (pH 7.5), 175 mM 
NaCl, 3 mM CaCl2, 5 mg/ml BSA, 24.5 µM phospholipids (DOPS:DOPC 10:90). At 
different time intervals 10 µl samples were transferred to 240 µl of prothrombinase mix 
(containing 25 mM Hepes (pH 7.5), 175 mM NaCl, 3 mM CaCl2, 0.5 mg/ml ovalbumin, 
FXa, prothrombin and DOPS/DOPC 10:90 molar ratio) yielding final concentrations of 5 
nM FXa, 540 nM prothrombin and 50 µM DOPS/DOPC vesicles. After 3 min incubation 
at 37°C prothrombin activation was stopped by subsampling 40 µl in 460 µl TN-EDTA 
(50 mM TRIS, 175 mM NaCl, 20 mM EDTA, 0.5 mg/ml ovalbumin, pH 7.9). 
Subsequently, 200 µl of this mix were transferred to a 96-wells plate and 25 µl of 
chromogenic substrate S-2238 (2.35 mM) was added, after which the amount of thrombin 
formed was measured kinetically on a Spectra III Thermo microtiter plate reader from 
Tecan (Salzburg, Austria). Under these conditions the formation of thrombin was linearly 
dependent on the FVa concentration present in the prothrombinase mixture. The FVa 
activity measured before the addition of APC (t=0) was set at 100%.  
 
Curve fitting of time courses of FVa inactivation 
Time courses of APC-catalyzed FVa inactivation were obtained by measuring loss of FVa 
activity as a function of time. Previous data [28] and data reported in this paper indicate 
that the APC-catalyzed inactivation of the activated rFV∆B mutants with only one APC 
cleavage site proceeds via two pathways: 
ViVaVa kB
k →→ 21   (1) 
ViVa k→ 3    (2) 
This model is similar to that for the inactivation of plasma FVa via cleavages at R506 and 
R306 [25]. In this model, k1 is the pseudo first-order rate constant for cleavage at either 
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R306, R506 or R679 depending on which rFVa mutant is inactivated, whereas k2 and k3 
represent the pseudo first-order rate constants that account for spontaneous inactivation and 
inactivation due to cleavage at the unidentified cleavage sites Rx1 or Rx2 of either the 
reaction intermediate VaB or intact Va [28]. Completely inactivated FVa is represented by 
Vi. 
Under first order conditions, i.e. conditions at which the inactivation rate is directly 
proportional to the factor Va and APC concentration, the loss of FVa cofactor activity is 
described by the following equation [25]: 
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In this equation Vat is the FVa activity at time t, Va0 is the FVa activity at time zero, B is 
the activity of the FVa intermediate generated after cleavage at either R506, R306 or R679, 
depending on which mutant is investigated. k1, k2 and k3 are the observed pseudo first-order 
rate constants, from which the second-order constants (k*) can be calculated as follows: k*1 
(second-order) = k1/[APC] et cetera. When the APC-catalyzed inactivation rates are of the 
same order of magnitude as the spontaneous (first order) inactivation of intact FVa or 
intermediate FVa products, a correction for the contribution of the spontaneous 
inactivation rate can be made as follows: k*2 = (k2-k’s)/[APC] and k*3 = (k3-ks)/[APC], in 
which k’s and ks are the first-order rate constants of spontaneous inactivation of the FVa 
intermediate (FVaB) and intact FVa, respectively. After rearrangement of the first-order 
rate, constants can also be derived from the second-order rate constants: k2 = k*2.[APC] + 
k’s. k3 = k*3.[APC] + ks. 
In many cases it was found that the initial cleavage of FVa at the single cleavage site 
available was much faster than spontaneous loss of activity or the slow alternative 
cleavage at Rx1 or Rx2, i.e. k1>> k3 , in which case the loss of FVa activity is described by 
the following equation: 
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SDS-PAGE and immunoblot analysis 
Polyacrylamide gel electrophoresis was performed on SDS/PAGE (TRIS/HCl prefab gels, 
Gradipore, French Forest, Australia) under reducing conditions according to Laemmli [33]. 
Protein transfer to PVDF membranes (Millipore Corporation, Bedford, MA, USA) was 
carried out semi-dry on a blot system from Pharmacia (Uppsala, Sweden). A murine 
monoclonal antibody against the heavy chain AHV-5146 was used to detect fragments 
from the heavy chain of FV. GAMPO in combination with the blotting substrate POD was 
used to visualise the immobilized antibodies. Both antibodies were checked for any cross-
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reaction with BSA present in the FV fractions and were found negative. Visualization with 
AHV-5146 was optimized to detect low molecular degradation fragments from the heavy 
chain. Due to the high sensitivity of this procedure small amounts of intact heavy chains 
still show significant staining (see also reference [27]).  
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Results 
Model to analyse the APC-catalyzed inactivation rFVa double mutants   
In order to investigate the functional and structural implications of the APC-catalyzed 
cleavages at individual cleavage sites in the heavy chain of FVa, purified rFV∆B mutants 
were used (see also Table 1) in which two or three APC-cleavage sites were mutated. In 
three of these FV mutants APC cleavage sites were singled-out and labelled as follows: 
rFV-RQA (R306 present), rFV-GRA (R506 present) and rFV-GQR (R679 present). 
Generation and purification of the rFV mutants have been described before [28]. The APC-
catalyzed inactivation of rFVa mutants was studied by activating the rFV mutants with 9 
nM thrombin, after which the APC-catalyzed inactivation of FVa was followed in time 
(see also [28]). Time courses of the loss of FVa activity were analyzed in a random 
ordered two-step model (Equations 3 and 4 in Experimental Procedures), which made it 
possible to estimate the contribution of the cleavages at Rx1 (near residue 506) or Rx2 
(near residue 306) and spontaneous inactivation of FVa-(intermediates) to FVa 
inactivation. Residual FVa activity was measured in a prothrombinase assay with the same 
FXa concentration (5 nM) as used in previous experiments using plasma-derived FV [25]. 
Parallel experiments were used to monitor cleavage of the heavy chain of factor Va by 
APC after SDS-PAGE and immunoblotting of the fragments. 
 
Table 1. Factor V molecules used in this study. Recombinant proteins were named after 
the amino acids present at the APC cleavage sites at positions 306, 506 and 679 using the 
one letter code for amino acids. The symbol ∆B indicates that a major part of the B-domain 
(∆ 827-1499) is lacking. Mutated positions are bold and underlined.  
 
Factor V Mutation Comments 
 rFV∆B-RQA R506Q, R679A R306 intact 
rFV∆B-GRA R306G, R679A R506 intact 
rFV∆B-GQR R306G, R506Q R679 intact 
rFV∆B-GQA R306G, R506Q, R679A No APC cleavage sites left 
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Analysis of the APC-catalyzed inactivation of FVa via cleavage at R506  
Time courses of the inactivation of rFVa-GRA with APC were biphasic with a rapid first 
phase resulting in a partially inactivated reaction intermediate followed by a much slower 
second phase (Fig. 1). The second phase was completely inactivating (data not shown). 
The generation of a single 75 kD fragment confirmed that the rapid first phase was 
associated with cleavage at R506 (Fig. 2a). The pseudo first-order rate constants for k1 
(cleavage at R506) and k2 were obtained by fitting the time course of rFVa-GRA 
inactivation with 0.15 nM APC to equation 4. This equation is identical to equation 3 after 
removal of k3, because k3<<k1. A representative curve is shown in Fig. 1a. This curve was 
optimally fitted with a pseudo first-order rate constant k1 being 1.6 x 10-2 s-1, from which a 
second-order rate constant for cleavage at R506 (k506) was calculated of 1.1 x 108 M-1s-1.  
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The second phase of the inactivation was much slower (k2 being 8.5 x 10-5 s-1) and 
could not be associated with the generation of additional heavy chain fragments apart from 
the 75 kD fragment (Fig. 2a). In theory two reactions contribute to k2: spontaneous 
inactivation of the FVa506 intermediate (k's) and cleavage at Rx2 (the alternative cleavage 
site near position 306 in the heavy chain of FVa, for which a second-order rate constant 
(kx2) has been calculated of 3.2 x 103 M-1s-1 [28]). The contribution of these two reactions is 
as follows: k2 = kx2.[APC] + k’s. It can be calculated then that the contribution of cleavage 
at Rx2 (kx2= 7.6 x 103 M-1 s-1) at 0.15 nM APC to k2 is negligible being 1.2 x 10-6 s-1. It 
seems likely therefore that the k2 of 8.5 x 10-5 represents spontaneous inactivation of the 
FVa506 molecule. This value is very close to the previously reported spontaneous 
inactivation rate for the rFVa-GQA intermediate cleaved at Rx1 (localized next to R506), 
being 5.6 x 10-5 s-1 [28].  
Figure 1. APC-catalyzed inactivation of activated rFV∆B-GRA. Activated rFV∆B-
GRA (1 nM) was incubated with APC in the presence of 24.5 µM phospholipid vesicles
(DOPS/DOPC, 10/90) in 25 mM Hepes (pH 7.5), 175 mM NaCl, 3 mM CaCl2 and 5
mg/ml BSA at 37°C. At the indicated time intervals FVa activity was measured as
described in “Experimental Procedures”. Data are presented as means of three individual
experiments +/- SD (note that at many time points the SD is very small and may therefore
fall away in the marks). The solid lines represent exponential curves obtained by fitting
the data to equation 4. In panel A rFVa-GRA was incubated 0.15 nM APC in the absence
of protein S, whereas in panel B rFVa-GRA was incubated with 0.07 nM APC in the
presence of 490 nM protein S. In panel C rFVa-GRA was incubated with 20 nM APC in
the absence of protein S () or in the presence of 490 nM protein S (●). In panel D rFVa-
GRA was incubated with 0.15 nM APC, after which residual FVa activity was measured
in the prothrombinase assay in the presence of 5 nM FXa () or 0.5 nM FXa (♦). 
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 Figure 2. Immunoblot analysis of APC-
catalyzed inactivation of activated
rFV∆B-GRA. Activated rFV-GRA (1 nM)
was incubated at 37°C in an inactivation
mixture containing 0.15 nM APC (Fig. 1a)
or 0.15 nM APC in the presence of 490 nM
protein S (Fig. 2b) or 20 nM APC in the
presence of 490 nM protein S (Fig. 2c) and
24.5 µM phospholipid vesicles
(DOPS/DOPC, 10/90) in 25 mM Hepes (pH
7.5), 175 mM NaCl, 3 mM CaCl2 and 5
mg/ml BSA (Fig. 2a). At indicated time-
points samples were drawn from the
inactivation mixture and subjected to 8%
(Fig. 2a and 2b) or 4-15% (Fig. 2c) SDS-
PAGE under reducing conditions followed
by immunoblot analysis. Fragments from the
heavy chain were visualized with mAb
AHV-5146 (epitope between R306 and
R506). Apart from the intact heavy chain
fragment of 105 kD also variable amounts of
90 kD fragment were observed, which was
most likely the result of thrombin cleavage
at R643 [37]
A) 
B) 
C) 
Chapter IIIb 
 
 
 
 
 94 
 
To investigate the effect of protein S on the APC-catalyzed cleavage at R506, 1 nM of 
rFVa-GRA was inactivated with 0.07 nM APC in the presence of 490 nM protein S (Fig. 
1b), after which the data were fitted to equation 4. This revealed that the APC-catalyzed 
cleavage at R506 was stimulated about 2-fold by protein S (k506 = 1.9 x 108 M-1s-1). Also 
the second slow inactivation reaction was somewhat stimulated by the presence protein S 
(k2 being 1.2 x 10-4 s-1), which is most likely the result of the reported stimulation (~50-
fold) of cleavage at Rx2 by protein S [28]. However, cleavage at Rx2 was still too slow to 
be visualized by immunoblotting (Fig. 2b).  
Inactivation of the FVa506 intermediate (slow phase in the inactivation curves) was 
further analyzed by following the APC-catalyzed inactivation of rFVa-GRA at 20 nM APC 
during 180 min (Fig. 1c). Under these conditions formation of a 30 kD fragment could be 
visualized corresponding to cleavage at Rx2 (Rx2-506), especially in the presence of 
protein S (Fig. 2c). The data obtained in the absence of protein S were optimally fitted (k1 
was fixed using the k506 obtained with 0.15 nM APC) to equation 4 with a k2 of 9.1 x 10-5 
s-1. This indicates that even at 20 nM APC the contribution of cleavage at Rx2 to the 
inactivation of the FVa506 intermediate is marginal (compare k2 of 9.1 x 10-5 s-1 at 20 nM 
APC with k2 of 8.5 x 10-5 s-1 at 0.15 nM APC). However, in the presence of protein S k2 
was increased to 1.2 x 10-3 s-1. This resulted in a second-order rate constant of 6.0 x 104 
M-1s-1 for kx2, which is in the range of the reported 8.1 x 104 M-1s-1 for kx2 in the presence 
of protein S [28].  
The residual FVa activity of the reaction intermediate formed by cleavage at R506 
(FVa506) was optimally fitted (data from Fig. 1a, 1b and 1c) with activities between 60 and 
75%. The effect of the FXa concentration on the activity of the FVa506 intermediate was 
investigated by measuring the FVa activity at 5 nM and 0.5 nM FXa in the prothrombinase 
assay (Fig. 1d). Lowering of the FXa concentration resulted in a reduction of the activity 
of the FVa506 intermediate from 75% at 5 nM FXa to ~38% at 0.5 nM FXa 
 
Analysis of the APC-catalyzed cleavage at R306    
Also the time courses of the APC-catalyzed inactivation of rFVa-RQA were biphasic, 
consisting of a rapid first phase, in which almost 90% of FVa activity was lost, and a 
second slow phase, in which FVa was completely inactivated at incubation times longer 
than 30 min (Fig. 3). Generation of a 60 kD fragment confirmed that the rapid first phase 
was associated with cleavage at R306 (Fig. 4a).  
The pseudo first-order rate constants for k1(cleavage at R306) and k2 were obtained by 
fitting the time course of rFVa-RQA inactivation with 6 nM APC to equation 4, because 
k1>>k3 (Fig. 3a). The curve was optimally fitted with a pseudo first-order rate constant k1 
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of 9.3 x 10-3 s-1, from which the second-order rate constant for cleavage at R306 (k306) was 
calculated: 1.6 x 106 M-1s-1.  
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Figure 3. APC-catalyzed inactivation of activated rFV∆B-RQA. Activated rFV∆B-RQA (1 nM)
was incubated with 6 nM APC in the absence of protein S () or with 1 nM APC in the presence 
of 490 nM protein S (●) (Fig. 3A). The inactivation mix contained 24.5 µM phospholipid vesicles
(DOPS/DOPC, 10/90) in 25 mM Hepes (pH 7.5), 175 mM NaCl, 3 mM CaCl2 and 5 mg/ml BSA 
at 37°C. At the indicated time intervals FVa activity was measured as described in “Experimental
Procedures”. Data are presented as means of three indiviual experiments +/- SD. The solid lines 
represent exponential curves obtained by fitting the data to equation 4. The effect of FXa
concentration on the FVa activity of the FVa306 intermediate was studied by incubating rFV-RQA 
with 6 nM APC (Fig 3B), after which FVa activity was measured at 5 nM FXa (□) or 0.5 nM FXa 
(×). 
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A) 
B) 
 
Figure 4. Immunoblot analysis of APC-catalyzed inactivation of activated rFV∆B-
RQA. Activated rFV-GRA (1 nM) was incubated at 37°C in an inactivation mixture
containing 6 nM APC in the absence of protein S (panel A) or 6 nM APC in the presence
of 490 nM protein S (panel B) and 24.5 µM phospholipid vesicles (DOPS/DOPC, 10/90)
in 25 mM Hepes (pH 7.5), 175 mM NaCl, 3 mM CaCl2 and 5 mg/ml BSA. At indicated
time points samples were drawn from the inactivation mixture and subjected to either 8%
(Fig. 4a) or 4-15% (Fig. 4b) SDS-PAGE under reducing conditions followed by
immunoblot analysis. Fragments from the heavy chain were visualized with mAb AHV-
5146 (epitope between R306 and R506).  
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For this mutant the second phase of the inactivation curve was much slower and was 
best fitted with a pseudo first-order rate constant (k2) of 4.5 x 10-4 s-1. It seems very 
unlikely that cleavage at Rx1 (the alternative cleavage site near position 506 in the heavy 
chain of FVa in the absence of R506) contributes to the k2, because cleavage at R306 
induces dissociation of the C-terminal fragment (307-709) of the heavy chain [34,35]. This 
seems in line with the observation that k2 was independent of the APC concentration 
between 1 nM and 20 nM APC (data not shown). Therefore, it seems most likely that the 
second inactivation phase represents spontaneous inactivation of the intermediate cleaved 
at R306 (FVa306). 
To investigate the effect of protein S on the APC-catalyzed cleavage at R306, 1 nM of 
rFVa-RQA was inactivated with 1 nM APC in the presence of 490 nM protein S (Fig. 3a). 
The data were fitted to equation 4 and revealed that the APC-catalyzed cleavage at R306 
was stimulated about 30-fold by protein S (k306 = 5.4 x 107 M-1s-1). The pseudo first-order 
rate constant for the second slow phase (k2) was unchanged by the presence of protein S, 
which is compatible with k2 being the spontaneous inactivation rate of FVa306. 
In contrast to what was observed for the residual activity of the FVa506 intermediate 
the residual activity of the FVa306 intermediate did not change when we reduced the 
concentration of FXa in the prothrombinase reaction 10-fold. It resulted in completely 
identical inactivation curves with a FVa306 intermediate containing ~10% residual FVa 
activity (Fig. 3b).  
 
Analysis of the APC-catalyzed inactivation of FVa via cleavage at R679  
The functional and structural implications of the APC-catalyzed cleavage at R679 were 
investigated by following the time course of the inactivation of the activated rFV-GQR 
mutant (Fig. 5a). Preliminary experiments indicated that the inactivation of rFVa-GQR by 
APC was much slower than that of rFVa-GRA and rFVa-RQA. Therefore, the rFVa-GQR 
mutant was incubated with high concentrations of APC (20 nM) and directly compared 
with the APC-catalyzed inactivation of rFVa-GQA to determine whether cleavage at R679 
contributed at all to the inactivation of FVa activity. Both in the absence and presence of 
phospholipids rFVa-GQR was inactivated faster than rFVa-GQA, which was mainly due to 
an acceleration of the first phase (Fig. 5a).  
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Figure 5. APC-catalyzed inactivation of activated rFV∆B-GQR and rFV∆B-GQA in the 
presence or absence of phospholipids. In Fig 5a activated rFV∆B-GQA (1 nM) was 
incubated with 20 nM APC in the presence (■) or absence (□) of 24.5 µM phospholipid 
vesicles (DOPS/DOPC, 10/90). Activated rFV∆B-GQR (1 nM) was incubated with 20 nM 
APC in the presence (▲) or absence (∆) of 24.5 µM phospholipid vesicles (DOPS/DOPC, 
10/90). The inactivation mix contained 25 mM Hepes (pH 7.5), 175 mM NaCl, 3 mM CaCl2
and 5 mg/ml BSA at 37°C. At the indicated time intervals FVa activity was measured as
described in “Experimental Procedures”. Data are presented as means of three individual
experiments +/- SD. In the absence of phospholipids the solid line of the time course of 
rFVa-GQA inactivation (□) represents a single exponential curve obtained by fitting the data
to an equation with one exponential, whereas in the presence of phospholipids the solid line
(■) was obtained by fitting the data to equation 4. The solid line of the time course of rFVa-
GQR in the absence of phospholipids (∆) represents an exponential curve obtained by fitting 
the data to equation 3, whereas the solid line in the presence of phospholipids (▲) was not 
fitted. In Fig 5b the APC-catalyzed inactivation of rFVa-GQR (▲) and rFVa-GQA (■), both 
measured at 5 nM Xa, are shown in a semi-logarithmic plot. From the extrapolated plot of 
the third phase of the rFVa-GQR inactivation it could be established that rFVa cleaved at
R679 and at Rx1 contains ~48% FVa activity. 
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In the absence of phospholipids the inactivation of rFVa-GQA by APC was 
monophasic and fitted with a k of 4.5 x 10-5 s-1, which is very close to the spontaneous 
inactivation rate of intact rFVa-GQA, being 3.0 x 10-5 s-1 [28]. This indicates that in the 
absence of phospholipids the contribution of cleavage at Rx1 and Rx2 by 20 nM APC to 
the inactivation of rFVa-GQR and rFVa-GQA can be neglected. In contrast to the 
inactivation of rFVa-GQA, the time course of inactivation of rFVa-GQR by APC in the 
absence of phospholipids was biphasic consisting of a rapid phase resulting in a reaction 
intermediate followed by a second slow inactivation phase. The inactivation data of rFVa-
GQR were fitted to equation 3 and were optimally fitted with a reaction intermediate of 
85% and pseudo-first order rate constants for k1 of 1.1 x 10-3 s-1, k2 and k3 of 5.4 x 10-5 s-1. 
These data suggest that in the absence of phospholipids the first rapid reaction is associated 
with cleavage at R679 resulting in a reaction intermediate (FVa679) with 85% activity. This 
reaction is followed by a slow inactivation phase most likely representing the spontaneous 
inactivation of FVa679. From k1 the second-order rate constant of k679 in the absence of 
phospholipids was calculated as 5.4 x 104 M-1s-1. It was not possible to visualize cleavage 
at R679 by immunoblot analysis, because the intact heavy chain (105 kD) and the product 
from cleavage at R679 (101 kD) migrated at indistinguishable rates (see Fig. 6). In the 
presence of negatively charged phospholipids the APC-catalyzed inactivation of rFVa-
GQR could not be fitted with a single exponential indicating that the inactivation reaction 
of rFVa-GQR was not monophasic. It was also difficult to fit the inactivation curve of 
rFVa-GQR to equation 3 or 4 (data not shown), which suggested that the curve consists of 
more than two phases. For this reason, the inactivation data of rFVa-GQA and rFVa-GQR 
in the presence of phospholipids were analyzed in a semi-logarithmic plot, which revealed 
that the inactivation of rFVa-GQR consisted of three phases in contrast to the inactivation 
of rFV-GQA, which consisted of two phases (Fig. 5b). Interestingly, the last phase of the 
inactivation of rFVa-GQR and rFVa-GQA proceeded at the same rate (cleavage at Rx2, 
see also [28]). This suggests that the last phase of the inactivation of rFVa GQR may also 
be associated with cleavage at Rx2. Therefore, it seems likely that the inactivation of 
rFVa-GQR by APC proceeds via rapid cleavage at R679 resulting in an intermediate 
(FVa679) with about 85% residual activity (see above), followed by slower cleavages at 
Rx1 and Rx2 as in rFVa-GQA. This is also in agreement with the appearance of fragments 
of 80 kD (1-Rx1) and 55 kD (Rx2-679) (Fig. 6a). 
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Figure 6. Immunoblot analysis of APC-catalyzed inactivation of activated rFV∆B-GQR.
Activated rFV-GQR (1 nM) was incubated at 37°C in an inactivation mixture containing 20 nM
APC in the absence of protein S (panel A) or 20 nM APC in the presence of 490 nM protein S
(panel B) and 24.5 µM phospholipid vesicles (DOPS/DOPC, 10/90) in 25 mM Hepes (pH 7.5),
175 mM NaCl, 3 mM CaCl2 and 5 mg/ml BSA. At indicated time points samples were drawn
from the inactivation mixture and subjected to 4-15% (panel B) SDS-PAGE under reducing
conditions followed by immunoblot analysis. Fragments from the heavy chain were visualized
with mAb AHV-5146. In panel C rFVa-GQA (1nM) was incubated at 37°C in the same
inactivation mixture containing 20 nM APC and 490 nM protein S (see also [28]). At indicated
time points samples were drawn from the inactivation mixture and subjected to 8% SDS-PAGE
under reducing conditions followed by immunoblot analysis. 
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Since there is no model available that describes the complex inactivation of rFVa-
GQR by APC, the following mathematical operation was performed to obtain an estimate 
for the rate at which R679 was cleaved by APC (k679). All FVa activities were corrected for 
the activity of the FVa intermediate cleaved at R679 and Rx1 (FVa679, x1) at the 
corresponding time interval. The latter activities were obtained by extrapolation of the 
straight line at t>60 min to t=0 in the semi-logarithmic plot of the rFVa-GQR inactivation 
(Fig. 5b). This operation converted the curve in a biphasic curve in which the first phase 
(cleavage at R679) was followed by a second slow phase (cleavage at Rx1), which allowed 
us to fit the curve to equation 3 in order to obtain estimates for k679 and kx1. The curve was 
best fitted with a first-order rate constant k1 of 3.1 x 10-3 s-1, from which a second-order 
rate constant (k679) was calculated of 1.5 x 105 M-1s-1. Furthermore, a k2 was obtained of 4.6 
x 10-4 s-1, from which a second-order rate constant was calculated of 2.3 x 104 M-1s-1. This 
rate constant is close to the reported rate constant of 5.4 x 104 M-1s-1 for kx1 [28].  
Fig. 7 shows the effect of a 10-fold reduction of the FXa concentration in the 
prothrombinase reaction on the APC-catalyzed inactivation of rFVa-GQR. Lowering of the 
FXa concentration mainly affected the first rapid phase of the inactivation curve. This 
indicates that the residual activity of the FVa679 intermediate like the residual activity of 
the FVa506 intermediate is dependent on the FXa concentration in the prothrombinase 
reaction.  
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The effect of protein S on k679 was studied by comparing the inactivation of 1 nM 
rFVa-GQR and rFVa-GQA by APC in the presence of 490 nM protein S (Fig. 8). The 
inactivation of rFVa-GQR, although incubated at a lower concentration of APC, was faster 
than the inactivation of rFVa-GQA. It was, however, very difficult to associate the various 
inactivation phases with the appearance of heavy chain fragments of FVa-GQR in the 
immunblots (see Fig 6b and 6c), especially because it was not possible to see the cleavage 
at R679 in our SDS/PAGE systems. Interestingly, the cleavage patterns from the APC-
catalyzed inactivation of rFVa-GQR and rFV-GQA in the presence of protein S were 
markedly different. The first inactivation phase of rFVa-GQR was associated with the 
appearance of a fragment of ~80 kD (see Fig. 6b), which most likely represents cleavage at 
Rx1 (amino acids 1-Rx1), whereas the first inactivation phase of rFVa-GQA (Fig. 6c) was 
mainly associated with the generation of a ~60 kD (Rx2-709) fragment, which reflects the 
strong stimulation of cleavage at Rx2 by protein S [28]. These data suggest that cleavage at 
R679 promotes cleavage at Rx1 in the presence of protein S.  
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Figure 7. Effect of Xa concentration on the APC-catalyzed inactivation of rFVa-
GQR. The effect of the FXa concentration in the prothrombinase reaction was studied
by incubating 1 nM of rFVa-GQR with 20 nM APC after which FVa activity was
measured both at 5 nM FXa (■) and at 0.5 nM FXa (♦). The inactivation mix contained
24.5 µM phospholipid vesicles (DOPS/DOPC, 10/90) in 25 mM Hepes (pH 7.5), 175
mM NaCl, 3 mM CaCl2 and 5 mg/ml BSA at 37°C. At the indicated time intervals FVa
activity was measured as described in “Experimental Procedures”. Data are presented as
means of two individual experiments +/- SD.  
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At present it is not possible to analyse the rFVa-GQR inactivation curves obtained in 
the presence of protein S in sufficient detail to calculate the second-order rate constants for 
the individual cleavages. 
  
 
Figure 8. Effect of protein S on the APC-catalyzed inactivation of rFVa-GQR and 
rFVa-GQA. The effect of protein S on cleavage at R679 was studied by incubating 1 nM of 
rFVa-GQR with 20 nM APC in the absence of protein S (■) or with 10 nM APC in the 
presence of 490 nM protein S (●). Time courses of the APC-catalyzed inactivation of 1 nM 
rFVa-GQA with 20 nM APC in the absence (□) or presence (О) of protein S are also shown 
(these curves have been reported before [28]). The inactivation mix contained 24.5 µM 
phospholipid vesicles (DOPS/DOPC, 10/90) in 25 mM Hepes (pH 7.5), 175 mM NaCl, 3 
mM CaCl2 and 5 mg/ml BSA at 37°C. At the indicated time intervals FVa activity was
measured as described in “Experimental Procedures”. Data are presented as means of three
individual experiments +/- SD. The solid lines represent exponential curves obtained by 
fitting the data to equation 3, whereas the dashed line is not obtained by fitting. 
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Discussion 
In this study detailed information was obtained about the functional and structural 
implications of the individual cleavages at R306, R506 and R679 in the heavy chain of 
FVa. This is the first study in which the time courses of the APC-catalyzed inactivation of 
rFVa mutants containing two or three mutations in the APC-cleavage sites were analyzed 
with a model that takes into account the contribution of the alternative cleavage sites Rx1 
and Rx2 and the spontaneous inactivation of FVa (intermediates). Our data show that in 
the absence of protein S the ranking of the second-order rate constants for cleavage at 
R506, R306 and R679 is: k506>k306>> k679. Cleavage at R679, R506 and R306 resulted in 
reaction intermediates with residual activities of 85% (FVa679), 60-75% (FVa506) and 10% 
(FVa306), as measured with 5 nM FXa in the prothrombinase assay. 
The APC-catalyzed cleavage at R506 was studied by following the time course of 
inactivation of rFVa-GRA by APC. We observed that the inactivation of rFVa-GRA by 
APC was biphasic. The first rapid phase was associated with cleavage at R506 and resulted 
in formation of FVa506. The second phase was associated with the spontaneous inactivation 
of FVa506 and, at high APC concentration in the presence of protein S, also with cleavage 
at Rx2 (Fig. 1). Cleavage at R506 resulted in a FVa506 molecule with a relatively high 
residual FVa activity, which varied between 60% to 75% (see also Fig.1). This is in line 
with the findings of Norstrøm et al., who also used a rFVa mutant in which the R506 was 
singled-out [27]. A 10-fold lowering of the FXa concentration in the prothrombinase assay 
resulted in a further reduction of the FVa activity of the FVa506 intermediate to ~35%. 
These data support the conclusion from Nicolaes et al. that cleavage at R506 affects the 
affinity of FVa for FXa, which explains why the FVa506 intermediate contains a somewhat 
reduced FVa activity when measured at FXa concentrations close to the reported K1/2Xa for 
FVa506 of 3.9 nM [25]. 
From the inactivation curve of rFVa-GRA a k506 of 1.1 x 108 M-1s-1 was obtained, 
which is equivalent to the rate constant observed by Norstrøm et al. [27], but somewhat 
higher than the k506 of 4.7 x 107 M-1s-1 reported by Nicolaes et al. [25]. This small 
difference may be explained by the fact that the k506 reported by Nicolaes et al. was 
calculated from the APC-catalyzed inactivation of purified plasma FVa (all APC cleavage 
sites present) [25], or by minor differences between recombinant FVa and plasma derived 
FV.  
We found that cleavage at R506 was stimulated 2-fold by protein S, which has also 
been reported by Norstrøm et al. [27]. This finding seems to be in contrast with the 
conclusion from Rosing et al. [26], who did not observe such stimulation. However, their 
conclusion was based on the inactivation of purified plasma FVa, which made it difficult 
to calculate the effect of protein S on the k506 directly.  
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The functional and structural implications of the APC-catalyzed cleavage at R306 
were investigated by analysing the time courses of inactivation of rFVa-RQA (Fig. 3). In 
contrast to previous reports cleavage at R306 did not result in the formation of a 
completely inactive FVa molecule [25,26]. From the time courses it was calculated that the 
FVa intermediate cleaved at R306 (FVa306) still contained about 10% activity. This activity 
was not affected by lowering the Xa concentration 10-fold. This confirms the findings of 
Norstrøm et al. [27], who also demonstrated that in contrast to the activity of FVa506, the 
activity of FVa306 could not be restored by increasing the FXa concentration. It seems most 
likely that cleavage at R306 results in the rapid dissociation of the C-terminal fragment of 
the heavy chain (307-709) as proposed by Mann et al. [34] and Gale et al. [35]. This would 
explain why 90% of the FVa activity is lost after cleavage at R306. The FVa306 molecule 
was completely inactivated in a second slow phase, which was independent of the APC 
concentration. Probably, this phase is associated with dissociation of the heavy chain 
fragment (1-306) from the light chain. This is supported by the observation that no other 
cleavage fragments were observed during the APC-catalyzed inactivation of rFVa-RQA 
than those corresponding to cleavage at R306 (Fig. 4).  
Protein S stimulated cleavage at R306 ~30-fold (Table 2), which shows that cleavage 
at R306 is more sensitive to the action of protein S than cleavage at R506. This result is in 
line with previous studies, which have reported that protein S accelerates the APC-
catalyzed cleavage at R306 ~20-fold [26,27].  
Table 2. Second-order rate constants for the APC-catalyzed cleavage of 
the heavy chain of FVa via the individual APC cleavage sites. Inactivation 
rates were obtained by fitting time courses of rFVa mutant inactivation in the 
presence of negatively charged phospholipids (see results). In the second 
column the FVa mutants are denoted that were analyzed to determine the 
second-order inactivation rates. 
 
  Rate 
constants 
  rFVa-
mutant - Protein S + Protein S
 
k506 (M-1s-1) rFVa-GRA 1.1 x 108 1.9 x 108 
k306 (M-1s-1) rFVa-RQA 1.6 x 106 5.4 x 107 
k679 (M-1s-1) rFVa-GQR ~1.5 x 105 N.D. 
kx1 (M-1s-1)* rFVa-GQA 5.4 x 104 5.4 x 104 
kx2 (M-1s-1) rFVa-GRA ~3 x 103 6.0 x 104 
  
*Data from van der Neut kolfschoten et al. [28]  
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We have also attempted to analyse the functional and structural implications the APC-
catalyzed cleavage at R679. So far, only one study has reported an estimate of the second-
order rate constant for cleavage at R679 (k679) using semi-quantitative data derived from 
the inactivation of purified plasma FVa [25]. We studied the effects of cleavage at R679 by 
analysing the inactivation of rFVa-GQR by APC in time (Fig. 5 and Fig. 7). The rFVa-
GQR mutant was inactivated at relatively high concentrations of APC, because preliminary 
data showed that cleavage at R679 was much slower than cleavage at R306 and R506. 
However, at high APC concentrations cleavage at Rx1 and Rx2 contribute strongly to the 
inactivation of FVa resulting in complex inactivation patterns, which were difficult to 
analyse. Besides, it was not possible to visualize cleavage at R679, because the 101 kD 
fragment (1-679) could not be separated from the intact heavy chain of 105 kD (1-709). 
For this reason the inactivation curve of rFVa-GQR was compared with the inactivation 
curve of rFVa-GQA to visualize the contribution of cleavage at R679 to the inactivation of 
FVa. In this way we were able to determine that cleavage at R679 results in a FVa 
intermediate (FVa679) with a slightly reduced FVa activity of ~85% (Fig. 5), which is most 
likely caused by a lower affinity for FXa. This hypothesis is supported by the observation 
that lowering of the FXa concentration in the prothrombinase assay from 5 nM to 0.5 nM 
resulted in a further reduction of the activity of FVa679 to ~60% (Fig. 7). Together these 
data are in line with the conclusion from Bakker et al. [36] that the C-terminal region of 
the heavy chain of FVa contains one of the binding sites for FXa (localized between 
residue 683 and 709), which is probably affected by cleavage at R679. 
In the absence of phospholipids the inactivation curve of rFVa-GQR was biphasic 
with a first rapid phase associated with cleavage at R679 followed by a second slow 
inactivation phase associated with spontaneous inactivation of FVa679 (Fig. 5). From this 
curve a k679 was calculated of 5.4 x 104 M-1s-1 (Table 2). In the presence of negatively 
charged phospholipids it was difficult to obtain a reliable estimate of k679, because under 
these conditions the inactivation curve of rFVa-GQR was more complex due to the 
influence of additional cleavages at Rx1 and Rx2. After comparison with the inactivation 
curve of rFVa-GQA (Fig. 7b) it seemed most likely that the inactivation of rFVa-GQR 
proceeds via a relatively rapid cleavage at R679, resulting in a FVa679 intermediate with 
85% activity, followed by cleavages at Rx1 (resulting in a FVa679,x1 molecule with 48% 
activity) and cleavage at Rx2 (resulting in complete inactivation). Since there is no model 
available to describe the inactivation of rFVa-GQR via cleavages at R679, Rx1 and Rx2, 
the first order rate constant for cleavage at R679 was estimated by correcting all FVa 
activities for the activity of the FVa679,x1 intermediate at the corresponding time interval. 
The resulting biphasic curve was fitted to equation 3, which yielded an estimate for k679 of 
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~1.5 x 105 M-1s-1, indicating that cleavage at R679 is also stimulated by negatively charged 
phospholipids, although the effect is not very strong.  
Finally, the effect of protein S on the inactivation of rFVa-GQR was investigated (Fig. 
8). In the presence of protein S the APC-catalyzed inactivation of rFVa-GQR was even 
more complex and could not be associated with individual cleavages, because the data 
from the blots were difficult to interpret. Therefore, we were not able to assess the effect of 
protein S on cleavage at R679. Probably, cleavage at Rx2 becomes very important, 
because this cleavage is stimulated about 50-fold in the presence of protein S [28]. 
Interestingly, in the presence of protein S cleavage at R679 seemed to facilitate the 
subsequent cleavage at Rx1. This could mean that cleavage at R679, enhances the 
'stimulating' effect of protein S on cleavage at Rx1 (and possibly also R506?). Clearly, 
more work has to be done to elucidate the precise role of protein S in the APC-mediated 
cleavage of R679. 
In conclusion, our results demonstrate that the APC-mediated cleavage at R506 in the 
heavy chain of FVa occurs at a higher rate than cleavage at R306 or R679, respectively. In 
addition, we showed that protein S is stimulatory for both the APC-mediated cleavages at 
R306 and R506, although this stimulation is much higher for cleavage at R306. The effect 
of protein S on cleavage at R679 remains to be elucidated. Furthermore, our results 
demonstrate that cleavage at the individual APC cleavage sites has different effects on the 
activity of the resulting FVa molecules. The activity of FVa306 is much lower than that of 
FVa506 and FVa679, the latter two being dependent on the FXa concentration used in the 
prothrombinase reaction. Under physiological conditions the contribution of cleavage at 
R679 to the inactivation of normal FVa seems to be at most marginal. Norstrøm et al. [17] 
have suggested that cleavage at R679 contributes to the inactivation of naturally occurring 
FV mutants with mutations at the R306 position (such as FV Hong-Kong or FV 
Cambridge). Based on our observations it seems, however, more likely that the APC-
catalyzed cleavage at Rx2 rather than cleavage at R679 contributes to the inactivation of 
FVa Hong-Kong or Cambridge. 
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Summary  
The R2 haplotype of the FV gene spans from exon 8 through 25 and comprises several 
strongly linked polymorphisms in the FV gene, including some missense mutations. 
Carriership of the R2-FV allele has been associated with reduced plasma FV levels, 
increased FV1/FV2 ratios and mild APC resistance. Some studies have reported that 
carriership of the R2-FV allele is associated with an increased risk of venous thrombosis. 
At this moment, the individual contribution to the R2-associated phenotypes of the 
different mutations linked to the R2 haplotype of FV is unclear. The main objective of our 
study was to obtain insight in the influence of the R2-related D2194G mutation on FV 
expression, FV structure and FV function using B-domainless rFV mutants. Replacing Asp 
at position 2194 by Gly resulted in a more than threefold reduction of rFV expression 
compared to rFV wild-type. Therefore, we propose that the R2-linked D2194G mutation is 
an important determinant of the association of the R2-FV allele with lower FV levels. 
Furthermore, the light chains from D2194G containing rFV mutants showed similar 
molecular weights as the light chains of the non-glycosylated rFVwt or the plasma FV2 
isoform, indicating that glycosylation at N2181 is not stimulated by the presence of a 
glycine in position 2194. Finally, the apparent Kd for dissociation of the FXaVa complex 
(K1/2Xa) was not higher in rFV mutants with the D2194G mutation than for rFVwt, 
suggesting that also the affinity for negatively charged phospholipids is not affected by 
substitution of Asp into Gly at position at 2194.    
 
Introduction 
Human coagulation factor V (FV) comprises two isoforms, designated FV1 and FV2 [1]. 
The dominant form in plasma and platelets is FV2, which accounts for approximately 70% 
of total FV and has a slightly lower molecular mass than FV1 [2]. The structural 
heterogeneity resides in the light chain of activated FV (FVa), which has either an apparent 
molecular mass of ~74 kD (FVa1) or ~71 kD (FVa2) [3]. Recently, it has been 
demonstrated that inefficient glycosylation of N2181 at the C-terminal end of the light 
chain is responsible for this heterogeneity [4-6]. 
The presence of an N-linked carbohydrate group at N2181 has structural as well as 
functional implications. Experiments using purified human FVa1 and FVa2 have shown 
that FVa1 has a lower affinity for negatively charged phospholipid membranes [1]. As a 
result FVa1 has a lower capacity to stimulate the prothrombinase complex, but is also less 
efficiently inactivated by activated protein C (APC). Hoekema and co-workers have 
demonstrated that under physiological conditions FVa1 is capable of generating more 
thrombin than FVa2 and is therefore more thrombogenic [7]. 
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In plasma from homozygous carriers of the so-called R2 haplotype of the FV gene the 
ratio of FV1/FV2 seems to be increased [8,9]. This R2 haplotype comprises several 
strongly-linked polymorphisms in the FV gene, some of which predict amino acid changes. 
This haplotype has first been described in 1996 by Lunghi et al [10]. Besides an increase 
in FV1/FV2 ratio, carrier-ship of the R2 allele (allele frequencies in Caucasians and non-
Caucasians range from 0.041 to 0.102 [11-17]) has also been associated with some other 
laboratory phenotypes.  
First, the R2 haplotype has been associated with lower levels of FV in plasma [10], an 
observation that has been confirmed in several independent studies [9,12,13,15]. The 
molecular basis for this association is not known. As no functional variations in the 
promoter region of the FV gene have been found linked to the R2 allele [13], it seems 
likely that one or more of the polymorphisms in the R2 haplotype have a direct effect on 
FV synthesis, secretion or stability. Furthermore, it has been observed that the R2 allele is 
associated with mild APC resistance (measured with the classical APTT-based APC-
resistance test) [9,11-15,18] and that the APC-cofactor function of R2-FV in FVIII 
degradation is decreased [9,14]. Finally, carriership of the R2-FV gene seems also 
associated with a small increased risk of venous thrombosis (especially in combination 
with the FV Leiden mutation) [12,13,15,19-21]. However, published data on both 
laboratory and clinical phenotypes are not always consistent. 
Castoldi and co-workers have proposed an explanation for the thrombogenic 
phenotypes associated with the R2-FV allele [8,9]. They observed that the affinity for 
negatively charged phospholipids of FVa from homozygous carriers of the R2-FV allele is 
decreased. It was postulated that the R2-linked D2194G substitution in the light chain of 
FVa is the functional determinant for the thrombogenic phenotype either via a positive 
effect on the glycosylation at N2181 (resulting in a relative increase of the thrombogenic 
FV1 isoform), or via a conformational change of the light chain. So far, there are no 
experimental data that (dis)prove this hypothesis. In the present study, recombinant FV 
molecules were used to obtain more insight in the influence of the D2194G mutation on 
FV expression, FV structure (e.g. glycosylation of N2181) and FV function. 
 
Materials and Methods 
Materials 
Luciferase assay reagent and 5x passive lysis buffer were from Promega Benelux b.v., 
Leiden, The Netherlands. Rapid ligation kit and the BM Chemiluminescence blotting 
substrate (POD) were obtained from Boehringer Mannheim, Mannheim, Germany. 
Plasmid isolation kits were from Qiagen, Chatsworth, CA, USA. DNA restriction 
fragments were purified from agarose gel using the cleanmix kit (Talent, Trieste, Italy). 
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CNBr-Sepharose and SP-Sepharose were obtained from Pharmacia, Uppsala, Sweden. 
Bovine Serum Albumin (BSA), benzamidine, phosphatidylcholine (PC), N-hydroxy-
succinimidobiotin and Hepes were from Sigma (St. Louis, MO, USA). 
Dioleoylphospatidylcholine (DOPC) and dioleoylphospatidylserine (DOPS) were obtained 
from Avanti Polar Lipids, Alabaster, Al, USA. EDTA was from Serva, Heidelberg, 
Germany. NH4Cl, TRIS and CaCl2 were purchased from Merck, Whitehouse Station, NJ, 
USA. Chromogenic substrate S-2238 was obtained from Chromogenix, Uppsala, Sweden. 
 
Proteins 
Restriction enzymes were from New England Biolabs, Beverly, MA, USA. Human factor 
Xa was from Haematologic Technologies Inc., Essex, VT, USA. Human factor V, 
activated protein C, prothrombin, thrombin and sheep anti-FV polyclonal antibody were 
purchased from Enzyme Research Laboratories (South Bend, IN, USA). Purified FVa1 and 
FVa2 were kind gifts from Dr. G. Tans, University of Maastricht. Monoclonal antibody 
(mAb) 3B1 directed against the heavy chain of human FV was a kind gift from Prof. B.N. 
Bouma, University of Utrecht. NeutraliteTM Avidin-HRP conjugate was from Southern 
Biotechnology Associated, Inc., Birmingham, AL, USA. 
  
Construction of B-domainless FV expression vector 
Expression vector pMT2FV, containing the full-length cDNA of human FV, was used to 
construct a FV expression vector lacking the major part of the B-domain (deletion from 
amino acid 828 to 1499) [22]. This B-domainless recombinant FV molecule has an 
estimated molecular weight of approximately 220 kD (Fig. 1). 
Two oligonucleotides were designed, based on the cDNA sequence of FV, with either a 
DraIII or a BspMI site in the 5’ region. These restriction sites are unique sites in the 
pMT2FV construct. The sequences of the two oligos were: 
5’-TTAAAGAATTCACTTGGTGCAAAGGAAGAGGTCCAGAGCAG-3’ (with the 
DraIII site) 
5’-ATAATGAATTCGCCTATGTTCAGCAGGTGTAACC-3’ (with the BspMI site) 
A large deletion relative to the FV cDNA was present between the GCA-codon (Ala 
827) and AAG-codon (Lys1500) in the first oligo nucleotide. The two oligos, were used to 
generate a PCR fragment of 905 basepairs using pMT2FV as a template. Subsequently, the 
905 basepair PCR fragment was digested with DraIII and BspMI and exchanged with a 3 
kb fragment coding for part of the B-domain from pMT2FV. The B-domainless construct, 
labelled pMT2FV∆B, was checked by direct DNA sequencing using the CEQ2000TM Dye 
Terminator Cycle Sequencing Kit from Beckman Coulter Inc., Fullerton, CA, USA.  
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Mutagenesis  
Expression vector pMT2FV was used as a template to introduce mutations in the C-
terminal part of FV. Mutations were introduced using the QuickchangeTM Site-Directed 
Mutagenesis Kit from Stratagene, La Jolla, CA, USA. The forward mutagenic oligos used 
for construction of three single mutants were: 
5’-CATTCCTAAAACATGGCAACAAAGTATTACACTTCGCCTGG-3’ (N2181Q), 
5’-CATTCCTAAAACATGGAACCAAACTATTACACTTCGCCTGG-3’ (S2183T), 
5’-GAACTCTTTGGCTGTGGTATTTACTAGTATTGAACATTCAAAAACCCC-3’ 
(D2194Gly) 
Nucleotides responsible for the missense mutations are presented in bold and are 
underlined. In the S2183T and D2194G mutagenic oligos additional silent mutations (in 
bold) were introduced to serve as a marker. Two double mutants were constructed by using 
the single N2181Q or S2183T construct as a template for D2194G mutagenesis.  
After mutagenesis, the presence of mutations was confirmed by direct DNA 
sequencing. Finally, the light chain mutations were inserted into pMT2FV∆B by exchange 
of the appropriate restriction enzyme fragments (Table 1). 
 
Transient expression of rFV∆B mutants 
B-domainless recombinant FV (rFV∆B) mutants were transiently expressed in COS-1 cells 
(75 cm2 culture flasks) using Fugene 6 Transfection Reagent from Roche Molecular 
Biochemicals, Hague Road, IN, USA. Twenty-four hours after transfection cells were 
 
Figure 1. Schematic representation of recombinant B-domainless FV used in this study.
A large part of the cDNA coding for the B-domain of FV was removed resulting in deletion
of amino acid 828 (nt 2656) to amino acid 1499 (nt 4671) and linking of Ala827 to Lys1500.
The estimated molecular weight of this B-domainless FV is 220 kD. Potential N-
glycosylation sites are indicated (•). 
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washed with phosphate-buffered saline (PBS) and incubated with serum-free medium 
(Optimem Glutamax, Life Technologies Ltd., Paisley, Scotland). Conditioned medium was 
harvested after 72h, centrifuged for 20 min at 1000 rpm (4°C) and frozen at -20°C. FV 
expression was measured by functional FV assay and ELISA. 
Factor V expression levels were calculated from experiments in which COS-1 cells 
(10 cm2 culture wells) were co-transfected with 4 µg pMT2FV∆B and 0.1 µg of the 
Luciferase Reporter Vector pGL3-Control (Promega, Leiden, The Netherlands). 
Conditioned media and lysates were harvested after 48h incubation with serum-free 
medium. FV was measured by a functional FV assay (U/ml) or ELISA (U/ml) and 
intracellular luciferase activity was measured using luciferase assay reagent and expressed 
as relative light units (RLUs). Factor V expression levels were adjusted for transfection 
efficiency by calculating the ratio of FV activity/luciferase activity. Finally, FV 
activity/luciferase activity ratios were normalized by setting the ratio for rFV∆B-wt on 
100%. In general, the transfection efficiency was very similar for the different FV 
constructs. 
Purification of recombinant FV 
Recombinant FV∆B mutants were isolated in a two step procedure essentially as 
previously described by van der Neut Kolfschoten [23]. Briefly, conditioned medium was 
thawed, supplemented with 10 mM benzamidine and loaded on an ion exchange column 
(SP-Sepharose fast flow), which was subsequently washed with a buffer containing 25 mM 
Hepes, 100 mM NH4Cl, 5 mM CaCl2, 10 mM benzamidine (pH 7.5), until the fall-through 
was protein free. FV was eluted from the column with elution buffer (25 mM Hepes, 1.5 M 
NH4Cl, 5 mM CaCl2, 10 mM benzamidine, pH 7.5). FV containing fractions were 
supplemented with 2 mg/ml ovalbumin, dialyzed against buffer containing 25 mM Hepes, 
50 mM NaCl, 5 mM CaCl2, 10 mM benzamidine (pH 7.3), pooled and applied at a speed of 
3 ml/h to an affinity column, consisting of 1 mg mAb-3B1/ml Sepharose. The column was 
washed with 25 mM Hepes, 50 mM NaCl, 5 mM CaCl2 (pH 7.3) and eluted with 25 mM 
Hepes, 1.8 M NaCl, 5 mM CaCl2, pH 7.3. Eluted fractions were screened for FV 
(activity/antigen) and analyzed by SDS-PAGE followed by silver staining or 
immunoblotting. FV containing fractions were supplemented with 2 mg/ml ovalbumin, 
dialyzed against 25 mM Hepes, 50 mM NaCl, 5 mM CaCl2 (pH 7.3), and stored at –80°C.   
 
FV activity assay 
Total FV activity was measured in a two-step procedure as previously described with 
minor modifications [2,23]. In the first step rFV∆B was completely activated with 4 nM 
thrombin in HBS-Ca (25 mM Hepes, 175 mM NaCl, 3 mM CaCl2, 5 mg/ml BSA, pH 7.5) 
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during a 20 min incubation at 37°C in a final volume of 150 µl. Subsequently, 10 µl was 
transferred to a 96 wells plate, 100 µl of prothrombinase mix (HBS-Ca containing FXa and 
DOPS/PC 10:90 molar ratio) was added and after five minutes the prothrombinase reaction 
was started by addition of 25 µl prothrombin (1.47 µM) in HBS-Ca. Final concentrations 
were: FXa (125 pM), prothrombin (280 nM) and DOPS/PC (50 µM). After a 4 min 
incubation at room temperature the reaction was stopped with 50 µl TN-EDTA (50 mM 
TRIS, 175 mM NaCl, 50 mM EDTA, 5 mg/ml BSA, pH 7.9). After the addition of 25 µl 
chromogenic substrate S-2238 (2.35 mM), the amount of thrombin formed was measured 
kinetically on a Spectra III Thermo microtiter plate reader from Tecan (Salzburg, Austria). 
The assay was calibrated using dilutions of pooled normal plasma (PNP) corresponding 
with 0-3 pM of FV.  
 
XaVa complex formation  
The potential of FVa to form a complex with FXa and express cofactor activity in 
prothrombin activation was determined by measuring prothrombin activation at varying 
concentrations of FXa and a fixed, limiting amount of FVa [9]. Briefly, rFV∆B mutants in 
conditioned medium or isolated fractions were diluted in HBS-Ca to a final concentration 
of ~140 pM and activated for 10 min with 10 nM thrombin at 37°C. Activated rFV (~5.5 
pM) was added to a reaction mixture (37°C) containing 25 mM Hepes, 175 mM NaCl, 5 
mg/ml BSA, 2.2 mM CaCl2, 2 µM phospholipid vesicles (DOPS/DOPC, 5/95, mol/mol) 
and 0-10 nM Xa (final concentrations). Prothrombin activation was started by adding 1 
µM prothrombin (final concentration) to the reaction mix. After 3.75 min 10 µl of the 
reaction mixture was added to 490 µl ice cold TN-EDTA, from which 200 µl was 
transferred to a 96 wells plate. Finally, 25 µl S-2238 (2.35 mM) was added to quantify the 
amount of thrombin formed. The apparent Kd for dissociation of the XaVa complex 
(K1/2Xa) and the prothrombin-converting activity of this complex (VXa→∞) were obtained by 
fitting the data to the equation for a single-site binding isotherm using non-linear least-
squares analysis.        
 
FV antigen assay 
FV light chain antigen was detected in an ELISA using two different monoclonal 
antibodies directed against the light chain of FV as described before [24]. In this ELISA, 
mAb V-6 was used as a coating antibody and biotinylated mAb V-9 as tagging antibody. 
The detection limit of this ELISA was about 0.05 U /ml (~50 ng/ml). 
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SDS-PAGE and immunoblot analysis 
Polyacrylamide gel electrophoresis was performed on gradient SDS/PAGE under reducing 
conditions according to Laemmli [25]. Gels were silver stained or subjected to 
immunoblotting. Transfer to a PVDF membrane (Millipore Corporation, Bedford, MA, 
USA) was carried out semi-dry on a blot system from Pharmacia (Uppsala, Sweden). To 
detect FV, biotinylated polyclonal antibody (sheep anti-FV) was used. Neutralite Avidin-
HRP in combination with blotting substrate POD was used to visualize the immobilized 
biotine.  
 
Results 
Expression of rFV∆B mutants  
A FV expression vector was constructed lacking the major part of the region coding for the 
B-domain (deletion of amino acid 828 to 1499) in order to increase FV expression (Fig 1). 
In conditioned medium of COS-1 cells expression levels (activity and antigen) of 
recombinant B-domainless FV wild-type (rFV∆Bwt) were 3 to 10 times higher than those 
of full-length recombinant FV wild-type (data not shown). To study the structural and 
functional effects of the R2-related D2194G mutation in the light chain of FV, different 
rFV∆B mutants were generated with mutations in the consensus sequence of the 
glycosylation site at N2181 and in amino acid D2194 (Table 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Factor V molecules used in this study. Recombinant proteins were named after 
amino acids in the C-terminal region of the light chain at positions 2181, 2183 and 2194 
using the one letter code for amino acids. Mutated positions are bold and underlined.  
Factor V Mutation Comments 
hFVa No mutations FVa isolated from human plasma 
hFVa1 No mutations FVa1 isolated from human plasma 
hFVa2 No mutations FVa2 isolated from human plasma 
rFV∆B-wt No mutations FV wild type del B-domain (∆ 827-1499) 
rFV∆B-QSD N2181Q Removal of glycosylation site at N2181 
rFV∆B-NTD S2183T Improved glycosylation at N2181 
rFV∆B-NSG D2194G Mutation present in R2-haplotype 
rFV∆B-QSG N2181Q, D2194G Double mutant 
rFV∆B-NTG S2183T, D2194G  Double mutant 
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The effect of the light chain mutations on FV expression was studied by comparing 
the FV expression levels of the different rFV∆B mutants in conditioned medium. COS-1 
cells were co-transfected with pMT2FV∆B and luciferase reporter vector pGL3-Control. 
Luciferase activity was used to adjust FV expression levels for transfection efficiency. FV 
expression levels were calculated using the adjusted rFV∆B-wt expression level as a 
reference (Table 2). Removal of glycosylation site at N2181 by replacing asparagine with 
glutamine did not influence FV expression, as rFV∆B-wt and rFV∆B-QSD showed very 
similar expression levels (Table 2). When glycosylation of N2181 was stimulated by 
introducing a threonine (rFV∆B-NTD) in the glycosylation consensus sequence Asn-X-
Ser/Thr at position 2183 FV expression decreased almost two-fold. The most dramatic 
effects were observed after introduction of the R2-linked D2194G mutation (rFV∆B-
NSG), which resulted in a more than three-fold reduction in FV expression. In 
combination with the N2181Gln (rFV∆B-QSG) or the S2183T mutation (rFV∆B-NTG) 
over five- and forty-fold reductions were observed, respectively. FV antigen levels showed 
the same expression pattern as for FV activity. This is reflected in similar activity/antigen 
ratios for the different FV mutants in the conditioned media (Table 2).  
Table 2. Expression of B-domainless recombinant FV mutants 
Factor V % FV activity
1,2  
(number of transfections) 
Activity/antigen1  
(number of transfections) 
rFV∆B-wt 100 ± 12.5 (23) 0.55 ± 0.28 (14) 
rFV∆B-QSD 104.6 ± 18.3 (6) 0.66 ± 0.21 (7) 
rFV∆B-NTD 62.7 ± 3.3 (12) 0.7 ± 0.19 (10) 
rFV∆B-NSG 27.9 ± 9.8 (23) 0.5 ± 0.17 (11) 
rFV∆B-QSG 13.3 ± 8.3 (17) 0.67 ± 0.1 (7) 
rFV∆B-NTG  2.6 ± 1.5 (11)  - 
 
1FV activity and FV antigen levels in conditioned medium were obtained by functional FV 
assay and FV ELISA, respectively, and expressed as U/ml, where 1 U is the amount of FV 
(activity or antigen) in 1 ml of pooled normal plasma. The FV activity/antigen ratio for the 
rFV∆B-NTG mutant could not be determined accurately due to very low expression levels.  
2FV activity (U/ml) was adjusted for transfection efficiency (see Methods section). For each 
experiment the mean of the adjusted FV activity of rFV∆B-wt was set at 100%. Mean 
expression of rFV∆B-wt was ~0.1 U/ml as measured in the FV activity assay and 0.18 U/ml 
(~1.8 µg/ml) in the FV antigen assay (calculated from activity/antigen ratio). 
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Activity and antigen levels of FV in the lysates of the transfected COS-1 cells (data 
not shown) showed a similar pattern (e.g. high levels for rFV∆Bwt and low levels for 
mutants containing the D2194G mutation) as observed for the conditioned media. 
 
Immunoblot analysis of activated rFV∆B mutants in freshly collected medium 
Possible mobility shifts on SDS-PAGE, as a result of glycosylation at N2181, of the light 
chains of the activated rFV∆B mutants were checked in freshly collected medium, to avoid 
potential influences of downstream processing. Figure 2 shows the heavy and light chains 
of thrombin-activated rFV∆B mutants after SDS-PAGE and immunoblotting with a 
polyclonal anti-FV antibody. It is clear that all heavy chains migrate at the same rate as the 
heavy chains from hFVa1 and FVa2 (~105 kD). Interestingly, the light chains of rFV∆B-
wt, rFV∆B-QSD, rFV∆B-QSG rFV∆B-NSG have the same mobility (~71 kD) as the (non-
glycosylated at N2181) light chain of plasma FVa2, whereas the rFV∆B-NTD mutant 
shows a mobility similar to that of the (glycosylated at N2181) light chain of plasma FVa1 
(~74 kD).  
  
     
 
 
 
            
            
    1          2            3          4          5           6            7           8
74 kD 
 
71 kD 
 
Figure 2. Immunoblot analysis of thrombin activated FV mutants in freshly 
collected medium. Samples of freshly collected conditioned medium were 
activated with 10 nM thrombin and analyzed by SDS-PAGE (7-9.5%) and 
immunoblotting Heavy and light chains of activated FV were visualized with a 
polyclonal antibody against human FV. Each lane contains about 20 ng of 
activated FV. Lane 1 and 8, hFVa2; lane 2, hFVa1; lane 3, rFV∆B-wt; lane 4, 
rFV∆B-QSD; lane 5, rFV∆B-NSG; lane 6, rFV∆B-QSG lane 7, rFV∆B-NTD 
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SDS-PAGE analysis of purified FV and FVa 
To perform a more detailed characterization of the properties of the recombinant FV 
molecules, the proteins were purified. The purity of the isolated rFV∆B mutants was 
checked by silverstaining after SDS-PAGE (Fig. 3a). In all preparations a dominant band 
was present with an estimated molecular weight of 240 kD, representing the full-length B-
domainless FV. This band was also observed after immunoblotting using a polyclonal anti-
FV antibody (not shown) and was susceptible to thrombin cleavage (see Fig. 3b). 
Figure 3. SDS-PAGE analysis of 
isolated rFV∆B  mutants.  
3a. Fractions containing purified rFV∆B 
mutants were analyzed by silverstaining 
after gradient (7-9.5%) SDS-PAGE. Each 
lane contained about 500 ng of 
recombinant FV (activity). Lane 1, 
rFV∆B-QSD; lane 2, rFV∆B-QSG; lane 
3, rFV∆B-NSG; lane 4, rFV∆B-NTD; 
lane 5, rFV∆B-wt.  
3b. Fractions containing purified rFV∆B 
mutants were activated with 10 nM of 
thrombin followed by electrophoresis (7-
9.5% gradient gel) and silverstaining. 
Note that the highly glycosylated heavy 
chain of the rFVa molecules did not stain 
very well. Each lane contained about 500 
ng of activated FV. Lane 1, 7 hFVa; lane 
2, rFV∆B-wt; lane 3, rFV∆B-QSD; lane 4, 
rFV∆B-QSG; lane 5, rFV∆B-NSG; lane 
6, rFV∆B-NTD 
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After thrombin cleavage, the heavy and light chains from the purified rFV∆B mutants 
were also analyzed by SDS-PAGE (Fig 3b). As in the conditioned medium the heavy 
chains of the rFV∆B mutants migrated at about the same rate (~105 kD) as the heavy chain 
from activated plasma FV. The light chains of rFV∆B-wt, rFV∆B-QSD, rFV∆B-QSG 
rFV∆B-NSG have the same mobility (~71 kD) as the light chain of plasma FVa2, but the 
light chain of rFV∆B-NTD has a lower mobility and migrates at the same rate as the light 
chain of plasma FVa1 (compare also with doublet from activated human FVa).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XaVa complex formation 
Kinetic analyses have shown that the ability of FVa to form a complex with FXa and 
express cofactor activity in prothrombin activation is dependent on both the concentration 
of phospholipid vesicles and their phosphatidylserine (PS) content [26]. In this study, the 
assembly of activated rFV∆B mutants in the prothrombinase complex was assessed in an 
assay system sensitive to small changes in the affinity of activated FV for negatively 
charged membranes (2µM phospholipids, 5% PS content and 5.5 pM rFVa) [1,2]. Due to 
the sensitivity of this assay we decided to compare only like-like results (recombinant FV 
vs recombinant FV). The FXa concentrations, at which half-maximal rates of prothrombin 
activation (K1/2Xa) were obtained (at limiting amounts of rFVa), are summarized in Table 3. 
Table 3. XaVa complex formation of activated B-domainless recombinant FV 
mutants 
Freshly collected medium1 Purified factor V1  
Factor V K1/2Xa  
(nM) 
Vmax 
(nM IIa/min/pM 
Va) 
K1/2Xa  
(nM) 
Vmax 
(nM 
IIa/min/pM Va) 
rFV∆B-wt 0.27 10.7 0.29 8.5 
rFV∆B-QSD 0.25 7.9 0.35 7.3  
rFV∆B-QSG 0.25 7.9 0.20 10.1 
rFV∆B-NSG 0.24 5.4 0.24 7.4 
rFV∆B-NTD  0.56 6.2 0.63  10.4 
 
1Due to the sensitivity of this assay for the phospholipid composition and concentration the 
inter-assay variability in K1/2Xa and Vmax was considerably larger than the intra-assay 
variability. In three separate experiments the K1/2Xa of rFV∆B-NTD mutant was 
reproducibly two- to threefold higher compared to the other mutants. The presented data for 
freshly collected and purified FV are representative and taken from a single experiment.    
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From this Table it is clear that the purification procedure did not affect on the ability of 
rVa mutants to form a complex with Xa (compare K1/2Xa, Vmax before and after 
purification). As expected, stimulation of glycosylation at N2181 (rFV∆B-NTD) affected 
the affinity for phospholipids resulting in a higher K1/2Xa (~0.6 nM) than that of the non-
glycosylated rFV∆B-wt (~0.25 nM) or rFV∆B-QSD (~0.24 nM). The K1/2Xa for mutants 
containing the R2-linked D2194G mutation (rFV∆B-NSG and rFV∆B-QSG) was the same 
as for rFV∆B-wt. Under the experimental conditions used purified FVa2 has a K1/2Xa of 
~0.2 nM, very similar to that of the non-glycosylated rFV mutants (~0.25 nM), whereas 
the K1/2Xa for FVa1 was 5 to 6 times higher. The reason for this apparent discrepancy is at 
present not known. 
 
Discussion 
The main objective of the present study was to identify the influence of the R2-linked 
D2194G substitution on FV expression and glycosylation of N2181 using B-domainless 
recombinant FV (rFV∆B) mutants in a transient expression system. Introduction of the 
D2194G mutation resulted in strongly reduced FV expression levels (three- to forty-fold 
depending on the sequence context), but did not result in stimulation of glycosylation at 
N2181 or a lower affinity for negatively charged phospholipids.  
Association of the R2-FV allele with moderately reduced FV levels (activity and 
antigen) has been found in several independent studies [9,10,12,13,15]. So far, the 
molecular basis for this association has not been found. Two studies using isolated platelet 
mRNA from heterozygous carriers of the R2-allele show conflicting results on the allelic 
expression of the R2-FV allele [27,28]. No effect on transcription is expected, as the 
promoter region of the FV gene is not in linkage disequilibrium with the R2 haplotype 
[13], which spans from exon 8 through exon 25 of the FV gene. Therefore, it seems more 
likely that one or more polymorphisms in this haplotype have a direct effect on FV 
synthesis, secretion or stability. Using a transient expression system, we found that 
stimulation of glycosylation by introducing a threonine at position 2183 (see rFV∆B-NTD 
in Table 2) resulted in an almost two-fold reduction of FV expression, which is in 
agreement with another study using a recombinant FV mutant with the S2183T 
substitution [5]. A strong effect on FV expression was observed upon the introduction of 
the D2194G mutation, which resulted in a three to forty-fold reduction of FV expression 
(compare rFV∆B-NSG, rFV∆B-QSG, rFV∆B-NTG with rFV∆B-wt in Table 2). 
The effect of the D2194G on FV expression can not be explained in terms of 
functional instability, because the activity/antigen ratios of the two D2194G containing 
rFV mutants are similar to the ratio of rFV∆B-wt, being around 0.6 in freshly collected 
medium (Table 2). There are also no indications that the reduced FV expression is caused 
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by impaired secretion, because there was no evidence of accumulation of factor V (activity 
and antigen) in the cells tranfected with mutant FV constructs (data not shown). Most 
likely, the D2194G mutation results in a conformation of the FV molecule, which is more 
susceptible to intracellular degradation. Possibly, the disulfide bridge of the adjacent 
Cys2193 is affected. In conclusion we like to propose that the R2-linked D2194G mutation 
is a functional determinant in the association of the FV R2-allele with moderately reduced 
FV levels. This conclusion is in line with a report from Yamazaki et al. [29] (published 
during the preparation of this thesis) on transient expression of full-length rFV mutants 
with several R2-linked missense mutations.  
Characterization of the rFV∆B mutants revealed that the B-domainless rFV molecules 
have an apparent molecular weight of about 240 kD (Fig. 2a), which is close to the 
estimated 220 kD. The rFV∆B mutants were still susceptible to thrombin activation (most 
likely via cleavage at Arg709 and Arg1545) (Figure 1 and 2b), although higher thrombin 
concentrations were required for complete cleavage of rFV∆B in its heavy and light chain 
than for cleavage of hFV or rFV-wt containing the complete B-domain.    
No effect of the D2194G mutation on the molecular weight of the light chain could be 
detected. Both in freshly collected medium and after purification, the light chains of 
activated rFV∆B-wt, rFV∆B-QSD, rFV∆B-NSG and rFV∆B-QSG migrated at the same 
rate as the light chain of hFVa2 (Fig 1 and 2b), whereas the activated rFV∆B-NTD mutant 
(containing the S2183T mutation, which stimulates glycosylation of N2181 [5]) showed a 
mobility shift in the light chain similar to that in the light chain from hFVa1. From these 
data it seems very unlikely that the R2-linked D2194G mutation has a stimulatory effect on 
the glycosylation of N2181, although we can not exclude that in vivo the glycosylation of 
N2181 is more sensitive for the D2194G substitution. Also, the large spatial distance 
between the two residues in the three-dimensional model of the C2 domain of FV makes it 
unlikely that the D2194G mutation will affect glycosylation of N2181 [30].  
Our data do not support the proposal of Hoekema et al. [8] and Castoldi et al. [9] that 
the relative increase in FV1, observed in the plasma of carriers of the R2-FV allele, is 
caused by more efficient glycosylation of N2181. Theoretically, the functional 
measurements in FV1/FV2 assays can also be influenced by changes in the efficiency of 
XaVa complex formation not related to glycosylation of N2181 (e.g., the D2194G 
mutation). Table 2 demonstrates that stimulation of glycosylation of N2181 in the rFV∆B-
NTD mutant indeed decreases the ability of the activated mutant (K1/2Xa ~0.6 nM) to 
promote XaVa complex formation under the used conditions. No differences in XaVa 
complex formation were detected for the two mutants containing the D2194G substitution 
(K1/2Xa ~0.25 nM) and for wild-type rFV (K1/2Xa ~0.25 nM), indicating that the D2194G 
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mutation has no effect on the efficiency of formation of the prothrombinase complex under 
the conditions used (low phospholipid concentration and limiting amounts of FVa). 
These latter findings are in line with a previous report from Kim et al. [31], in which 
no important effect could be found on the prothrombinase activity of rFVa containing a 
D2194A substitution. Our findings seem also consistent with results from Hoekema et al. 
[9], who observed that under limiting conditions R2-FVa exhibited only marginal 
differences compared to normal FVa in its ability to promote VaXa complex formation 
(K1/2Xa). Also no differences in the susceptibility of R2-Va for APC were observed under 
conditions that FVa1 inactivation by APC is significantly delayed. On the other hand 
Kalafatis et al. [32] using a different experimental approach reported that activated FV in 
pseudo-homozygous R2 plasma is less susceptible to APC inactivation than FVa from 
normal pooled plasma. 
The observation that the affinity of rFVa for negatively charged phospholipids is not 
lower in FV mutants containing the D2194G mutation, makes it unlikely that this mutation 
is responsible for a thrombogenic phenotype of R2-FV via a mechanism of impaired 
phospholipid binding like is the case for FV1 [7]. We can not exclude that the D2194G 
mutation contributes to a thrombogenic phenotype of R2-FV via another mechanism, e.g. a 
lower APC-cofactor activity in FVIIIa degradation. To study this rFV mutants containing 
the full-length B-domain are needed [33-35].  
Taken together, we conclude that the singled-out D2194G mutation is a functionally 
important determinant for decreased FV levels in R2-FV gene carriers. Most likely, the 
reduced expression of R2-FV is responsible for the enhanced APC-resistant phenotype in 
compound heterozygous FV Leiden/R2 carriers (see also [11,13,27]. No structural 
evidence was obtained that the D2194G substitution is a determinant of the putative 
thrombogenic phenotype of R2-FV either via promoting glycosylation at N2181 or via 
lowering of the affinity for negatively charged phospholipids. 
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Summary 
Background: During the study of a family with hereditary FV deficiency (FV Amersfoort, 
1102A>T in exon 7) we identified an individual with 5% FV heavy chain antigen (FVHC) 
and 50% FV light chain antigen (FVLC). Further testing revealed that apart from the FV 
Amersfoort allele a second variant FV allele was segregating in this family, which encodes 
for a FV molecule with a reduced affinity for mAb V-23 used in the FV heavy chain 
ELISA (ELISAHC). Objective: Identification and characterization of the molecular basis 
responsible for the reduced affinity of the variant FV for mAb V-23. Methods: Family 
members of the proband were screened for mutations in the exons coding for the heavy 
chain of FV, after which the recombinant variant FV could be generated and characterized. 
Next, the cases and controls of the Leiden Trombophilia Study (LETS) were genotyped for 
carriership of the variant FV. Results: In the variant FV allele a polymorphism in exon 3 
(409G>C) was identified, which predicts the replacement of aspartic acid 79 by histidin 
(D79H). Introduction of this mutation in recombinant factor V confirmed that it reduces 
the affinity for binding to mAb V-23. The substitution has no effect on FV(a) stability and 
Xa-cofactor activity. In Caucasians the frequency of the FV-79H allele is ~5%. Analysis of 
the LETS revealed that the FV-79H allele is not associated with FV levels (FVLC), 
activated protein C sensitivity (using an activated partial thromboplastin time-based test) 
or risk of venous thrombosis (OR 1.07, CI 95: 0.7 – 1.7). Conclusion: The D79H 
substitution in FV should be considered as a neutral polymorphism. The monoclonal 
antibody V-23, which has a strongly reduced affinity for FV-79H, is not suitable for 
application in diagnostic tests. 
 
 
Introduction 
Human coagulation factor V (FV) is a large plasma glycoprotein that plays an important 
role in blood coagulation. In plasma, FV circulates as a single-chain procofactor and is 
activated by thrombin via limited proteolysis [1-3]. Activated FV (FVa) consists of two 
polypeptide chains (designated as heavy and light chain), which are non-covalently linked 
via a Ca2+ ion [4]. FVa serves as the non-enzymatic cofactor of the serine protease Xa, 
which is responsible for the proteolytic activation of prothrombin in the prothrombinase 
complex, consisting of FVa, FXa, and negatively charged phospholipids. Down-regulation 
of FVa is mediated by activated protein C (APC) through proteolytic cleavage of the heavy 
chain of FVa at Arg306, Arg506 and Arg679 [5]. Procofactor FV contains also APC-
cofactor activity in the inactivation of factor VIIIa (FVIIIa) [6,7].  
FV plays an important role both in the up and down-regulation of thrombin generation 
(see also reviews [8] and [9]). This dual role of FV is reflected in the disorders associated 
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with molecular defects in FV, which can be either hemorrhagic or thrombotic. A mild to 
severe bleeding tendency has been reported in patients with nonsense or missense 
mutations in the factor V gene (F5) which prevent FV synthesis or result in dysfunctional 
FV (a large selection of FV mutations is summarized in references [8] and [10]). On the 
other hand the common R506Q mutation (FV Leiden), which impairs degradation of FVa 
by APC, is associated with an increased risk of venous thrombosis [11-13].  
Measurement of FV antigen levels is an important tool in the laboratory diagnosis of 
FV deficiency (parahaemophilia), which is a rare autosomal recessive bleeding disorder 
with an estimated prevalence of 1 to 1,000,000 [14]. Also, in the laboratory screening of 
thrombophilia FV antigen measurements are important, as compound heterozygosity for 
FV Leiden and a FV null allele results in a pseudo-homozygous phenotype (severe APC-
resistance) [15-20].  
Several immunologic assays for the measurement of FV in plasma are available. In 
our laboratory we have developed two enzyme-linked immunosorbent assays (ELISA) for 
measuring FV antigen, one for the light chain and one for the heavy chain. The light chain 
ELISA (ELISALC) has first been described by Guasch et al. [21] and uses two murine 
monoclonal antibodies (mAbs), V6 and V9, the epitopes of which have been mapped on 
the light chain of FVa. The heavy chain ELISA (ELISAHC) uses two murine mAbs (V-23 
and V39) directed against the heavy chain of FVa.  
During the study of the family of an asymptomatic heterozygous carrier of the FV 
Amersfoort allele (1102A>T in exon 7 [22]), we observed a striking discrepancy between 
FV light chain and heavy chain antigen levels in some of the family members. Further 
analysis showed that this abnormality cosegregated with a 409G>C transversion in exon 3 
of F5 predicting an amino acid substitution (D79H) in the heavy chain of FV (first 
reported by Cargill et al. [23]). So far, the effect of the D79H substitution on the function 
of FV is not clear. Recently, however, it has been reported that carriership of FV-79H is 
associated with moderately decreased FV levels and may serve as a trans-acting gene 
mutation in heterozygous carriers of FV Leiden by lowering the sensitivity of plasma to 
APC [24]. The latter observations prompted us to further investigate the effects of the 
D79H substitution on FV function, FV levels, APC-sensitivity ratios and risk of venous 
thrombosis. 
 
Materials and Methods 
Materials 
Plasmid isolation kits were from Qiagen (Chatsworth, CA, USA). DNA restriction 
fragments were purified from agarose gel using the Cleanmix kit (Talent, Trieste, Italy). 
Bovine Serum Albumin (BSA), benzamidine, phosphatidylcholine (PC), N-hydroxy-
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succinimidobiotin was from Sigma (St. Louis, MO, USA). Dioleoylphospatidylcholine 
(DOPC) and dioleoylphospatidylserine (DOPS) were obtained from Avanti Polar Lipids 
(Alabaster, Al, USA). dNTP were from Serva (Heidelberg, Germany). Chromogenic 
substrate S-2238 was obtained from Chromogenix (Uppsala, Sweden).  
 
Proteins 
Restriction enzymes were from New England Biolabs (Beverly, MA, USA). Human factor 
Xa was from Haematologic Technologies Inc. (Essex, VT, USA). Amplitaq DNA 
polymerase was from Applied Biosystems (Foster City, CA, USA). Activated protein C, 
prothrombin, thrombin and sheep anti-FV polyclonal antibody were purchased from 
Enzyme Research Laboratories (South Bend, IN, USA). NeutraliteTM Avidin-HRP 
conjugate was from Southern Biotechnology Associated Inc. (Birmingham, AL, USA). 
 
FV deficient family  
We studied the family of an asymptomatic FV deficient individual who was heterozygous 
for an 1102A>T substitution in exon 7 (FV Amersfoort, see van Wijk et al. [22]). 
  
FV antigen assays 
FV light chain antigen was detected in an ELISA using two different monoclonal 
antibodies (mAbs) directed against the light chain of FV as described before [21,25]. In 
this ELISA, mAb V-6 was used as a coating antibody and biotinylated mAb V-9 as tagging 
antibody. FV heavy chain antigen was detected in an ELISA recently developed in our 
laboratory. This ELISA shows identical dose response curves for plasma and serum factor 
V, indicating that it identifies a fragment of the heavy chain of factor Va, which is not 
cleaved during activation or inactivation of factor V(a). Monoclonal antibody mAb V-23 
was used as coating antibody and biotinylated mAb V-39 as tagging antibody. For both 
light chain and heavy chain ELISA, samples were diluted in 50 mM tetraethylammonium 
(TEA), 100 mM NaCl, 10 mM EDTA and 0.1% Tween, pH 7.5. Dilutions of pooled 
normal plasma (1:25 to 1:1600 dilution) were used to calibrate the assays. Results are 
expressed in %, where 100% refers to the concentration of factor V in pooled normal 
plasma. 
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Table 1. Primers used for amplification and sequencing of exons 1 to 13 of the FV gene. 
Ex
on
 
Primer Sequence (5’-3’) Position 
(relative to exon) 
Tm 
(°C) PC
R
  
pr
od
uc
t 
(b
p)
 
1 
PrFV1-F 
PrFV1-R 
CCACAGCCTCTAGAGCTCAT 
CACCCGGACTCCACACCTG 
 -113 to -92  
intron 1,  +25 to +7 63 296 
2 
PrFV2-F 
PrFV2-R 
GTGAACAAATAGTTATCACAACAGG 
TTAGATGCATGTGAATGCCA 
intron 1, –223 to –199 
intron 2, +73 to +54 58 388 
3 
PrFV3-F 
PrFV3-R 
TGATGACCCTGAATACAGAC 
GTTGATGCTGGTATTAAAGA 
intron 2, –45 to –26 
intron 3, +64 to 45 58 232 
3’ PrFV3(79)-F
1 
PrFV3(79)-R1 
GGAGGAATGGTAGCAATCACTCTTGG 
TCCTTGAGGATGGATGCTCAGATGCTTAT2 
intron 2, -120 to -93 
exon 3, 438 to 410 
63 208 
4 PrFV4-F 
PrFV4-R 
CTCATCTTAGCTATCCCAGAT 
TGACAGAACTCCTGACCATTCC 
intron 3, –87 to 67 
intron 4, +62 to 41 
58 362 
5 PrFV5-F 
PrFV5-R 
CTGCAGTGCTACTGAAAACA 
TGGTCAACTCTAGTGCTTTG 
intron 4, –37 to –18 
intron 5, +88 to +69 
55 269 
6 PrFV6-F 
PrFV6-R 
GCCTAATCCTTTAGCAATCCCTG 
TCTGCATTGAGAAGCAAGAC 
intron 5, –290 to -269 
intron 6, +39 to  +20 
58 551 
7 PrFV7-F 
PrFV7-R 
CTTCTCTTGAGTTATTTCATTG 
GTCTTGAACCTTTGCCCAG 
intron 6, –41 to –20 
intron 7, +42 to 24 
58 249 
8 PrFV8-F 
PrFV8-R 
GCAGAATGTTTAAGCACAAGG 
AATAACCAGGTACTCCATAATA 
intron 7, –422 to -401 
intron 8, +68 to +47 
58 333 
9 PrFV9-F 
PrFV9-R 
GATGACTTCAAAGACAGTGTCC 
CTGAAGTGAGAAGGGTTTGGCTGTGAT 
intron 8, –422 to 401 
intron 9, +157 to +131 
60 679 
10 PrFV10-F 
PrFV10-R 
TATCATGAAATAACTTTGCAAATG 
CTTGAAGGAAATGCCCCATTA 
intron 9, –53 to –30 
intron 10, +99 to +79 
58 367 
11 PrFV11-F 
PrFV11-R 
CTGAGTCTCCTATTCTGTTC 
CAACCACAGGAATGAAAAACTG 
intron 10, –73 to –54 
intron 11, 49 to 28 
62 273 
12 PrFV12-F 
PrFV12-R 
CATAGACTTGGAATTTTAACAG 
ATTCAAAGCAAGCTTCCTCT 
intron 11, –37 to –16 
intron 12, +44 to 25 
58 294 
13 PrFV13(1)-F 
PrFV13(1)-R 
GATTATTGTGTTTTCATGTCT 
CTGCAAGGTTATTGACAGTG 
intron 12, –67 to 47 
exon 13, 2467 to 2448 
55 468 
 
1Primers used for detection of D79H mutation in exon 3  
2This oligonucleotide contains a mismatch (underlined), which generates a BsaBI recognition site in the amplification  
fragment of the FV-79D allele 
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DNA amplification and sequence analysis 
The exons coding for the heavy chain of FV were amplified according to standard PCR 
procedures. PCR reactions were performed using 0.1-1 µg genomic DNA, 200 ng primers, 
200 µM dNTP and 1U of DNA polymerase in PCR buffer containing 67 mM TRIS-HCl 
(pH 8.8), 6.7 mM MgCl2, 6.7 µM EDTA, 16.6 mM (NH4)2 SO4, 0.1 mg/ml BSA, 10% 
DMSO and 10 mM β-mercapto-methanol. For exons 5 and 13, however, a different PCR 
buffer was used containing 25 mM TRIS-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 
0.01% w/v gelatin. Sequence reactions were performed using the CEQ2000TM Dye 
Terminator Cycle Sequencing Kit (Beckman Coulter Inc., Fullerton, CA, USA) according 
to the instructions of the manufacturer and subsequently analyzed on a SEQTM8000 
Genetic Analysis System (Beckman Coulter Inc., Fullerton, CA, USA). In Table 1 details 
about the primers are listed that were used for both PCR amplification and DNA 
sequencing. Nucleotides of the cDNA were numbered according to Jenny et al. [26]. 
 
Mutagenesis  
Expression vector pMT2FV [27] was used as template to introduce the D79H (409G>C) 
variation in the heavy chain of FV. Mutations were introduced using the QuikchangeTM 
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). The forward mutagenic 
oligonucleotide used for construction of rFV-79H was: 
5'-GTTCACTTTAAGAATAAGGCACATAAGCCCTTGAGC-3'  
The nucleotide responsible for the missense mutation is presented in bold and 
underlined. In this oligo an additional silent mutation (in bold) was introduced, which 
removes a DraI restriction site, to serve as a marker. After mutagenesis, the presence of the 
mutations was confirmed by direct DNA sequencing. Finally, the mutated fragment was 
inserted into a non-mutagenized pMT2FV by exchange of the appropriate restriction 
enzyme fragments. Details about this procedure are available on request. 
 
Transient expression of recombinant factor V 
Recombinant FV was transiently expressed in COS-1 cells (75 cm2 culture flasks) using 
Fugene 6 Transfection Reagent (Roche Molecular Biochemicals, Hague Road, IN, USA). 
Twenty-four hours after transfection cells were washed with phosphate-buffered saline 
(PBS) and incubated with serum-free medium (Optimem Glutamax, Life Technologies 
Ltd., Paisley, Scotland). Conditioned medium was harvested after 72h, centrifuged for 20 
min at 1000 rpm (4°C) and frozen at -20°C.  
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FV activity assay 
Total FV activity was measured in a two step procedure as described before [28,29]. 
Briefly, FV was completely activated by 5 nM thrombin in HBS-Ca (25 mM Hepes, 175 
mM NaCl, 3 mM CaCl2, 5 mg/ml BSA, pH 7.5) during a 20 min incubation at 37°C in a 
final volume of 150 µl. Subsequently, 10 µl was transferred to a 96 wells plate, 100 µl of 
prothrombinase mix (HBS-Ca containing FXa and DOPS/PC 10:90 molar ratio) was added 
and after five minutes the prothrombinase reaction was started by addition of 25 µl 
prothrombin (1.47 µM) in HBS-Ca. Final concentrations were: FXa (125 pM), 
prothrombin (280 nM) and DOPS/PC (50 µM). After a 4 min incubation at room 
temperature the reaction was stopped with 50 µl TN-EDTA (50 mM TRIS, 175 mM NaCl, 
50 mM EDTA, 5 mg/ml BSA, pH 7.9). After the addition of 25 µl chromogenic substrate 
S-2238 (2.35 mM), the amount of thrombin formed was measured kinetically on a Spectra 
III Thermo microtiter plate reader from Tecan (Salzburg, Austria). The assay was 
calibrated using dilutions of pooled normal plasma (PNP) corresponding with 0-3 pM of 
FV.  
 
FV(a) stability 
FVa stability was assessed by following the spontaneous loss of Xa-cofactor activity as a 
function of time in the presence and absence of phospholipids as described before [30]. 
Spontaneous inactivation rates were obtained by fitting the curves in a single-exponential 
model using non-linear least-squares analysis. 
 
Synthetic peptides overlapping region of amino acid 79 
Two synthetic peptides were constructed homologous to the amino acid sequence of 
human FV with either an aspartic acid or histidine at position 79: 
PEP79D: 71-KVHFKNKADKPLSIH-85 (D at residue 79) 
PEP79H: 71-KVHFKNKAHKPLSIH-85 (H at residue 79) 
The affinity of these peptides for mAb V-23 was assessed from experiments in which 
plasma FV was used as competitor. In brief, a 96-wells plate was coated with mAb V-23, 
after which the wells were incubated with pooled normal plasma (1/300 diluted in a buffer 
containing 50 mM TEA, 100 mM NaCl, 10 mM EDTA and 0.1% Tween, pH 7.5), mixed 
1:1 with increasing concentrations of peptides in 50 mM TEA, 100 mM NaCl, pH 7.5 
(final concentration 1 mM). After washing with ELISA buffer, the plate was incubated 
with biotinylated sheep anti-human factor V polyclonal antibody (1:500 dilution), which 
was detected with Neutralite Avidin-HRP. In the final step, the plate was colored with 
3,3’,5,5’-tetramethylbenzidine. 
                                                                        Characterization of D79H mutation 
 
139   
Study population 
Patients and control subjects included in the present study were from a large population-
based case-control study on risk factors for a first venous thrombosis, the Leiden 
Thrombophilia Study (LETS), which has been described in detail before [31,32]. 
 
Detection of 409G>C transversion in genomic DNA  
Carriership of the 409G>C transversion in exon 3 of the F5 (corresponding to the D79H 
mutation) was detected by PCR followed by restriction enzyme digestion. The PCR was 
performed using 0.1-1 µg genomic DNA, 200 ng primers, 200 µM dNTP and 1U of Taq 
DNA polymerase in PCR buffer containing 67 mM TRIS-HCl (pH 8.8), 6.7 mM MgCl2, 
6.7 µM EDTA, 16.6 mM (NH4)2SO4, 0.1 mg/ml BSA, 10% DMSO and 10 mM 
β-mercapto-ethanol. A 208 bp fragment was amplified with the following primers (see also 
Table 1): 
PrFV3(79)-F: (5’-GGAGGAATGGTAGCAATCACTCTTGG-3’)  
PrFV3(79)-R: (5’-TCCTTGAGGATGGATGCTCAGATGCTTAT-3’)  
In primer PrFV3(79)-R a mismatch sequence (underlined) was introduced to generate a 
BsaBI restriction site after amplification of the FV-79D allele. Digestion of this fragment 
by BsaBI resulted in cleavage products of 25 bp and 183 bp, whereas the amplified 
fragment of the FV-79H allele was not digested by BsaBI. 
 
APC-resistance test  
The activated partial thromboplastin time (APTT)-based APC-sensitivity ratio (APC-SR) 
was measured as described by Koster et al. [31]. APC-sensitivity ratios were normalized 
by dividing them by the APC-SR of pooled normal plasma.  
 
Statistical analysis 
Odds ratios (ORs) and ninety-five percent confidence intervals (95% CI) were calculated 
in the standard unmatched fashion. The OR estimates the risk of venous thrombosis in the 
presence of a risk factor (eg, carriership of the FV-79H allele) relative to the absence of the 
particular risk factor, the reference category. An OR of 1 indicates no effect on risk, while 
an OR above 1 indicates an increase in risk. 
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Results 
FV activity and antigen in FV deficient family  
FV Amersfoort is characterized by the 1102A>T substitution in exon 7 of F5, resulting in a 
premature stop at codon 310 [22]. To investigate whether the truncated FV protein (amino 
acids 1-310) is expressed in plasma, we measured FV heavy chain antigen (FVHC) and FV 
light chain antigen (FVLC) in plasma of an asymptomatic heterozygous carrier of FV 
Amersfoort and his first degree relatives. The results are summarized in Table 2. In none 
of the FV Amersfoort carriers (father, child 1 and  child 2) an excess of FVHC was 
observed, because in none of the plasma samples the FVHC/FVLC ratio exceeded 1. 
Remarkably, in some individuals the FVHC level was much lower than the FVLC level, 
resulting in strongly reduced FVHC/FVLC ratios. The mother, child 1, 2 and 4 all seemed to 
be heterozygous for a variant FV molecule, which is poorly recognized by one or both 
mAbs used in the ELISAHC. To test this, three additional FV ELISAs were designed using 
either mAb V-23, V-39 or V-6 as catching antibody and a polyclonal anti FV conjugate as 
tagging antibody. Subsequently, plasma of child 1 (FVHC/FVLC ratio 0.07) was analyzed 
with these ELISAs. The FV antigen levels were 0%, 41% and 61% as measured with 
ELISAV-23, ELISAV-39 and ELISAV-6, respectively, which indicates that mAb V-23 poorly 
recognizes FV in this individual.  
Table 2. FV activity and antigen levels in members of FV deficient family. 
Family FV activity2 (%)  FVLC (%) FVHC (%)  FVHC/FVLC 
Father 1 34 51 41 0.80 
Mother  125 136 89 0.65 
Child 11 62 69 5 0.07 
Child 21 60 64 65 1.02 
Child 3  109 142 69 0.49 
Child 4 93 136 57  0.42 
 
1Heterozygous carrier of the FV Amersfoort allele 
2FV activity was measured using a one stage clotting assay (data from van Wijk et al. [22]) 
                                                                        Characterization of D79H mutation 
 
141   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identification of an immunologic polymorphism in the heavy chain of factor V 
The ‘absence’ of an epitope for mAb V-23 in the FV of some members of this FV deficient 
family most likely is the result of an amino acid substitution in the heavy chain of FV. 
Therefore, we sequenced the exons coding for the heavy chain of FV of the father and the 
mother. In total five nucleotide changes with respect to the sequence of Jenny et al. were 
identified (summarized in Table 3) including the FV Amersfoort mutation in exon 7. From 
the data in Table 2 and Table 3 haplotypes were constructed (Figure 1). Carriership of the 
haplotype 327A, 409C, 495A, 642T, 1102A cosegregated with reduced FVHC/FVLC ratios. 
Within this haplotype only the 409G>C polymorphism in exon 3 predicts an amino acid 
substitution (D79H). This made the D79H substitution a good candidate for the mutation 
that causes the reduced affinity for mAb V-23. It should be noted that the 409G>C 
transversion is also present in the FV Amersfoort allele (1102T), which is not expressed in 
plasma. Therefore, some members of this family are heterozygous for the D79H 
substitution, whereas they have a normal FVHC/FVLC ratio (i.e. child 2).  
  
Table 3. Polymorphisms in exons coding for FV heavy chain in members of 
FV deficient family  
 
Exon 
Nucleotide 
change 
(Amino acid 
change) F
at
he
r 
 
M
ot
he
r 
C
hi
ld
 1
 
C
hi
ld
 2
 
C
hi
ld
 3
 
C
hi
ld
 4
 
Exon 2 327G>A  
(Q51Q) 
GA AA AA AA GA GA 
Exon 3 409G>C  
(D79H) 
GC GC CC GC GC GC 
Exon 4 495G>A 
(A107A) 
GA GA AA GA GA GA 
Exon 4 642G>T 
(S156S) 
GT GT TT GT GT GT 
Exon 7 1102A>T
1 
(K310Term) 
AT AA AT AT AA AA 
 
1Mutation resulting in premature stop (FV Amersfoort) [22] 
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Analysis of the epitope of mAb V-23  
To confirm that the molecular basis of the reduced affinity of FV for mAb V-23 resides in 
the D79H mutation, we introduced this mutation in an expression vector containing the 
cDNA of human FV (pMT2-FV). After transfection of COS-1 cells, conditioned medium 
containing recombinant FV was collected and analyzed (Table 4). The expression levels of 
both rFV-79D and rFV-79H were similar as measured by functional FV assay and 
ELISALC (~7% of normal plasma level), which indicates that rFV-79H has a normal 
specific activity (FVa/FVLC). However, using the ELISAHC very low FV levels were 
detected in medium containing rFV-79H, while the FVHC in the medium of rFV79D was 
similar to the FVLC. This confirmed that the ELISAHC was affected by the D79H 
Figure 1. Pedigree of FV deficient family. In this pedigree FV deficiency (FV 
Amersfoort) and reduced FV(HC)/FV(LC) antigen ratios (Table 2) are indicated
together with the genotypes for the polymorphisms found in the exons coding for the 
heavy chain (Table 3). The proband of this family is child 1.  
 
                                                                        Characterization of D79H mutation 
 
143   
substitution, which most likely disrupts the epitope of mAb V-23 (see also first section of 
results).   
 
 
 
 
 
 
 
 
 
 
 
We tried to obtain more information about the epitope of mAb V-23 using synthetic 
peptides. Two peptides (PEP-79D and PEP-79H) homologous to the region surrounding 
amino acid 79 were synthesized and tested for their ability to compete with plasma FV for 
binding to mAb V-23. However, peptide concentrations up to 1 mg/ml did not affect the 
binding of plasma FV to mAb V-23 (data not shown).   
The region surrounding residue 79 was also analyzed in a 3-dimensional model for the 
heavy chain of FVa [33]. This model revealed that this region is surface exposed, 
indicating that it might contain an epitope for an antibody. Replacement of 79D by 79H 
did not result in conformational changes in the experimental FVa model (data not shown), 
which suggests that the D79H substitution affects electrostatic interactions between the 
epitope and mAb V-23.  
Finally, conservation of region surrounding amino acid 79 was analyzed between 
different species. In Table 5 the amino acid sequences surrounding residue 79 (residues 71 
to 85) of 7 different species are shown. Homology ranges from 60% for the zebrafish to 
93% for some mammals. The aspartic acid at position 79 was conserved between several 
species, but not in cow and pipid frog. 
 
Table 4. Specific activity and FVHC/FVLC ratio of recombinant FV-79D and 
FV-79H. FV activity and FV antigen (FVHC and FVLC) were measured in 
conditioned medium containing either rFV-79D or rFV-79H.  
 
rFV FVa/FVLC1 FVHC/FVLC 
rFV-79D 0.94 0.83 
rFV-79H  1.04 0.06 
 
1FV activity was measured as described in Materials and Methods. 
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Further characterization of the D79H substitution  
Recently, it has been reported that carriership of the FV-79H allele is associated with 
moderately reduced FV activity in plasma [24], as measured in a one stage clotting assay. 
Also, indications have been obtained that carriership of the FV-79H allele may lower the 
APC sensitivity in subjects carrying the FV Leiden allele [24]. Therefore, it may act as a 
trans-acting gene in carriers of FV Leiden in a similar way as has been demonstrated for 
the FV-R2 allele [34-37]. To further investigate this, we genotyped the cases and controls 
from a large population-based case-control study on risk factors for venous thrombosis 
(LETS) and determined the effect on FV levels, n-APC-SR and risk of thrombosis.  
To investigate the effect of the D79H substitution on plasma FV levels, we used the 
data from the 433 healthy controls from the LETS. Carriers of the FV-R2 allele were 
excluded from this analysis (no compound heterozygous carriers of the FV-79H allele and 
FV-R2 were found in this group). Table 6 shows that the mean FVLC level in carriers of the 
FV-79H allele (138 U/dl) is similar to that in non-carriers (133 U/dl).  
Table 5. Alignment of amino acid sequence surrounding residue 79 in the 
heavy chain of FV. Conservation of the region surrounding postion 79 (residue 71 
to 85) in the heavy chain of FV was assessed by comparing the human amino acid 
sequence with the amino acid sequence of 6 different species. Position 79 is bold 
and underlined. 
 
Species FV amino acid sequence Homology 
Homo sapiens KVHFKNKADKPLSIH - 
Bos taurus KVHFKNKAHKPLSIH 93 % 
Mus musculus KVHFRNKADKPLSIH 93 % 
Sus scrofa KVHFRNKADKPLSIH 93 % 
Gallus gallus VVHFKNMADKPISIH 87 % 
Xenopus tropicalis QVHFKNMANKPLTIH 80 % 
Danio rerio IVTFRNMADHPCSLH 60 % 
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Theoretically, the reduced procoagulant FV activity reported by Bossone et al. [24] 
for carriers of FV-79H may be caused by increased instability of the activity of FV-79H. 
To assess this possibility, the loss of (activated) rFV activity was followed as a function of 
time. The first-order rate constant for spontaneous inactivation (ks) of rFV-79D was similar 
to that for rFV-79H, being around 3.0 x 10-6 s-1 (Table 7). Also the ks for activated rFV-
79D was similar to that for activated rFV-79H, being around 3.0 x 10-5 s-1. The presence of 
phospholipids did not influence the stability of the activated rFV molecules.  
Table 6. FV antigen levels (U/dl) and APC sensitivity ratios according to 
carriership of FV-79H. Carriership of FV-79H allele, FV light chain (FVLC) levels 
and n-APC-SR were determined in control subjects of the LETS.  
 
FVLC1 n-APC-SR2  
D79H 
 
N Mean (95% CI) (U/dl) N Mean (95% CI) 
D/D 390 133 (130-139) 374 1.02 (1.01-1.03) 
D/H 42 138 (129-147) 42 1.05 (1.02-1.08) 
H/H 1 115    1 0.98    
 
1FV-R2 carriers (n=38) were excluded  
2 FV Leiden carriers and individuals using oral anticoagulants were excluded (n=54) 
Table 7. Stability of recombinant FV-79D and FV-79H in the absence or presence of 
phospholipids. Spontaneous inactivation rates (ks) were obtained by fitting time courses 
(30 hours) of rFV(a) inactivation with a single exponential. Incubation conditions are 
described in Methods (~1 nM FVa in 25 mM Hepes (pH 7.5), 175 mM NaCl, 3 mM 
CaCl2, 5 mg/ml BSA +/- 24.5 µM phospholipids (10:90 DOPS:DOPC) at 37°C). 
 
+ PL - PL 
FV 
Spontaneous inactivation rates (s-1) 
rFV-79D N.D. 3.0 x 10-6 
rFV-79H  N.D. 2.6 x 10-6 
Activated  
rFV-79D 5.1 x 10
-5 2.6 x 10-5 
Activated 
rFV-79H 6.2 x 10
-5 3.6 x 10-5 
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Next, we investigated the effect of the D79H substitution on the APTT-based normalized-
APC sensitivity ratio [31]. For this analysis carriers of FV Leiden were excluded. The n-
APC-SRs in the absence of the FV Leiden mutation are summarized in Table 6 and 
demonstrate that carriership of the FV-79H allele is not associated with a lower n-APC-
SR. Exclusion of FV-R2 carriers did not alter this result (data not shown). In this analysis, 
it was not possible to investigate whether carriership of FV-Leiden in trans with the FV-
79H allele is associated with a further decrease of the n-APC-SR, because none of the 
healthy controls were compound heterzozygous for FV-Leiden and FV-79H. Therefore, we 
screened all patients in the LETS for compound heterozygosity for FV-Leiden and FV-
79H. In total 8 patients were found compound heterozygous for FV-Leiden and FV-79H 
with a mean n-APC-SR of 0.57 (range 0.53-0.64). 
 
 
 
 
 
 
 
 
 
 
 
 
Finally, we analyzed the association of the D79H substitution with risk of thrombosis. 
For this analysis all cases and controls of the LETS were genotyped for this 
polymorphism. The allele frequency of the FV-79H allele was 5.0 % in patients and 4.7 % 
in controls (Table 8), which is in agreement with previously reported allele frequencies (5 
to 15 %) in different healthy Caucasian populations [23,24]. The odds ratio (OR), 
calculated as a measure of the relative risk of venous thrombosis, for subjects carrying the 
FV-79H allele (both heterozygous and homozygous) was 1.07 (CI 95: 0.7 – 1.7) compared 
to homozygous FV-79D carriers. Exclusion of all FV Leiden carriers did not alter this OR.   
Table 8. Frequencies of D79H polymorphism in LETS. 
D79H Patients Controls 
D/D 426 428 
D/H 45 42 
H/H 1 1 
 
Odds ratio of FV-79H carriers: 1.07 (CI 95: 0.7 – 1.7) 
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Discussion 
In this study, we have analyzed a variant FV that was not recognized by a monoclonal 
antibody (mAb V-23) directed against the heavy chain of FV. Haplotype analysis of the 
variant FV allele suggested that an amino acid substitution at residue 79 (D79H) was 
responsible for the absence of the epitope for mAb V-23. This was confirmed by 
introducing this substitution in recombinant FV (rFV-79H). Functional tests with rFV-79H 
showed that this substitution did not affect the Xa-cofactor function or the stability of 
FV(a). Furthermore, carriership of the FV-79H allele (allele frequency ~5%) is not 
associated with FV levels (FVLC), APC sensitivity (using an APTT-based test) or risk of 
venous thrombosis (OR 1.07, CI 95: 0.7 – 1.7). Together, these results indicate that the 
frequent D79H polymorphism in FV is neutral.  
Initially, we were interested in the question whether truncated FV molecules were 
expressed in plasma from carriers of the FV Amersfoort allele, which refers to a 1102A>T 
mutation in exon 7 of F5 resulting in a premature stop in codon 310 [22]. For this purpose 
plasma samples of the relatives of a heterozygous carrier of FV Amersfoort were screened 
with ELISAs for FV heavy chain (FVHC) and FV light chain (FVLC). Recent data indicate 
that both antibodies used in the ELISAHC recognize an epitope at the amino-terminal end 
(1-306) of factor V (data not shown). Because no FVHC/FVLC ratios higher than 1 were 
observed (Table 2) it seems unlikely that substantial amounts of FV Amersfoort are 
expressed, although it can not excluded that the affinity of the truncated FV molecule for 
mAb V-23 or V-39 has been affected. This possibility could not be tested, because we 
have not generated recombinant FV Amersfoort. Instead, we have tested another truncated 
rFV molecule, labelled M-fragment, consisting of the first 909 amino acids of FV, which 
has been constructed before [29]. This showed that the affinity of the M-fragment for mAb 
V-23 and V-39 was not affected (data not shown). Taken together, it seems most likely 
that mRNA transcribed from the FV Amersfoort allele is degraded in the nonsense-
mediated mRNA decay pathway [38].  
Unexpectedly, we observed strongly reduced FVHC/FVLC ratios in some family 
members (see Table 2). This observation suggested that in this family a variant FV was 
segregating, which was poorly recognized by one of the mAbs (V-23 or V-39) used in our 
ELISAHC. Further testing revealed that mAb V-23 poorly recognized this variant FV and 
that the strongly reduced FVHC/FVLC ratios cosegregated with a factor V haplotype 
containing one single missense mutation in the heavy chain (D79H). This made this 
mutation a strong candidate to affect the epitope for mAb V-23 (Fig. 1). Introduction of the 
D79H mutation in recombinant FV confirmed that it strongly reduced the affinity for mAb 
V-23 (FVHC/FVLC antigen ratio for rFV-79H is ~0.06 compared to 0.83 for rFV-79D, 
Table 4). Further tests revealed that mAb V-23 did not bind synthetic peptides homologous 
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to the region around residue 79 (71-85). This can not easily be explained by the absence of 
post-translational modifications on these peptides, because in the region from 71 to 85 no 
modifications are known. This suggests that the epitope for mAb V-23 is not linear, which 
is in agreement with the observation that mAb V-23 did not detect FV in Western blots 
under reducing conditions (data not shown). Furthermore, replacement of 79D into 79H in 
the experimental model of FVa [33] did not result in conformational changes in the heavy 
chain of FVa, which suggests that the D79H mutation rather has an effect on the 
electrostatic interactions between the epitope and mAb V-23. 
Little is known about the effect of the D79H substitution on the function of FV. So 
far, this polymorphism has only been reported twice. The first time was in 1999 in a study 
by Cargill et al. [23]. They included this polymorphism in an extensive catalogue of 
single-nucleotide polymorphisms (SNPs) in the coding regions of human genes, which 
could be used in association studies. This report, however, gives no information on the 
functionality of this polymorphism. More recently, it has been reported that carriership of 
FV-79H is associated with slightly reduced procoagulant FV activity levels and possibly 
with a lower sensitivity to APC in heterozygous carriers of the FV Leiden allele [24]. This 
suggested that the D79H substitution, in analogy to the FV-R2 mutation, increases the 
APC-resistent phenotype of plasma from heterozygous carriers of the FV Leiden mutation 
via reduced FV expression of the FV-79H allele [34,39].  
We did not observe an association between carriership of the FV-79H allele and lower 
FVLC levels in 433 healthy individuals from the LETS (Table 6). This suggests that this 
allele is not associated with reduced FV antigen levels, which seems to be different from 
the results reported by Bossone et al. [24]. This may be explained by the size of the group 
studied by Bossone (n=150 compared to 433 in our study). It also is possible that FV-79H 
has a slightly reduced specific procagulant activity. However, we found no indications that 
the D79H substitution has an effect on the Xa-cofactor activity of FVa: the specific activity 
(FVa/FVLC) of rFV-79H was similar to that of rFV-79D (Table 4). This is in agreement 
with the results from Zeibdawi et al. [40], who studied the effect of the D79A substitution 
on the cofactor function of FVa. Also, the D79H substitution did not affect the stability of 
the (activated) FV molecule (see Table 7), like the amino acid substitutions A221V and 
D111A, which have been reported to weaken the interaction between the heavy and light 
chain of activated FV [40,41].  
Carriership of the FV-79H allele is not associated with a lower n-APC-SR after 
exclusion of FV Leiden carriers (Table 6), which is in line with the findings from Bossone 
et al. [24]. We did not find that heterozygous carriers of FV Leiden, who carry the FV-79H 
allele on the other chromosome have a more APC-resistant phenotype than subjects (n=8) 
carrying the alleles for FV Leiden and FV-79D (mean n-APC-SR = 0.57). This ratio is 
identical to the ratio of 0.57 (range 0.5-0.67) previously reported for heterozygous carriers 
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of FV Leiden [11,37]. Finally, carriership of the FV-79H has no effect on the risk of 
venous thrombosis (Table 8), which is reflected in an odds ratio of 1.07 (CI 95: 0.7 – 1.7). 
Taken together, our data suggest that the D79H substitution has no effect on FV(a) 
function or thrombosis risk. This is in agreement with the fact that so far no functional 
domains have been identified in the region surrounding residue 79 in FV (see also the 
review by Mann and Kalafatis [8]). Also the fact that the aspartic acid at position 79 is not 
fully conserved between the species aligned in Table 5, suggests that residue 79 is not 
critical for the function of FV.  
We conclude that the D79H substitution should be considered as a neutral 
polymorphism with an allele frequency of ~5% in the Caucasian population. FV-79H is 
poorly recognized by mAb V-23. Therefore, it is recommended not to use mAb V-23 in 
diagnostic tests, because it would result in falsely reduced FV levels in 10% of the 
population. 
 
References 
 1. Esmon CT. The subunit structure of thrombin-activated factor V. Isolation of activated factor 
V, separation of subunits, and reconstitution of biological activity. J Biol Chem 
1979;254:964-73. 
 2. Kane WH, Majerus PW. Purification and characterization of human coagulation factor V. J 
Biol Chem 1981;256:1002-7. 
 3. Suzuki K, Dahlbäck B, Stenflo J. Thrombin-catalyzed activation of human coagulation factor 
V. J Biol Chem 1982;257:6556-64. 
 4. Guinto ER, Esmon CT. Formation of a calcium-binding site on bovine activated factor V 
following recombination of the isolated subunits. J Biol Chem 1982;257:10038-43. 
 5. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and 
human factor Va by activated protein C. J Biol Chem 1994;269:31869-80. 
 6. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in 
degradation of factor VIIIa. J Biol Chem 1994;269:18735-8. 
 7. Varadi K, Rosing J, Tans G, Schwarz HP. Influence of factor V and factor Va on APC-
induced cleavage of human factor VIII. Thromb Haemost 1995;73:730-1. 
 8. Mann KG, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde. Blood 
2003;101:20-30. 
 9. Nicolaes GA, Dahlbäck B. Factor V and thrombotic disease: description of a janus-faced 
protein. Arterioscler Thromb Vasc Biol 2002;22:530-8. 
 10. Montefusco MC, Duga S, Asselta R, Malcovati M, Peyvandi F, Santagostino E, Mannucci 
PM, Tenchini ML. Clinical and molecular characterization of 6 patients affected by severe 
deficiency of coagulation factor V: broadening of the mutational spectrum of factor V gene 
and in vitro analysis of the newly identified missense mutations. Blood 2003;102:3210-6. 
 11. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden 
PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to 
activated protein C. Nature 1994;369:64-7. 
 12. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. 
Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, 
stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-7. 
 13. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients 
homozygous for factor V leiden (activated protein C resistance). Blood 1995;85:1504-8. 
Chapter V 
 
 
 150 
 14. Owren P.A. Parahaemophilia: haemorrhagic diathesis due to absence of a previously 
unknown clotting factor. Lancet 1947;446-8. 
 15. Girolami A, Simioni P, Venturelli U, Girolami B, Zanon E. Factor V antigen levels in APC 
resistance, in factor V deficiency and in combined APC resistance and factor V deficiency 
(pseudohomozygosis for APC resistance). Blood Coagul Fibrinolysis 1997;8:245-8. 
 16. Guasch JF, Lensen RPM, Bertina RM. Molecular characterization of a type I quantitative 
factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein 
C resistance. Thromb Haemost 1997;77:252-7. 
 17. Kalafatis M, Simioni P, Bernardi F. Phenotype and genotype expression in 
pseudohomozygous R2 factor V. Blood 2001;98:1988-9. 
 18. Lunghi B, Castoldi E, Mingozzi F, Bernardi F, Castaman G. A novel factor V null mutation 
detected in a thrombophilic patient with pseudo-homozygous APC resistance and in an 
asymptomatic unrelated subject. Blood 1998;92:1463-4. 
 19. Kalafatis M, Bernardi F, Simioni P, Lunghi B, Girolami A, Mann KG. Phenotype and 
genotype expression in pseudohomozygous factor VLEIDEN : the need for phenotype 
analysis. Arterioscler Thromb Vasc Biol 1999;19:336-42. 
 20. Castoldi E, Kalafatis M, Lunghi B, Simioni P, Ioannou PA, Petio M, Girolami A, Mann KG, 
Bernardi F. Molecular bases of pseudo-homozygous APC resistance: the compound 
heterozygosity for FV R506Q and a FV null mutation results in the exclusive presence of FV 
Leiden molecules in plasma. Thromb Haemost 1998;80:403-6. 
 21. Guasch JF, Cannegieter S, Reitsma PH, Van't Veer-Korthof ET, Bertina RM. Severe 
coagulation factor V deficiency caused by a 4 bp deletion in the factor V gene. Br J Haematol 
1998;101:32-9. 
 22. van Wijk R, Nieuwenhuis K, van den BM, Huizinga EG, van der Meijden BB, Kraaijenhagen 
RJ, van Solinge WW. Five novel mutations in the gene for human blood coagulation factor V 
associated with type I factor V deficiency. Blood 2001;98:358-67. 
 23. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, 
Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, 
Daley GQ, Lander ES. Characterization of single-nucleotide polymorphisms in coding 
regions of human genes. Nat Genet 1999;22:231-8. 
 24. Bossone A, Cappucci F, D'Andrea G, Brancaccio V, Cibelli G, Iannaccone L, Grandone E, 
Margaglione M. The factor V (FV) gene ASP79HIS polymorphism modulates FV plasma 
levels and affects the activated protein c resistance phenotype in presence of the FV Leiden 
mutation. Haematologica 2003;88:286-9. 
 25. Kamphuisen PW, Rosendaal FR, Eikenboom JC, Bos R, Bertina RM. Factor V antigen levels 
and venous thrombosis: risk profile, interaction with factor V leiden, and relation with factor 
VIII antigen levels.  Arterioscler Thromb Vasc Biol 2000;20:1382-6. 
 26. Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, Kaufman RJ, Mann 
KG. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad 
Sci U S A 1987;84:4846-50. 
 27. Kaufman RJ. Vectors used for expression in mammalian cells. Methods Enzymol 
1990;185:487-511. 
 28. van der Neut Kolfschoten M, Dirven RJ, Vos HL, Bertina RM. The R2-haplotype associated 
Asp2194Gly mutation in the light chain of human factor V results in lower expression levels 
of FV, but has no influence on the glycosylation of Asn2181. Thromb Haemost 2003;89:429-
37. 
 29. van der Neut Kolfschoten M, Dirven RJ, Tans G, Rosing J, Vos HL, Bertina RM. The 
activated protein C (APC)-resistant phenotype of APC cleavage site mutants of recombinant 
factor V in a reconstituted plasma model. Blood Coagul Fibrinolysis 2002;13:207-15. 
 30. van der Neut Kolfschoten M., Dirven RJ, Tans G, Rosing J, Vos HL, Bertina RM. Factor Va 
is inactivated by APC in the absence of cleavage sites at Arg306, Arg506 and Arg679. J Biol 
Chem 2004;279:6567-75 
                                                                        Characterization of D79H mutation 
 
151   
 31. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous 
thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia 
Study. Lancet 1993;342:1503-6. 
 32. van der Meer FJ, Koster T, Vandenbroucke JP, Briet E, Rosendaal FR. The Leiden 
Thrombophilia Study (LETS). Thromb Haemost 1997;78:631-5. 
 33. Villoutreix BO, Dahlbäck B. Structural investigation of the A domains of human blood 
coagulation factor V by molecular modeling. Protein Sci 1998;7:1317-25. 
 34. Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, Mannucci PM. A factor 
V genetic component differing from factor V R506Q contributes to the activated protein C 
resistance phenotype. Blood 1997;90:1552-7. 
 35. Alhenc-Gelas M, Nicaud V, Gandrille S, van Dreden P, Amiral J, Aubry ML, Fiessinger JN, 
Emmerich J, Aiach M. The factor V gene A4070G mutation and the risk of venous 
thrombosis. Thromb Haemost 1999;81:193-7. 
 36. Faioni EM, Franchi F, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Finazzi G, 
Mannucci PM. Coinheritance of the HR2 haplotype in the factor V gene confers an increased 
risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). Blood 
1999;94:3062-6. 
 37. de Visser MC, Guasch JF, Kamphuisen PW, Vos HL, Rosendaal FR, Bertina RM. The HR2 
haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity 
ratios and the risk of venous thrombosis. Thromb Haemost 2000;83:577-82. 
 38. Frischmeyer PA, Dietz HC. Nonsense-mediated mRNA decay in health and disease. Hum 
Mol Genet 1999; 8:1893-900. 
 39. Lunghi B, Iacoviello L, Gemmati D, Dilasio MG, Castoldi E, Pinotti M, Castaman G, 
Redaelli R, Mariani G, Marchetti G, Bernardi F. Detection of new polymorphic markers in 
the factor V gene: association with factor V levels in plasma. Thromb Haemost 1996;75:45-8. 
 40. Zeibdawi AR, Grundy JE, Lasia B, Pryzdial EL. Coagulation factor Va Glu96-Asp111:A 
chelator-sensitive site involved in function and subunit association. Biochem J 2004;377:141-
8. 
 41. Steen M, Miteva M, Villoutreix BO, Yamazaki T, Dahlbäck B. Factor V New Brunswick: 
Ala221Val associated with FV deficiency reproduced in vitro and functionally characterized. 
Blood 2003;102:1316-22. 
 
 
 
 
 
 
 
 
 
 
 
Chapter VI 
 
 
 
 
 
 
 
General discussion 
 
 
Chapter VI 
 
 
 
 
 154 
 
The discovery of the R506Q mutation in coagulation factor V (FV Leiden) in 1994 has 
resulted in a boost of FV research aimed at the elucidation of the role of FV in the 
prothrombinase complex and the role of FV in the anticoagulant protein C pathway. For 
this type of studies the use of recombinant DNA techniques has become increasingly 
important. Also in this thesis recombinant FV mutants were generated and characterized to 
learn more about the structure and function of FV with a special emphasis on the 
proteolytic down-regulation of activated FV (FVa) by activated protein C (APC). The 
main results will be summarized and discussed in this chapter. 
 
 
Three-dimensional model of human FVa 
A three-dimensional (3D) model of FV is helpful to understand the function of FV and to 
identify functional regions of FV. Unfortunately, attempts to crystallize human FV or FVa 
and analyse the crystals with X-ray diffraction have failed so far, which is probably due to 
the many modifications and sticky properties of the FV molecule. The only part of human 
FV that has successfully been crystallized is the C2 domain, from which the coordinates 
have been used to construct a three-dimensional model of the two C-domains of the light 
chain of FVa [1]. For the heavy chain also a model has been developed based on the 
coordinates of ceruloplasmin, which is strongly homologous to the A-domains of FV. 
From these data a theoretical 3D-model of FVa has been constructed (Fig. 1), which has 
been deposited to the Protein Database Bank [2]. Very recently, however, Adams et al. 
have succeeded to crystallize a large fragment of the bovine FVa molecule [3]. Analysis of 
this structure revealed that the domain arrangement of the human FVa model should be 
revised. Therefore, we have constructed a new 3D model of human FVa based on the 
theoretical human model and the bovine crystal structure (Fig. 1). This FVa model is used 
to illustrate some of the results presented in this thesis.  
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Figure 1. Three-dimensional models of FVa. A solid ribbon model of the theoretical model of
human FVa (PDB code: 1FV4 [2]) is presented in Fig. 1A. This model of FVa has been based on the
X-ray crystallographic structures of ceruloplasmin and the C2 domain of factor V. The heavy chain
of FVa (domain A1 and A2) is depicted in yellow and consists of the first 663 amino acids, which
indicates that 46 amino acids at the C-terminus have not been included, amongst which APC-
cleavage site at R679. The light chain (domain A3-C1-C2) is depicted in magenta and consists of
amino acids 1546 to 2196. The APC cleavage sites R306 and R506 are depicted in green and red,
respectively. This colour code has been used in all panels. In panel B the crystallographic structure
of bovine FVai (PDB code 1SDD [3]) is depicted, in which the A2 domain is absent. Based on the
theoretical FVa model (A) and the bovine structure FVa (B) a new 3D model for human FVa (C and
D) has been calculated by Sander Meijer (from the department of Plasma Proteins at Sanquin) using
Modeller software. In the heavy chain of the new FVa model the first 663 amino acids have been
included, whereas in the light chain the amino acids 1546 to 2196 have been included. All structures
have been visualized with Discovery Studio ViewerPro (Accelrys Inc.).  
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 APC-resistant phenotype of rFV with mutations at the APC-cleavage sites 
An important reaction in the regulation of blood coagulation is the inactivation of FVa by 
activated protein C, which exerts its anticoagulant function by proteolytic degradation of 
the heavy chain of FVa. Three APC cleavage sites have been identified in the heavy chain 
of FVa, which are localized at R306, R506 and R679. Only R306 and R506 have been 
included in the 3D model of FVa, which shows that R306 (green residue) is located in the 
loop between the A1 and A2 domain and R506 (red residue) in the middle of the A2 
domain (Fig. 1). In FV Leiden, the APC-cleavage site at position 506 is absent due to the 
R506Q mutation [4-6], which results in a reduced sensitivity of plasma towards APC and 
changes the phenotype of plasma into an APC-resistant phenotype [7]. Traditionally, the 
sensitivity of plasma towards APC is determined in an assay based on the increase of 
activated partial thromboplastin time (APTT) after addition of a fixed amount of 
exogenous APC. Importantly, carriership of FV Leiden is associated with an increased risk 
of deep-vein thrombosis [8,9], which makes FV Leiden the most important heritable risk 
factor for venous thrombosis due to the high allele frequency, being about 2% in 
Caucasian populations [4]. Apart from the R506Q mutation some other missense mutations 
in the APC-cleavage sites of human Factor V (FV) have been reported. These rare 
mutations affect the APC-cleavage site at R306 in the heavy chain of FVa, from which the 
most important are FV Hong-Kong (R306G) and FV Cambridge (R306T) [10,11].  
So far no uniform theory has been postulated to explain the mechanism of APC 
resistance in plasma of carriers of FV Leiden. Initially, APC resistance was attributed to 
delayed inactivation of activated FV Leiden by APC, but more recently an additional 
mechanism has been proposed in which FV loses its APC-cofactor function in the 
degradation of FVIIIa when arginine 506 is replaced by glutamine [12-15]. The 
contribution of each of these two mechanisms to the final phenotype is not clear and seems 
to some extend to depend on the type of assay that is used [16]. 
The first aim of this thesis was to investigate whether factor V mutants with the 
naturally occurring mutations R306G and R306T were associated with an APC-resistant 
phenotype (Chapter 2). In addition, the APC-resistant phenotype of FV mutants without 
the APC-cleavage site R679 was investigated. To study this, recombinant FV mutants were 
generated, purified and reconstituted in FV-deficient plasma, after which normalized APC-
sensitivity ratios (n-APC-SRs) were measured in two clot-based APC-resistance tests. 
These tests were based on either the activated partial thromboplastin time (APTT) or the 
Russell Viper venom time (RVVT). The mutations introduced in FV were: R306G, 
R306T, R506Q, R679A and combinations of these mutations. An interesting observation 
made during this study was that n-APC-SRs were almost identical in the APTT- and the 
RVVT-based tests, which suggests that the final APC resistant phenotype of FV mutants is 
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equal in both the APTT and the RVVT regardless of any contribution of APC-cofactor 
function of FV in the degradation of FVIIIa. This may seem contradictory to other reports 
on the APC-cofactor activity of FV [13,17,18], but in these studies no clot-based 
experiments were performed. Alternatively, it could be that FV expresses APC-cofactor 
activity in the inactivation of FVa instead of FVIIIa. In theory, the contribution of this 
mechanism would be the same in both the APTT and the RVVT test. 
The APC-sensitivity ratios revealed that the naturally occurring mutations at R306 
(i.e. FV Hong-Kong and FV Cambridge) result in a mildly reduced sensitivity for APC (n-
APC-SR 0.74-0.87) in comparison to the much lower values (n-APC-SR 0.41-0.51) 
obtained for the R506Q mutation. No effect on the n-APC-SR was observed for the 
recombinant FV mutant containing a single R679A mutation, which indicates that in these 
clotting assays the role of cleavage at R679 in the inactivation of FVa by APC is 
negligible.  
The question whether mutations at the R306 have an effect on the risk of venous 
thrombosis could not be answered in this experimental set-up. However, a mildly reduced 
sensitivity for APC (as measured in the APTT test), not caused by FV Leiden, has been 
demonstrated to be a risk factor for venous thrombosis [19]. Therefore, we hypothesise 
that mutations at the R306 position in FV might also be associated with a mild increase of 
the risk of venous thrombosis. Due to the low frequency of FV Hong-Kong and FV 
Cambridge very large epidemiological studies will be needed to elucidate this question.  
It would also be informative to measure the APC sensitivity of plasma containing rFV 
Hong-Kong or rFV Cambridge using a thrombin generation-based test. Such a test has 
been developed by Nicolaes et al. [20] and determines the effect of APC on the 
endogenous thrombin potential (ETP), in which the thrombin potential is defined as the 
time integral of thrombin generation during coagulation of extrinsically triggered plasma 
[21]. Recently, it has been demonstrated that the ETP-based APC-resistance in analogy to 
the APTT-based tests predicts an increased risk for venous thrombosis in the presence and 
absence of FV Leiden [22]. Furthermore, it has been shown that protein S (the cofactor of 
activated protein C, which accelerates preferentially APC-mediated cleavage at R306) is 
an important determinant in this ETP-based test [23], i.e. low protein S levels result in 
reduced sensitivity towards APC. Therefore, an ETP-based APC-resistance test would 
provide more insight into the thrombogenic properties of FV mutants with mutations at the 
R306 (or R679) position.  
 
APC-catalyzed inactivation of FVa 
The data from chapter 2 do not provide much information about the mechanism via which 
FVa is inactivated by APC, because the used assays are based on clotting times. So far, 
knowledge of the complex mechanism of APC-catalyzed inactivation of FVa has mainly 
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been obtained from studies using (purified) plasma FVa. These studies have revealed that 
the inactivation of FVa activity is catalyzed by APC and is associated with proteolysis of 
three peptide bonds in the heavy chain of FVa, which have been localized at R306, R506 
and R679 [24]. Further investigations have demonstrated that cleavage of the heavy chain 
of FVa by APC is stimulated by negatively charged phospholipids [25-27] and protein S 
[27-29], which is a non-enzymatic cofactor of APC. In the presence of negatively charged 
phospholipids the inactivation of FVa by APC proceeds via a rapid and a slow phase, 
which are associated with cleavages at R506 and R306, respectively [24,30]. Cleavage at 
R506 yields a reaction intermediate with reduced FVa activity, which is completely 
inactivated by the subsequent cleavage at R306. Inactivation of FVa Leiden on the other 
hand is monophasic and associated with cleavage at R306, which is stimulated ~20-fold by 
protein S [31]. In the presence of negatively charged phospholipids the contribution of the 
cleavage at R679 to the inactivation of FVa seems to be minor and has been difficult to 
assess [30].  
The main objective in Chapter 3 was to obtain more detailed kinetic data about the 
individual APC-catalyzed cleavages. To study this, B-domainless recombinant factor V 
mutants (rFV∆B) were generated in which two or three of the known APC-cleavage sites 
were mutated. These rFV mutants were purified, activated and incubated with APC, after 
which the time courses of APC-catalyzed inactivation of the FVa mutants were followed 
and analyzed. Interestingly, rFVa-GQA (rFVa in which the arginines at positions 306, 506 
and 679 were replaced by glycine, glutamine and alanine, respectively) was still 
inactivated by APC, although at a much lower rate than normal FVa. The first aim was to 
learn more about the mechanism underlying this unexpected observation (chapter 3a).  
It was observed that the APC-catalyzed inactivation of rFVa-GQA was phospholipid 
dependent and sensitive to an inhibitory monoclonal antibody against protein C. Kinetic 
analysis of the inactivation of rFVa-GQA by APC revealed that under pseudo-first order 
conditions (FVa concentration ranging from 1 to 5 nM [30]) rFVa-GQA was inactivated in 
a biphasic reaction, indicating that analogous to the inactivation of normal FVa also the 
inactivation of rFVa-GQA was associated with at least two cleavages (designated Rx1 and 
Rx2). This conclusion was supported by SDS-PAGE analysis of the reaction products. 
During inactivation of rFVa-GQA a FVa intermediate (FVax1) with ~80% of the original 
FVa activity was formed via rapid cleavage at Rx1. This intermediate was completely 
inactivated via a second slow cleavage at Rx2. The calculated second-order rate constant 
of the rapid reaction (kx1 = 5.4 x 104 M-1.s-1) was approximately 20-fold higher than that of 
the slow reaction (kx2 = 3.2 x 103 M-1.s-1), which is still 50 and 1000-fold lower than those 
reported for cleavage at R306 and R506, respectively, but somewhat higher than the 
second-order rate constant for cleavage at R679, which has been estimated at 7.6 x 103 
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M-1.s-1 [30]. Inactivation of rFVa-GQA was accelerated by protein S, most likely via 
stimulation of the slow phase, which is associated with cleavage at Rx2.  
The positions of the cleavage sites Rx1 and Rx2 were estimated by analysis of the 
fragments generated during the APC-catalyzed degradation of rFVa-GQA by SDS-PAGE 
and immunoblotting. The antibody used for this analysis recognizes an epitope between 
residue 306 and 506 on the heavy chain of FVa, from which we have determined a more 
exact epitope as explained in Fig. 2. The immunoblot analysis revealed that Rx1 is located 
within 5 residues from position 506 and Rx2 about 10-20 residues carboxy-terminal from 
position 306. Currently, attempts are made to produce sufficient amounts of rFV∆B-GQA 
to identify the precise location of Rx1 and Rx2 by N-terminal sequencing. Besides, site-
directed mutagenesis has been used to mutate candidate positions for Rx1 and Rx2. 
Preliminary data indicate that residues 316 and 321 are strong candidates for the location 
of Rx2 and residue 505 for Rx1 (unpublished data from S.C. Man and R.J. Dirven).  
This is the first time that APC-cleavage sites have been reported in the heavy chain of 
FVa different from the sites at R306, R506 and R679. During the inactivation of plasma 
FVa by APC, cleavage at Rx1 or Rx2 will hardly occur, because the second-order rate 
constants are much lower than those reported for cleavage at R506 and R306, even in the 
presence of protein S. This might explain why the sites of Rx1 and Rx2 have not been 
identified before in studies using normal FVa [24,30]. Also, no novel APC-cleavage sites 
have been observed in studies using rFV molecules in which R306 and R506 had been 
mutated [32-35]. However, the conditions used in these studies were such (much lower 
APC concentrations and shorter incubation time) that cleavages at Rx1 and Rx2 could not 
be detected.  
In chapter 3a it was also observed that Rx1 is not cleaved by APC as an alternative for 
R506 during the inactivation of activated FV Leiden, most likely because of dissociation of 
the A2 domain after cleavage at R306. Inactivation of activated rFV∆B-GRA (only R506 
present) on the other hand clearly demonstrated that cleavage at Rx2 may occur as an 
alternative for cleavage at R306. Therefore, cleavage at Rx2 may be relevant in the APC-
catalyzed inactivation of activated FV Hong-Kong or FV Cambridge and may explain the 
unexpected mild APC resistant phenotype associated with the carriership of these FV 
mutants. Furthermore, knowledge of the existence of additional cleavage sites for APC, 
one close to residue 306 and one close to residue 506, is important in the study of the 
APC-mediated cleavages of the individual sites R306, R506 or R679 and needs to be taken 
into account (especially in the case of analysis of cleavage at R679). 
The next step was to investigate the contribution of each individual cleavage at R306, 
R506 or R679 to the kinetics of the APC-catalyzed inactivation of FVa (Chapter 3b). To 
study this the same methodology was used as for the study of the inactivation of rFVa-
GQA, i.e. time courses of APC-catalyzed inactivation of the FVa mutants were followed of 
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B-domainless recombinant factor V mutants in which two of the three known APC-
cleavage sites were mutated.  
The APC-catalyzed cleavage at R506 was studied by following the time course of 
inactivation of rFVa-GRA by APC. It was observed that inactivation of rFVa-GRA by 
APC was biphasic, in which the first rapid phase was associated with cleavage at R506 and 
the second phase with spontaneous inactivation of the FVa intermediate cleaved at R506 
(FVa506) or with cleavage at Rx2 depending on the inactivation conditions  (APC 
concentration and absence or presence of protein S). Cleavage at R506 resulted in a FVa506 
molecule with a relatively high residual FVa activity, which varied between 60% to 75%. 
This variability is likely due to the fact that the cofactor activity of FVa is measured at a 
FXa concentration close to the K1/2Xa for FVa506, which has been reported to be 3.9 nM 
[30]. The fact that cleavage at R506 affects the affinity for FXa was also demonstrated by 
a 10-fold lowering of the FXa concentration in the prothrombinase assay, which resulted in 
a further decrease of the FVa activity of the FVa506 intermediate to ~35%. A residual 
activity of FVa506 between 60% and 75% is in line with the findings of Norstrøm et al., 
who also used rFVa mutants in which the R506 mutant were singled-out [35]. Together, 
these data support the conclusion from Nicolaes et al. that cleavage at R506 affects the 
affinity of FVa for FXa, which explains that the FVa506 intermediate contains a somewhat 
reduced FVa activity when measured at FXa concentrations equal to or lower than 3.9 nM 
(K1/2Xa for FVa506) [30]. From the inactivation curve of rFVa-GRA a k506 of 1.1 x 108 M-1s-1 
was obtained, which is equivalent to the rate observed by Norstrøm et al. [35], but 
somewhat higher than the k506 of 4.7 x 107 M-1s-1 reported by Nicolaes et al. [30]. This 
small difference may be explained by the fact that the k506 reported by Nicolaes et al. was 
indirectly calculated from the APC-catalyzed inactivation of normal FVa with intact R306 
and R506 [30]. Furthermore, we found that cleavage at R506 was stimulated about 2-fold 
in the presence of protein S, which is in line with the findings of Norstrøm et al. [35]. The 
fact that cleavage at R506 is stimulated by protein S seems to be in contrast with the 
conclusion from Rosing et al. [31], who did not observe that the APC-mediated cleavage at 
R506 was stimulated in the presence of protein S. However, their conclusions were based 
on the inactivation of normal FVa from plasma, which made it difficult to calculate 
directly the effect of protein S on the k506.  
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Figure 2. Epitope of murine monoclonal AHV5146. In chapter 3 generation of FV heavy
chain fragments was analyzed by immunoblot using the murine monoclonal antibody AHV-
5146. It has been reported by the manufacturer that the epitope of mAb AHV-5146 is localized
between R306 and R506, which are indicated in the solid ribbon model of FVa in green and
red, respectively. The blue space-filled residues represent the epitope of mAb AHV-5146,
which ranges from residue 427 to 440. In this study we have determined the exact epitope by
calculating the antigenic regions in this area, after which the murine amino acid sequence of
these regions were compared with the human sequence. Subsequently peptides were designed
and synthesized homologous to the regions, which contained differences between the murine
and human sequence. In competition experiments it was found that a synthetic peptide
homologous to the surface-exposed amino acid sequence from 427 to 440 strongly inhibited
the binding of AHV-5146 to FV. 
Chapter VI 
 
 
 
 
 162 
 
The functional and structural implications of the APC-catalyzed cleavage at R306 
were investigated by following the time courses of inactivation of rFVa-RQA. In contrast 
to previous reports [30,31] cleavage at R306 did not result in a completely inactive FVa 
molecule, but in FVa intermediate (FVa306) with ~10% activity, which was not affected by 
lowering the FXa concentration 10-fold. These data support the concept that cleavage at 
R306 results in dissociation of the C-terminal fragment (307-709) of the heavy chain 
according to the mechanism proposed by Mann et al. [36]. Dissociation of this fragment 
would result in a severely impaired FVa, which has lost virtually all affinity for FXa. 
Subsequently, the FVa306 molecule was completely inactivated in a second slow phase, 
which was not APC-dependent. Most likely, this second slow inactivation phase is 
associated with dissociation of the heavy chain fragment (1-306) from the light chain, 
which is supported by the fact that no other cleavage fragments were observed during the 
APC-catalyzed inactivation of rFVa-RQA apart from fragments corresponding to cleavage 
at R306 (see also model of Fig. 3b). Also the effect of protein S on the APC-mediated 
cleavage at R306 was studied. This revealed that the presence of protein S stimulated 
cleavage at R306 ~30-fold, which demonstrates that cleavage at R306 is more sensitive to 
the action of protein S than cleavage at R506. This result is in line with previous studies, 
which have reported that protein S accelerates the APC-catalyzed cleavage at R306 ~20-
fold [30,35,35], although it is not completely understood why the action of protein S is 
mainly aimed at the R306 cleavage (see also review of Dahlbäck [37]). Interestingly, in the 
new model of FVa (see Fig. 1) R306 and R506 are located in the same plane about 90 Ǻ 
above the membrane surface. Therefore, the proposed role of protein S to lower the active 
site APC seems less likely [38].  
Finally, an attempt was made to analyze the APC-catalyzed cleavage at R679 by 
following the APC-catalyzed inactivation of rFVa-GQR in time. In contrast to the APC-
cleavage sites at R306 and R506 the functional and structural implications of cleavage at 
R679 have not been addressed in other studies. So far, only one study has tried to estimate 
kinetic parameters associated with the cleavage at R679 using semi-quantitative data 
derived from the inactivation of purified normal FVa from plasma [30]. The rFVa-GQR 
mutant was inactivated at relatively high concentrations of APC, because cleavage at R679 
was much slower than cleavage at R306 and R506. Under these conditions cleavage at Rx1 
and Rx2 also contributed to the inactivation of FVa, which made it difficult to interpret the 
data. Besides, it was not possible to visualize cleavage at R679, because the 101 kD 
fragment (1-679) could not be separated from the intact heavy chain of 105 kD (1-709). 
For this reason the inactivation curve of rFVa-GQR was compared with the inactivation 
curve of rFVa-GQA to calculate the contribution of cleavage at R679 to the inactivation of 
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FVa. In this way we were able to determine that cleavage at R679 resulted in a FVa 
intermediate (FVa679) with a slightly reduced FVa activity of ~85%, which was most likely 
caused by a lower affinity for FXa. This hypothesis is supported by the fact that lowering 
of the FXa concentration in the prothrombinase assay from 5 nM to 0.5 nM resulted in a 
further reduction of the activity of the FVa679 molecule to ~60%. It seems likely that the C-
terminal region of the heavy chain of FVa contains a binding site for FXa (Bakker et al. 
[39] have reported a FXa binding site between residue 683 and 709), which is affected by 
cleavage at R679. In addition, a reduced activity of the FVa679 intermediate may also 
reflect lower affinity of FVa for prothrombin, because recently it has been reported that the 
region from 695 to 698 is important for the binding of FVa to prothrombin [40].  
In the absence of phospholipids the inactivation curve of rFVa-GQR was biphasic 
with a first rapid reaction associated with cleavage at R679 followed by a second slow 
inactivation phase associated with spontaneous inactivation of FVa679. From this curve a 
k679 was calculated of 5.4 x 104 M-1s-1. In the presence of negatively charged phospholipids 
it was difficult to obtain a reliable estimate of k679, because under these conditions the 
inactivation curve of rFVa-GQR was more complex due to the influence of additional 
cleavages at Rx1 and Rx2. After comparison with the inactivation curve of rFVa-GQA it 
seemed most likely that the inactivation of rFVa-GQR proceeds via a relatively rapid 
cleavage at R679, resulting in a FVa679 intermediate with 85%, followed by cleavages at 
Rx1 (resulting in a FVa679,x1 molecule with 48% activity) and cleavage at Rx2. Since there 
is no model available to describe the inactivation of rFVa-GQR via cleavages at R679, 
Rx1 and Rx2, the inactivation rate for cleavage at R679 was estimated by correcting the 
inactivating curve with the residual activity of the FVa679,x1 intermediate. In this way a 
biphasic curve was created, which could more easily be analyzed. From this curve an 
estimate for k679 being ~1.5 x 105 M-1s-1 was obtained, which indicates that this cleavage is 
also stimulated by negatively charged phospholipids, although this effect is not very 
strong. 
We were not able to assess the effect of protein S on cleavage at R679. More detailed 
information about the effect of protein S on the APC-catalyzed cleavage at R679 may be 
obtained by rFV mutants, in which the cleavage sites at Rx1 and Rx2 have been mutated.  
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Figure 3. Overview of the most relevant pathways via which rFVa-mutants are inactivated by
APC. The kinetic parameters used in this overview were obtained from the APC-catalyzed
inactivation curves of rFVa mutants (in which two or three of the known APC-cleavage sites are
absent) in the presence of phospholipids and in the absence of protein S. Residual FVa activities
were measured in a prothrombinase assay using 5 nM FXa. In this scheme the most relevant
second-order rate constants and residual FVa activities of intermediate molecules (between
brackets) are indicated. Completely or almost completely inactivated FVa molecules (activities
between 0 and 10%) are indicated as FVi. In panel A the inactivation of rFVa-GQA is depicted.
The activity of FVi, which remains after dissociation of the Rx2-709 fragment, is estimated from
the FV306 intermediate, since Rx2 is localized close to residue 306. In panel B and C the
inactivation of rFVa-RQA and rFVa-GRA are presented, respectively. A model of the inactivation
pathways of the APC-catalyzed inactivation of rFV-GQR is depicted in panel D. At this moment it
is not clear whether cleavage at R679 results in dissociation of the 680-709 fragment. Further
details about the APC-mediated inactivation of rFVa can be found in this chapter and chapter 3.   
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Taken together, the kinetic data obtained in this thesis validate the model proposed by 
Nicolaes et al. [30], in which FVa is mainly inactivated via parallel cleavages at R506 and 
R306. Under physiological conditions the contribution of cleavage at R679 to the 
inactivation of normal FVa seems to be at most marginal. Norstrøm et al. [33] have 
suggested that cleavage at R679 contributes to the inactivation of naturally occurring FV 
mutants with mutations at the R306 position (such as FV Hong-Kong or FV Cambridge). 
Based on our observations it seems, however, more likely that the APC-catalyzed cleavage 
at Rx2 rather than cleavage at R679 contributes to the inactivation of FVa Hong-Kong or 
Cambridge. Based on the data from chapter 3 an overview has been constructed of the 
different pathways via which rFVa mutants are inactivated by APC (Fig. 3).  
 
Effect of D2194G mutation on expression and glycosylation of factor V 
Apart from mutations in the APC-cleavage sites several other naturally occurring 
mutations in FV have been found, which may be associated with APC-resistance or 
thrombotic risk. Examples of these mutations are the D79H, I359T and R485K in the 
heavy chain of FV [41-43], although the association of the D79H and R485K mutation 
with APC-resistance or thrombotic risk is still a matter of debate. Also, a polymorphism 
(4070A>G) in the B-domain of FV has been associated with APC-resistance and risk of 
venous thrombosis, although published data on both laboratory and clinical phenotypes are 
not always consistent. This polymorphism was first described in 1996 and predicts a His to 
Arg substitution at residue 1299 [44]. A number of other polymorphisms in the FV gene 
are strongly linked to the H1299R mutation, which is also referred to as R2-haplotype. 
This haplotype is widely spread amongst Caucasian and non-Caucasian populations with 
allele frequencies ranging from 0.041 to 0.102 [45-51]. The association between 
carriership of the R2-haplotype and a thrombogenic phenotype has not been firmly 
established. It seems more firmly established that carriership of the R2-FV gene in 
combination with the FV Leiden gene results in an increased APC-resistant phenotype and 
increased risk of venous thrombosis [45,47,52]. Most likely, reduced expression of R2-FV 
is responsible for this enhanced thrombophilic phenotype, because an association of the 
R2-FV allele with moderately reduced FV levels (activity and antigen) has been found in 
several independent studies [44,46,47,49,53]. 
Castoldi and co-workers have proposed an explanation for the thrombogenic 
phenotypes associated with the R2-FV allele [53,54]. They observed that the affinity of 
FVa for negatively charged phospholipids from homozygous carriers of the R2-FV allele is 
decreased. Therefore, it was postulated that the R2-linked D2194G substitution in the light 
chain of FVa is the functional determinant for the thrombogenic phenotype either via a 
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positive effect on the glycosylation at N2181 (resulting in a relative increase of the 
thrombogenic FV1 isoform), or via a conformational change of the light chain. So far, 
there are no experimental data that (dis)prove these hypotheses.  
In Chapter 4, recombinant FV molecules were used to gain more insight into the 
influence of the D2194G mutation on FV expression, FV structure (e.g. glycosylation of 
N2181) and FV function. In a transient expression system, we found that replacing Asp at 
position 2194 by Gly results in a more than threefold reduction of rFV expression 
compared to rFV wild-type. Therefore, we propose that the R2-linked D2194G mutation is 
an important determinant in the association of the R2-FV allele with lower FV levels. This 
conclusion is in line with a report from Yamazaki et al. [55] on transient expression of 
full-length rFV mutants with several R2-linked missense mutations. Most recently, Miteva 
et al. have also confirmed these results in a transient expression system [56].  
No indications were found that reduced FV expression is caused by impaired 
secretion, because there was no accumulation observed of factor V (activity and antigen) in 
cells transfected with mutant FV constructs. Therefore, it seems more likely that the 
D2194G mutation affects the conformation or stability of the C2 domain by disturbing the 
electrostatic interactions with K2101 and K2103 (see also model in Fig. 4) resulting in a 
FV molecule that is more susceptible to intracellular degradation. This hypothesis has 
recently been confirmed by computational data from Miteva et al. who have shown that 
the D2194G mutation induces an overall destabilization of the C2 domain using molecular 
dynamics and electrostatic computations [56].  
The light chains from D2194G containing rFV mutants showed similar molecular 
weights as the light chains of the non-glycosylated rFV-wt or the plasma FV2 isoform, 
indicating that glycosylation at N2181 is not stimulated by the presence of a glycine in 
position 2194. From these data it seems very unlikely that the R2-linked D2194G mutation 
has a stimulatory effect on the glycosylation of Asn2181, although we can not exclude that 
in vivo the glycosylation of Asn2181 is more sensitive for the D2194G substitution. Also, 
the large spatial distance between the two residues in the 3D model of FV makes it 
unlikely that the D2194G mutation can affect glycosylation of Asn2181 (see Fig. 4).  
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The data from chapter 4 do not support the proposal of Hoekema et al. [53] and 
Castoldi et al. [54] that the relative increase in FV1, observed in the plasma of carriers of 
the R2-FV allele, is caused by more efficient glycosylation of Asn2181. Theoretically, the 
functional measurements in FV1/FV2 assays could also be influenced by changes in the 
efficiency of XaVa complex formation not related to glycosylation of N2181 (e.g., the 
D2194G mutation). We confirmed that stimulation of glycosylation of N2181 (using the 
rFV∆B-NTD mutant) indeed decreases the ability of the activated mutant (K1/2Xa ~0.6 nM) 
to promote XaVa complex formation under the used conditions. However, no differences 
in XaVa complex formation were detected for the two mutants containing the D2194G 
substitution (K1/2Xa ~0.25 nM) and for wild-type rFV (K1/2Xa ~0.25 nM), indicating that the 
D2194G mutation has no effect on the efficiency of formation of the prothrombinase 
complex under the conditions used (low phospholipid concentration and limiting amounts 
of FVa). 
These latter findings are in line with a previous report from Kim et al. [57], in which 
no important effect could be found on the prothrombinase activity of rFVa containing a 
D2194A substitution. The data from chapter 4 seem also to be consistent with data from 
Figure 4. D2194 and other residues in the light chain of FVa. A solid-ribbon model of the FVa
molecule (A) and a close-up view of the light chain (B) are presented. In the light chain (magenta)
of FVa the position of D2194 is indicated in red. This residue is part of a salt-bridge network
involving residues K2101 (green) and K2103 (cyan blue). N2181 (dark blue residue) is located in
the same plane as W2063 and W2064 (yellow residues), which are important residues for the
interaction with phospholipids. Therefore, a carbohydrate side-chain at N2181 (as in the FV1
isoform) is likely to interfere with the binding to phospholipid surface.
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Hoekema and co-workers [53], who observed that under limiting conditions R2-FVa 
exhibits only marginal differences compared to normal FVa in its ability to promote XaVa 
complex formation (K1/2Xa). In addition no differences in the susceptibility of R2-Va for 
APC were observed under conditions that FVa1 inactivation by APC is significantly 
delayed. On the other hand Kalafatis et al. [58] using a different experimental approach 
reported that activated FV in pseudo-homozygous R2 plasma is less susceptible to APC 
inactivation than FVa from normal pooled plasma. 
The observation that the affinity of rFVa for negatively charged phospholipids is not 
lower in FV mutants containing the D2194G mutation, makes it unlikely that this mutation 
is responsible for a thrombogenic phenotype of R2-FV via a mechanism of impaired 
phospholipid binding like is the case for FV1 [59]. Therefore, it seems more likely that the 
D2194G mutation contributes to a thrombogenic phenotype of R2-FV via another 
mechanism, e.g. a lower APC-cofactor activity in FVIIIa degradation. Recent experimental 
data from Castoldi et al. [16] strongly suggest that R2-FV indeed contains reduced APC-
cofactor activity in the degradation of FVIIIa, which contributes to an APC resistant 
phenotype in both the APTT as well as the ETP-based APC resistance tests. Further 
information about the APC-cofactor function of R2-FV may be obtained in FVIIIa 
degradation assays or thrombin generation-based assays using rFV mutants containing a 
full-length B-domain and singled-out mutations of the R2-haplotype [13,18,60].  
In conclusion, the data from chapter 4 show that the singled-out D2194G mutation is a 
functionally important determinant for decreased FV levels in R2-FV gene carriers. Most 
likely, reduced expression of R2-FV is responsible for the enhanced APC-resistant 
phenotype in compound heterozygous FV Leiden/R2-FV carriers (see also [45,47,52]). No 
structural evidence has been obtained that the D2194G substitution is a determinant of the 
putative thrombogenic phenotype of R2-FV either via promoting glycosylation at N2181 
or via lowering of the affinity for negatively charged phospholipids. 
 
Characterization of the D79H polymorphism in the heavy chain of factor V 
In the last part of this thesis (Chapter 5) a variant FV was analyzed that was not 
recognized by a monoclonal antibody (mAb V-23) directed against the heavy chain of FV. 
This variant FV was found during the study of the family of an asymptomatic 
heterozygous carrier of the FV Amersfoort allele (1102A>T in exon 7 [61]). In some 
members of this family we observed a striking discrepancy between FV light chain and 
heavy chain antigen levels as measured by ELISA. This abnormality co-segregated with a 
409G>C transversion in exon 3 of F5 predicting an amino acid substitution (D79H) in the 
heavy chain of FV (first reported by Cargill et al. [62]). Introduction of this substitution in 
recombinant FV (rFV-79H) confirmed that the D79H substitution was responsible for the 
absence of the epitope for mAb V-23. 
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To learn more about the epitope of mAb V-23 binding experiments were performed, 
which revealed that mAb V-23 did not bind to synthetic peptides homologous to the region 
around residue 79 (amino acids 71 to 85). This result could not easily be explained by the 
absence of post-translational modifications on these peptides, because in the region from 
71 to 85 no such modifications are known. This suggested that the epitope for mAb V-23 
is not linear, which is in agreement with the observation that mAb V-23 does not detect FV 
in Western blots under reducing conditions. This conclusion is also supported by the 3D 
model of FVa, which shows that the region surrounding residue 79 is only partially 
surface-exposed (Fig. 5). Possibly, residue K34 is also involved in the epitope, because the 
side-chain of this residue is located in the proximity (about 3.5 Ǻ) of the side chain of 
residue D79 (Fig. 5). Two mechanisms may explain why the D79H substitution affects the 
interaction with mAb V-23. The most obvious explanation would be that substitution of a 
negatively charged residue (D) into a positively charged residue (H) abrogates the 
electrostatic interactions between the epitope and mAb V-23. However, it remains also 
possible that the D79H substitution causes conformational changes due to the absence of 
an electrostatic interaction (salt bridge) between residue D79 and residue K34.  
Little is known about the effect of the D79H substitution on the function of FV. So 
far, this polymorphism has only been reported twice. The first time was in 1999 in a study 
by Cargill et al. [62]. They included this polymorphism in an extensive catalogue of 
single-nucleotide polymorphisms (SNPs) in the coding regions of human genes, which 
could be used in association studies. This report, however, gives no information on the 
functionality of this polymorphism. More recently, however, it has been reported by 
Bossone et al. that carriership of FV-79H is associated with moderately decreased FV 
levels (as measured in clotting-based FVa activity assay) and may serve as a trans-acting 
gene mutation in heterozygous carriers of FV Leiden by lowering the sensitivity of plasma 
to APC [43]. This suggested that the D79H substitution, in analogy to the FV-R2 mutation, 
increases the APC-resistant phenotype of plasma from heterozygous carriers of the FV 
Leiden mutation via reduced FV expression of the FV-79H allele [44,45]. The latter 
observations prompted us to further investigate this by genotyping of the cases and 
controls from a large population-based case-control study on risk factors for venous 
thrombosis (LETS) in order to determine the effect on FV levels, n-APC-SR and risk of 
thrombosis. 
The effect of the D79H substitution on plasma FV levels was studied using the data 
from 433 healthy controls from the Leiden Thrombophilia Study (LETS). No association 
between carriership of the FV-79H allele and reduced FV antigen levels was observed. 
This seemed to be different from the results reported by Bossone et al. [43], but may be 
explained by the size of the group studied by Bossone (n=150 compared to n=433 in our 
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study). It could also be possible that FV-79H has a slightly reduced specific procoagulant 
activity. However, we found no indications that the D79H substitution has an effect on the 
Xa-cofactor activity of FVa, because the specific activity (FVa/FVLC) of rFV-79H was 
similar to that of rFV-79D. This is in agreement with the results from Zeibdawi et al. [63], 
who studied the effect of the D79A substitution on the cofactor function of FVa. 
Furthermore, the D79H substitution did not affect the stability of the (activated) FV 
molecule, like the amino acid substitutions A221V and D111A, which have been reported 
to weaken the interaction between the heavy and light chain of activated FV [63,64].  
Further analysis showed that carriership of the FV-79H allele is not associated with a 
lower n-APC-SR after exclusion of FV Leiden carriers, which is in line with the findings 
from Bossone et al. [43]. Also we did not find that heterozygous carriers of FV Leiden, 
who carry the FV-79H allele on the other chromosome, have a more APC-resistant 
phenotype than subjects (n=8) carrying the alleles for FV Leiden and FV-79D (mean n-
APC-SR = 0.57). This ratio is identical to the ratio of 0.57 (range 0.5-0.67) previously 
reported for heterozygous carriers of FV Leiden [4,47]. Finally, carriership of the FV-79H 
has no effect on the risk of venous thrombosis (Table 8), which is reflected in an odds ratio 
of 1.07 (CI 95: 0.7 – 1.7). 
Taken together, our data suggest that the D79H substitution has no effect on FV(a) 
function or thrombosis risk. This is in agreement with the fact that so far no functional 
domains have been identified in the region surrounding residue 79 in FV (see also the 
review by Mann and Kalafatis [65]). Also the fact that the aspartic acid at position 79 is 
not fully conserved between species, suggests that residue 79 is not critical for the function 
of FV.  
In conclusion, chapter 5 demonstrates that the D79H substitution should be considered 
as a neutral polymorphism with an allele frequency of ~5% in the Caucasian population. It 
is recommended not to use mAb V-23 in diagnostic tests, because it would result in falsely 
reduced FV levels in 10% of the population. 
 
Concluding remarks 
In the last decade coagulation factor V has been investigated by a large and still growing 
number of research groups. For this type of studies the use of recombinant DNA 
technology has become more and more important. The benefit of the use of recombinant 
FV molecules has also been demonstrated in this thesis. It is to be expected that in the near 
future additional recombinant FV mutants will be generated to gain more insight into the 
relationship between structure and function of this coagulation factor.  
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Unfortunately, FV is a large protein (~330kD) and contains many posttranslational 
modifications, which is probably the cause of the rather low stability and expression levels 
of rFV. Part of these problems can be overcome by expressing B-domainless rFV 
molecules, but these molecules may be not informative in some assays, such as the APC-
cofactor activity of FV in the APC-mediated degradation of FVIIIa. Furthermore, during 
the work presented in this thesis evidence has been obtained that rFV molecules are not 
only expressed as single-chain molecules, but also as molecules with one or more 
cleavages in the B-domain. This conclusion was based on SDS-PAGE analysis under 
reducing conditions, which revealed additional fragments apart from the single chain 
fragment. Also FV in plasma shows similar heterogeneous fragments, although it is to be 
expected that under physiological conditions the FV molecule is held together by non-
covalent interactions. More research is needed to explain this heterogeneity, as this may 
also interfere with the crystallization of FV. A challenge in FV research will be to increase 
the expression levels and the stability of rFV molecules.  
 
Figure 5. Area surrounding residue D79 in the heavy chain of FVa. Two orientations
of FVa are presented, in which the area from K75 to H85 is indicated in blue. These
amino acids surround residue D79 (red). The distance between the side chains of residue
D79 and residue K34 (cyan blue) is about 3.5 Ǻ, which strongly suggests that these two
residues are involved in an electrostatic interaction (salt bridge).  
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Summary 
The coagulation cascade entails a series of enzymatic reactions culminating in the 
production of large amounts of thrombin, which converts soluble fibrinogen into insoluble 
fibrin fibres. Down-regulation of activated clotting factors is important to prevent 
unnecessary clotting. An important anticoagulant system is the so-called "protein C 
pathway" in which activated protein C (APC) exerts its anticoagulant activity by 
proteolytic inactivation of activated FVIII (FVIIIa) and activated FV (FVa). The 
inactivation of FVIIIa by APC seems less relevant, because under physiologic conditions 
FVIIIa inactivates also in the absence of APC via spontaneous dissociation. In contrast, 
FVa is a stable molecule and requires the serine protease APC for its inactivation, which 
cleaves the heavy chain of FVa at R306, R506 and R679. Studies using isolated FV have 
shown that inactivation of FVa by APC proceeds in a biphasic fashion, a rapid reaction 
associated with cleavage at R506 and a slow reaction associated with cleavage at R306. 
Both cleavages are strongly dependent on the presence of negatively charged 
phospholipids. The contribution of the APC cleavage at R679 to the inactivation of FVa by 
APC is uncertain but seems to be minor. Furthermore, the APC-catalyzed inactivation of 
FVa is strongly stimulated by the non-enzymatic cofactor protein S, which specifically 
promotes the cleavage at R306.  
Theoretically, mutations in the APC cleavage sites of FVIIIa and FVa can result in a 
reduced sensitivity towards APC and thereby change the phenotype of plasma into an 
APC-resistant phenotype. No naturally occurring mutations in the APC cleavage sites of 
human FVIII have been found so far, whereas several mutations have been reported in 
APC cleavage sites of human FV. The most important mutation is FV Leiden, in which 
arginine 506 has been replaced by glutamine. This mutation results in APC resistance and 
is associated with an increased risk of deep-vein thrombosis. Moreover, the high allele 
frequency of FV Leiden (2-8 % in Caucasian populations), makes this mutation the most 
important heritable risk factor for venous thrombosis. Other missense mutations in the 
APC cleavage sites affect the R306 position. Whether these mutations result in APC 
resistance and are associated with a risk of thrombosis is not clear. The first aim of this 
thesis was to identify the APC resistant phenotype of plasma containing factor V 
molecules with different mutations in the APC cleavage sites (chapter 2). To study this, 
purified recombinant FV mutants were reconstituted in FV-deficient plasma, after which 
normalized APC-sensitivity ratios (n-APC-SRs) were measured in APTT- and RVVT-
based APC-resistance tests. Mutations introduced in FV were: R306G, R306T, R506Q, 
R679A and combinations of these mutations. Based on the APC-sensitivity ratios, we 
conclude that the naturally occurring mutations at R306 (i.e. FV Hong-Kong and FV 
Cambridge) result in a mildly reduced sensitivity for APC (n-APC-SR 0.74-0.87), whereas 
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much lower values (n-APC-SR 0.41-0.51) were obtained for the mutation at R506 (FV 
Leiden). No effect on the n-APC-SR was observed for the recombinant FV mutant 
containing the single A679 mutation. Because reduced sensitivity for APC, not due to FV 
Leiden, is a risk factor for venous thrombosis, these data suggest that mutations at R306 
might be associated with a mild risk of venous thrombosis. 
So far, three APC cleavage sites have been identified in the heavy chain of FVa: 
R306, R506 and R679. To obtain more insight in the structural and functional implications 
of each individual cleavage, recombinant factor V mutants were constructed in which two 
or three of the APC-cleavage sites were mutated (chapter 3). After expression in COS-1 
cells, rFV mutants were purified, activated with thrombin and inactivated by APC. During 
this study we observed that activated rFV-GQA (rFVa-GQA) -in which the arginines at 
positions 306, 506 and 679 were replaced by glycine, glutamine and alanine, respectively- 
was still inactivated by APC. Further analysis showed that the inactivation of rFVa-GQA 
by APC was phospholipid dependent and sensitive to an inhibitory monoclonal antibody 
against protein C. Inactivation proceeded via a rapid phase (kx1 = 5.4 x 104 M-1s-1) and a 
slow phase (kx2 = 3.2 x 103 M-1s-1). Analysis of the inactivation curves showed that the 
rapid phase yielded a reaction intermediate which retained ~80% of the original FVa 
activity, whereas the slow cleavage resulted in formation of a completely inactive reaction 
product. Inactivation of rFVa-GQA was accelerated by protein S, most likely via 
stimulation of the slow phase. Immunoblot analysis using a monoclonal antibody 
recognizing an epitope between R306 and R506 indicated that during the rapid phase of 
inactivation a fragment of 80 kD was generated that resulted from cleavage at a residue 
very close to R506 (designated Rx1). The slow phase was associated with the formation of 
fragments resulting from cleavage at a residue 1.5-2 kD carboxyterminal to R306 
(designated Rx2). Our observations may explain the unexpectedly mild APC resistance 
associated with mutations at R306 in the heavy chain of FV. 
The knowledge of the APC-dependent cleavage at the alternative sites (Rx1 and RX2) 
could subsequently be used in the analysis and interpretation of APC-mediated inactivation 
of rFVa, which contained only one of the three known APC-cleavage sites (R306, R506 or 
R679). Our data show that APC-mediated cleavage at R506 occurs at a 100-fold and 2000-
fold higher rate than cleavage at R306 or R679, respectively. Like the cleavages at R506 
and R306, the APC-catalyzed cleavage at R679 was also stimulated by the presence of 
negatively charged phospholipids, but the effect was not very strong. Protein S stimulates 
both the APC-mediated cleavages at R306 and R506, although this stimulation is much 
stronger for cleavage at R306. The effect of protein S on the APC-mediated cleavage at 
R679 remains to be elucidated. Finally, our results demonstrate that cleavages at the 
individual APC cleavage sites have different effects on the residual FVa activities of the 
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reaction intermediates being, 85% (FVa679), 60-75% (FVa506) and 10% (FVa306) as 
measured with 5 nM FXa in the prothrombinase assay. These data suggest that the 
physiological relevance of the APC-catalyzed cleavage at R679 is less important than 
cleavage at the as yet unidentified cleavage site Rx2, which is located near position 306. 
In the next part of this thesis (Chapter 4) the structural and functional effects of the 
D2194G mutation in FV was studied. This mutation is part of the R2 haplotype of the FV 
gene, which spans from exon 8 through 25 and comprises several strongly linked 
polymorphisms in the FV gene, including some missense mutations. Carriership of the R2-
FV allele has been associated with reduced plasma FV levels, increased FV1/FV2 ratios 
and mild APC resistance. Some studies have reported that carriership of the R2-FV allele 
is also associated with an increased risk of venous thrombosis. The individual contribution 
to the R2-associated phenotypes of the different mutations linked to the R2 haplotype of 
FV is not completely clear, but it has been suggested by others that the D2194G mutation 
has a stimulatory effect on the glycosylation of residue N2181. Therefore, the influence of 
the R2-related D2194G mutation on FV expression, FV structure and FV function was 
studied using B-domainless rFV mutants. Replacing Asp at position 2194 by Gly resulted 
in a more than threefold reduction of rFV expression compared to rFV wild-type (rFV-wt). 
These data strongly suggest that the R2-linked D2194G mutation is an important 
determinant of the association of the R2-FV allele with lower FV levels. Furthermore, the 
light chains from D2194G containing rFV mutants showed similar molecular weights as 
the light chains of the non-glycosylated rFV-wt or the plasma FV2 isoform, indicating that 
glycosylation at N2181 is not stimulated by the presence of a glycine in position 2194. 
Finally, the apparent Kd for dissociation of the FXaVa complex (K1/2Xa) was not higher in 
rFV mutants with the D2194G mutation than for rFV-wt, suggesting that also the affinity 
for negatively charged phospholipids is not affected by substitution of Asp into Gly at 
position at 2194.    
Finally, the D79H substitution in FV was investigated (chapter 5). The interest for 
this polymorphism came from the observation that some members of a FV deficient family 
carried a FV variant with strongly reduced affinity for a monoclonal antibody (V-23) used 
in our FV heavy chain ELISA. The molecular defect responsible for the reduced affinity of 
the variant FV for mAb V-23 appeared to be the D79H mutation. Short after this 
observation it was reported that carriership of this mutation is associated with lower FV 
levels and APC-resistance, which prompted us to genotype cases and controls of the 
Leiden Trombophilia Study (LETS), a large case control study in which 474 consecutive 
patients with a deep-vein thrombosis and 474 age- and sex-matched controls have been 
included, for carriership of the D79H mutation. This revealed that the frequency of the FV-
79H allele is ~5% and that carriership of the FV-79H allele is not associated with FV 
antigen levels (FVLC), activated protein C sensitivity (using an activated partial 
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thromboplastin time-based test) or risk of venous thrombosis (OR 1.07, CI 95: 0.7 – 1.7). 
Furthermore, introduction of this mutation in recombinant factor V showed that the D79H 
substitution has no effect on FV(a) stability and Xa-cofactor activity. Therefore, the D79H 
substitution in FV should be considered as a neutral polymorphism. Monoclonal antibody 
V-23, which has a strongly reduced affinity for FV-79H, is not suitable for application in 
diagnostic tests. 
Nederlandse samenvatting 
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Het doel van dit onderzoek was om meer inzicht te verkrijgen in de structuur en de functie 
van stollingsfactor V (FV), een eiwit dat een belangrijke rol speelt in de regulatie van de 
bloedstolling. De bloedstolling bestaat uit een serie (cascade) van enzymatische reacties 
die uiteindelijk resulteren in de productie van een grote hoeveelheid trombine, een enzym 
dat oplosbare fibrinogeen moleculen omzet in onoplosbare fibrine draden. Aangeboren 
afwijkingen in FV kunnen de regulatie van de bloedstolling flink verstoren en kunnen 
leiden tot verschijnselen die uiteen lopen van bloedingen (parahemofilie) tot overmatige 
bloedstolling (trombose). Een belangrijke erfelijke afwijking in FV is de R506Q mutatie 
(een aminozuur verandering op positie 506 in de aminozuur keten van FV). Dit afwijkende 
FV molecuul (ook wel FV Leiden genoemd naar de stad waar de eerste patient bij wie deze 
afwijking werd aangetroffen werd geboren) is geassocieerd met een zevenvoudig verhoogd 
risico op trombose en komt frequent voor in de Westerse bevolking (2-8%). Van alle 
erfelijke risico factoren voor trombose die tot nu toe ontdekt zijn is FV Leiden de 
belangrijkste (in de Westerse wereld althans). 
FV wordt pas actief na activering van de bloedstolling en wordt dan aangeduid als 
FVa. Tijdens de activering van FV wordt een groot deel van de eiwit keten eruit geknipt 
waardoor er een FV molecuul ontstaat met twee ketens, een zware en een lichte keten. 
Vervolgens kan FVa via de lichte keten aan membranen van geactiveerde bloedplaatjes 
binden (deze bloedplaatjes assisteren bij het stelpen van bloedingen). Eenmaal gebonden 
aan het membraan functioneert FVa als co-factor (hulp factor) van het enzym FXa, dat 
protrombine omzet in trombine. Als de bloedstolling zijn werk gedaan heeft wordt FVa 
inactief gemaakt door het antistollende enzym geactiveerd protein C (APC). Deze 
inactivering van FVa door APC speelt een belangrijke rol in het stilleggen van de 
bloedstolling. APC is in staat om de zware keten van FVa te knippen op drie plaatsen, 
R306, R506 en R679, waarbij elke knip gepaard gaat met een bepaalde mate van verlies 
aan FVa activiteit. De knip van de R506 is de belangrijkste. Deze knipplaats is afwezig in 
FV Leiden waardoor FVa Leiden in grote mate ongevoelig (resistent) wordt voor de 
inactiverende werking van APC. Dit verklaart waarom de R506Q mutatie in FV zo een 
groot effect heeft op trombose risico.  
De aanwezigheid van FV Leiden in plasma kan in het laboratorium gemeten worden 
door de stoltijden van plasma te meten. De stoltijden van plasma met FV Leiden worden 
veel minder verlengd door het toevoegen van APC dan de stoltijden van plasma met 
normaal FV. Daarom wordt het plasma waarin FV Leiden aanwezig is APC-resistent 
genoemd. Aangeboren of verworven APC-resistente eigenschappen van plasma gaan altijd 
gepaard met een verhoogd risico op trombose, ook als FV Leiden niet de oorzaak hiervan 
is.  
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Sinds de ontdekking van FV Leiden in 1994 is de aandacht voor FV enorm gegroeid, 
het aantal wetenschappers dat onderzoek doet aan FV neemt nog steeds toe. Vooral aan de 
inactivering van FVa door APC wordt veel onderzoek gedaan. Ook in deze dissertatie 
stond de inactivering van FVa door APC centraal. Daarnaast zijn een aantal natuurlijk 
voorkomende afwijkingen in FV gekarakteriseerd. Hiertoe werden met behulp van 
recombinant DNA technieken FV mutanten gemaakt en gekarakteriseerd.  
In de eerste fase van dit onderzoek is onderzocht of mutaties in de APC knipplaats op 
positie R306 ook geassocieerd zijn met APC-resistentie (Hoofdstuk 2). Het bleek dat de 
natuurlijk voorkomende FV varianten met mutaties op de R306 positie (FV Hongkong en 
FV Cambridge) geassocieerd zijn met een zeer milde vorm van APC-resistentie. Op basis 
van deze data lijkt het waarschijnlijk dat mensen die dragers zijn van het gen voor deze FV 
varianten een licht verhoogd risico hebben op veneuze trombose. Verder bleek dat FV 
mutanten met een mutatie in de R679 knipplaats niet geassocieerd zijn met APC 
resistentie. Vervolgens werd de snelheid en het effect op de FVa activiteit onderzocht van 
de individuele APC knippen m.b.v FVa mutanten waarin 1, 2 of 3 APC knipplaatsen 
afwezig waren (Hoofdstuk 3). Tijdens deze experimenten werd ontdekt dat FVa zonder de 
bekende APC knipplaatsen nog steeds geknipt en geïnactiveerd wordt door APC via 
knippen op tot nu toe onbekende posities in de zware keten van FVa. Deze onbekende 
knippen zijn vervolgens uitgebreid gekarakteriseerd en bleken een grotere invloed te 
hebben op de inactivering dan de R679 knip. Deze kennis werd vervolgens gebruikt om de 
inactivering van FVa door APC tot in detail te bestuderen. 
Naast mutaties in de zware keten van FVa is er ook gekeken naar een veel 
voorkomende mutatie (D2194G) in de lichte keten van FVa (Hoofdstuk 4). Eerdere 
studies leken erop te wijzen dat de D2194G mutatie de versuikering van de lichte keten 
tijdens de synthese van FV kan stimuleren waardoor het FVa molecuul minder goed aan 
membraan oppervlakken kan binden en minder goed door APC geknipt kan worden. In ons 
model systeem bleek echter dat deze mutatie geen enkele invloed heeft op de versuikering 
van de lichte keten en ook geen invloed heeft op de binding van FVa aan celmembranen. 
Wel kon de hypothese bevestigd worden dat de D2194G mutatie verantwoordelijk is voor 
verlaagde FV spiegels in plasma. Deze verlaagde FV spiegels verklaren zeer waarschijnlijk 
waarom de D2194G mutatie in combinatie met FV Leiden een hoger risico geeft op 
trombose. Een lagere spiegel van het FV-D2194G zorgt er namelijk voor dat er 
verhoudingsgewijs meer FV Leiden in het plasma aanwezig is. 
Tenslotte, is de veelvoorkomende D79H mutatie in FV onderzocht, waarvan 
gerapporteerd is dat deze wellicht een rol speelt in de verlaging van FV spiegels en APC 
resistentie (Hoofdstuk 5). Onze belangstelling voor deze mutatie kwam voort uit de 
waarneming dat sommige leden van een FV deficiënte familie een FV variant bezaten met 
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een sterk verlaagde affiniteit voor het monoklonaal antilichaam (V-23), dat gebuikt werd 
in onze zware keten FV ELISA. De oorzaak voor deze verlaagde affiniteit bleek de D79H 
mutatie te zijn. Met behulp van recombinant FV-79H en een grote populatie studie kon 
aangetoond worden dat de D79H mutatie geen invloed heeft op FV spiegels, APC 
resistentie of trombose risico. Verder bleek dat de FV-D79H mutant een normale FVa 
activiteit heeft en daarom als een neutrale substitutie beschouwd dient te worden, die bij 
~10% van de westerse populatie voorkomt.        
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Nawoord 
 
Het promotie onderzoek beschreven in dit proefschrift werd uitgevoerd bij de afdeling 
Trombose en Hemostase Onderzoek van het Leids Universitair Medisch Centrum onder 
supervisie van Prof. Dr. R.M. Bertina. Tijdens dit onderzoek is er een breed scala aan 
biochemische en moleculaire technieken gebruikt om de structuur en functie van 
stollingsfactor V te bestuderen. Zonder de hulp van anderen zou dit nooit zijn gelukt, vandaar 
dat ik in dit nawoord een aantal mensen wil bedanken. 
 
In de eerste plaats wil ik alle medewerkers van de afdeling Trombose en Hemostase 
Onderzoek bedanken voor de fijne werksfeer, die voor een groot deel te danken is aan de 
spontane borrels en aan andere sociale activiteiten. Vooral de samenwerking met Richard heb 
ik zeer gewaardeerd. Jouw kennis van zaken, zowel op digitaal als op praktisch gebied, is van 
grote waarde geweest voor dit onderzoek. Het feit dat een Rotterdammer en een 
Amsterdammer het zo lang met elkaar hebben uitgehouden maakt deze samenwerking extra 
bijzonder.  
 
Een groot deel van dit onderzoek werd uitgevoerd in samenwerking met het Cardiovasculair 
Onderzoeksinstituut Maastricht, dat onder leiding staat van Prof. Dr. Jan Rosing. Van deze 
groep wil ik in het bijzonder José, Lico en Stella bedanken voor de gastvrijheid en de hulp in 
het lab om factor V te karakteriseren. De samenwerking met Jan Rosing en Guido Tans heb ik 
als zeer inspirerend en zeer leerzaam ervaren. De manier waarop jullie wetenschap bedrijven 
zou een voorbeeld voor velen moeten zijn. 
 
Niels en Elaine, fijn dat jullie mij op de dag “des oordeels” willen begeleiden als paranimfen. 
 
Marc, jij hebt deze mooie omslag gemaakt en bovendien heb je mij vele malen bij tij en ontij 
vakkundig advies gegeven over de lay-out van het binnenwerk. Ik heb dat zeer gewaardeerd. 
 
Verder wil ik mijn familie en vrienden bedanken voor de belangstelling die ze getoond hebben 
voor het onderzoek waaraan ik de afgelopen jaren heb gewerkt.  
 
Sommige stollingsenzymen hebben hulpeiwitten (co-factoren) nodig om optimaal te 
functioneren. Sommige mensen kunnen ook goed een “co-factor” gebruiken. Ik ben in de 
gelukkige omstandigheid dat ik tijdens mijn promotie onderzoek een humane co-factor heb 
ontmoet. Sylvia, ik vind het fijn om dit project samen met jou af te ronden. Op naar het 
volgende project………..  
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Curriculum vitae 
 
 
De auteur van dit proefschrift werd op 9 augustus 1971 geboren in Amsterdam. Na het 
behalen van zijn gymnasium diploma aan het Willem de Zwijger college te Bussum ging hij 
in '89 Scheikunde studeren aan de Universiteit van Amsterdam. Daar koos hij voor de 
afstudeerrichting Biochemie en liep in 1994 een bijvakstage bij het E.C. Slater Instituut (Dr. P. 
Postma) en vervolgens zijn hoofdvakstage in het AMC bij de afdeling Biochemie in het AMC 
(Prof. Dr. J.M. Aerts). Na het schrijven van zijn doctoraalscriptie getiteld “The Rev protein 
from HIV-1” behaalde hij in 1995 zijn doctoraalbul.  
 
Na een sabbatical van een jaar begon hij begin 1997 met zijn promotieonderzoek bij de sectie 
Trombose/Hemostase van de afdeling Hematologie van het Leids Universitair Centrum. Dit 
onderzoek, dat onder de supervisie van Prof. Dr. R.M. Bertina stond, is voor een groot deel 
uitgevoerd in samenwerking met het Cardiovascular Research Institute Maastricht (Prof. J. 
Rosing en Dr. G. Tans). De resultaten hiervan staan beschreven in dit proefschrift.  
 
Sinds 2003 is de auteur onderzoeker bij de afdeling Immunopathologie van Sanquin locatie 
Amsterdam.  
 
 
